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ABSTRACT 
 
Malaria and the mosquito that induces the disease in humans have hounded the 
military for decades.  Malaria represents one of the most important infectious 
disease threats to deployed military forces.  Malaria in soldiers has a serious 
economic impact, both in terms of lost productivity and treatment cost for the state.  
A contingent of South African National Defence Force members has been 
deployed in Burundi since November 2001, as part of a peacekeeping mission.  At 
the time of the study no information was available regarding the prevalence of 
malaria among military personnel during deployments in Burundi and East Africa. 
 
In Africa, the saying is that malaria is the disease of poverty and a cause of 
poverty.  To combat malaria, it is of vital importance that the recommended 
medication be taken exactly as prescribed and that the course is completed.  
However, one of the greatest challenges facing the African continent in the present 
fight against malaria is drug resistance.  The discovery of Mefloquine and the 
subsequent development of suitable drugs, have been intimately associated with 
military imperatives, contingencies and requirements.  Since World War II, the 
development of Chloroquine-resistant falciparum malaria has driven the search for 
new drugs.  Mefloquine, developed by the Walter Reed Army Institute of Research 
in the United States, was first shown effective as a prophylaxis and treatment of 
resistant falciparum malaria in the 1970’s. 
 
To obtain data, questionnaires were administered to SANDF soldiers deployed in 
Burundi, East Africa.  The total size of the population under investigation was 336 
with a final sample size of 111 respondents.  The sample was selected by using 
simple random sampling.  The questionnaire aimed to determine the perception of 
respondents regarding the malaria threat, their compliance with taking the 
medication, and their experiencing of possible side-effects which might occur due 
to the chemoprophylaxis and the prophylactic efficacy of Mefliam®.  
 
The fact that, of the 111 people who used Mefliam®, only four presented with any 
malaria symptoms, is an indicator that Mefliam® is an effective option as an 
antimalarial drug to be used in East Africa and Burundi. 
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The results of this study will be used by the personnel of the South African National 
Defence Force (SANDF) and other military forces deployed in East Africa.  It is 
envisaged that the results will be used by military policy- and decision-makers as a 
control programme and by others involved in the control of malaria.  The findings 
and recommendations should also be of interest to anyone visiting the area 
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ABSTRAK 
 
Malaria en die muskiet is al dekades lank ‘n uitdaging vir die internasionale militêre 
gemeenskap.  Malaria verteenwoordig een van die grootste bedreigings as 
oordraagbare siekte vir militêre magte tydens ontplooiings.  Soldate geinfekteer 
met malaria het ‘n ernstige ekonomiese impak in terme van verlies in produktiwiteit 
en mediese kostes vir die onderskeie regerings.  ‘n Kontingent soldate van die Suid 
Afrikaanse Nasionale Weermag is sedert November 2001 in Burundi ontplooi, as 
deel van ‘n vredesmissie.  Geen inligting aangaande die voorkoms van malaria by 
militêre personeel tydens ontplooings in Burundi en Oos-Afrika is beskikbaar nie. 
 
Malaria word as die siekte van armes beskou en terselfder tyd is dit ook die 
oorsaak van armoede.  Dit is van kardinale belang dat die voorgeskrewe medikasie 
presies gebruik word soos voorgeskryf, en dat die kurses voltooi moet word.  Een 
van die grootste uitdagings, aangaande die bekamping van malaria, is die malaria 
muskiet se groeiende weerstandigheid teen die antimalaria medikasie. 
 
Die 
ontdekking van Mefloquine en die ontwikkeling van anti-malaria medikasies is 
grootliks deur militêre behoeftes gedryf.  Sedert die Tweede Wêreld Oorlog het die 
weerstandigheid van muskiete teen Chloroquine die soeke na nuwe antimalaria 
medikasie genoodsaak.  Mefloquine, ontwikkel deur die Walter Reed Navorsings 
Sentrum in die Verenigde State, het in die 1970’s bewys dat dit effektief is vir 
gebruik as profalaksis en behandeling van weerstandige falciparum malaria. 
 
Vraelyste is aan SANW soldate wat in Burundi, Oos Afrika, ontplooi is uitgedeel.  
Die grootte van die populasie was 336 lede en die finale moniterings groep was 
111 individue.  Die groep is deur middel van die eenvoudige lukrake metode 
gekies.  Die vraelyste het ten doel gehad om die persepsie van die gebruiker ten 
opsigte van die malaria bedreiging te toets, die gebruiker se onderworpenheid aan 
die gereelde gebruik van die medikasie te bepaal, potensiële newe effekte wat mag 
presenteer as gevolg van die gebruik van die chemoprofalaksis te indentifiseer en 
die effektiwiteit van Mefliam® te bepaal.  
 
 vi 
 
Die feit dat 111 persone Mefliam® gebruik het, en net vier persone malaria 
simptome getoon het, is ‘n goeie aanduiding dat Mefliam® ‘n ideale opsie is as 
antimalaria medikasie in Oos-Afrika en Burundi. 
 
Die resultate van hierdie studie sal beskikbaar wees vir die gebruik van personneel 
van die Suid Afrikaanse Nasionale Weermag (SANW) en ander magte wat in die 
toekoms in Burundi, Oos Afrika ontplooi kan word.  Die resultate kan deur ander 
weermagte gebruik word as kontrole programme en deur ander beleidmakers en 
gesagstrukture in die beheer van malaria.  Hierdie inligting sal ook van belang 
wees vir enige persoon wat die gebied besoek. 
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who instilled in me my love and passion for 
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We must be prepared to meet malaria by training as strict and earnest 
as that against enemy troops. We must be as practiced in our weapons 
against it as we are with a rifle. 
(Field Marshal Viscount Sir Archibald Wavell) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quemadmodum vivas, quandiu vivas 
As long as you live, keep learning how to live 
(Seneca) 
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DEFINITION OF TERMS 
 
Airport malaria: malaria caused by infected “jet–setting” mosquitoes that 
travel on international flights and spread the disease 
(Lusina, 2000:75-76). 
 
Services: different divisions within a national defence force, 
namely Army, Air Force, Navy and Military Health 
Services (Fourie, 2003:personal communication). 
   
Chemoprophylaxis: antimalarial drugs taken orally or intravenously to 
prevent malaria infection or used as a therapeutic 
medication to treat the symptoms of the disease, 
malaria (Maharaj, 2004:personal communication; 
Barnes, 2005:personal communication).   
 
Clinical testing: tests of antimalarial drugs on humans with induced 
malaria in a controlled environment (Hlolongwane, 
2002:personal communication; Maharaj, 2004:personal 
communication). 
 
Congenital: “present, belong to one” (Hornby, 1985:179). 
 
Essential medicines: Essential medicines are those drugs that satisfy the 
priority health care needs of the population.  They are 
selected with due regard to public health relevance, 
evidence on efficacy and safety and comparative cost-
effectiveness.  Essential medicines are intended to be 
available within the context of functioning health 
systems at all times in adequate amounts, in the 
appropriate dosage forms and with assured quality and 
adequate information at a price the individual and the 
community can afford (ACT: The way forward for 
treating malaria, 2001:1). 
 xviii 
 
Idiopathic: disease or condition without a cure (Hlolongwane, 2002: 
personal communication; Barnes, 2005:personal 
communication). 
 
Induced malaria: “malaria acquired through artificial means e.g. blood 
transfusion or of shared syringes” (Macarthur, Levin, 
Mungai, Roberts, Bloland, Kachur, Newman, Steketee 
and Parise, 2001:28). 
 
Monotherapies: a single drug used as a stand-alone treatment 
(Hlolongwane:personal communication, 2002; Maharaj: 
personal communication, 2004). 
 
Paroxysm: “sudden attack or outburst” (Hornby, 1985:611). 
 
Pathogenesis: “the production or development of a disease” (Brusher 
and Joers, 1997:CD ROM).  
 
Prophylaxis: “preventive treatment of disease” (Hornby, 1985:671). 
 
Relapsing Malaria:  “renewed manifestations (i.e. clinical symptoms and/or 
parasitemia) of malarial infection that are separated 
from previous manifestations of the same infection by 
an interval greater than the usual periodicity of the 
paroxysms” (MacArthur et al., 2001:28).  
 
Teratogenicity: “an agent as a chemical or disease that causes 
malformation of a fetus” (Brusher and Joers, 1997:CD 
ROM). 
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ABBREVIATIONS 
 
ACT:  Artemisinin-based Combination Therapies 
DDT:  Dichlorodiphenyltrichloroethane 
DEET:  Diethylmetatoluamide 
DoD:  Department of Defence  
DoD GEIS: The Global Emerging Infections Surveillance and 
 Response Systems 
EPI:  Expanded Programme on Immunisation  
EU:  European Union 
GIS:  Geographic Information Systems 
IDE: Intervention Development and Implementation Research  
ITN:  Insecticide-Treated Nets 
MAL: World Health Organisation Malaria Control Department  
MARA: Mapping Malaria Risk in Africa 
MIM:  Multilateral Initiative on Malaria   
MIT:  Intermittent treatment with antimalarials  
MMV:  Medicines for Malaria Venture (MMV 
MRU:  Medical Research Unit  
MR4: Malaria Research and Reference Reagent Resource Centre 
MSF:  Medecins Sans Frontieres 
NIAID: National Institute of Allergy and Infectious Diseases  
RBM: Roll Back Malaria 
SANDF:  South African National Defence Force   
SCAT:  Sub-Committee for Chemoprophylaxis and Therapy 
SN: The abbreviation for the Latin secundum naturam, which  
 means “According to Nature” 
STR:  The Basic and Strategic Research  
TB:  Tuberculosis 
TDR:  Programme for Research and Training in Tropical Diseases 
UNICEF:  United Nations Children’s Fund 
US:  United States of America 
USAMRU:  United States of America’s Medical Research Unit  
WHO:  World Health Organisation 
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WHOPES: WHO Pesticide Evaluation Scheme 
WR: Chemical Compounds that were designed by the WRAIR  
®:  Registered Brandname of a Product 
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CHAPTER 1 
1. THE PROBLEM AND ITS SETTING 
1.1 INTRODUCTION 
 
Malaria-bearing mosquitoes have hounded the military for decades.  Some 
instances were recorded in ancient Macedonia, where Alexander’s army was 
crippled by malaria.  In the 12th century malaria was known as “marsh fever” 
(Borza, 1987:1). 
 
When peacekeeping military forces are deployed, malaria represents one of the 
principal threats of infectious disease.  The majority of military personnel from 
developed countries are not immune to malaria, and are therefore potentially at risk 
of being infected and of contracting clinical malaria.  This is especially true for 
forces which are deployed on the African continent in countries with a high endemic 
status and where drug resistant malaria is widespread (Sanchez, Bendet, Grogl, 
Lima, Pang, Guimaraes, Guedes, Milhous, Green & Todd, 2000:275).  It is 
estimated that malaria was the major cause of mortality among British troops 
stationed in West Africa in 1940-1945, accounting for attack rates of 30 to 83 cases 
per 10 000 members per year (Sanchez et al., 2000:275-276). 
 
Long-term chemoprophylaxis issued to United States soldiers was found to be 
suboptimal.  Long-term chemoprophylaxis with Mefloquine (250 mg weekly), or 
Doxycycline (100 mg daily), of United States (US) soldiers deployed to Somalia for 
“Operation Restore Hope” in 1992-1993, was found to be inferior in a cross section 
assessment year.  In 1993, a total of 48 malaria cases was reported among these 
soldiers while in Somalia, mostly due to Plasmodium falciparum, and an additional 
79 cases were detected after the soldiers had returned home (Smart, Heppner, 
Magill, Gasser & Oster, 1993:889-890). 
 
Long-term chemoprophylaxis has also been found to be only 91% effective among 
United Nations peacekeeping forces deployed in Cambodia in 1993 (Hopperus 
Buma, Van Thiel & Lobel, 1996:1506). Alternative agents, such as Doxycycline 
taken daily, Chloroquine, or Proguanil (200 mg) prophylactics, used among French 
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soldiers in Gabon and the Central African Republic, have also been found not to be 
effective (Sanchez et al., 2000:275,277).  Failure of Mefloquine prophylactics due 
to poor compliance and/or substandard doses has been documented in Southeast 
Asia, East Africa, West Africa and more recently in Somalia (Sanchez et al., 
2000:275-276).  Malaria in soldiers has a serious economic impact in terms of loss 
due to reduction of productivity and treatment cost for the state (Robert, 2001:67-
73).  
 
Since November 2001, a contingent of South African National Defence Force 
(SANDF) members are deployed in Burundi, as part of a peace keeping mission.  
This operation is South Africa’s contribution to maintain peace in the country during 
the transition from the Tutsi to the Hutu-ruled democratic government.  Burundi is 
situated in Eastern Africa, three degrees south of the equator.  The country’s 
equatorial climate, with its annual rainfall of above 1200 mm, is conducive to the 
living and breeding of the Anopheles mosquito.  Plasmodium falciparum is the most 
common mosquito species found in eastern Africa and it is therefore responsible 
for most malaria infections (Miambu, Ndayiragiije, Le Bas & Chaperon, 1993:399-
401).  
 
Data for the study were collected from SA soldiers during their deployment in 
Burundi from February to July 2002.  As the Red Cross and United Nations offices 
in Bujumbura could provide only limited information regarding the effectiveness of 
Mefliam® among soldiers in Burundi and eastern Africa, it was deemed of vital 
importance to conduct this study. 
 
1.2 THE PROBLEM STATEMENT 
 
Mefloquine Hydrochloride- Mefliam® has been used for the treatment of malaria 
infection amongst military forces deployed in Burundi, East Africa.  However, the 
chemoprophylactic efficacy and usability of this drug have never been determined 
in that country. 
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1.3 THE IMPORTANCE OF THE STUDY 
 
The incidence of malaria causes concern in eastern Africa, as well as South Africa 
and many other areas in the world.  Current information on drug-resistant malaria in 
the tropical and subtropical regions of Africa is limited.  Although endemic malaria 
no longer occurs in many temperate zone countries and well-developed areas of 
tropical countries in Africa, the disease is still a major cause of ill health in many 
parts of the tropics and subtropics where socio-economic development is deficient.  
Current information on foci of drug-resistant malaria in the tropical and subtropical 
regions of Africa is insufficient and unreliable, and it is therefore necessary to 
establish the efficacy of Mefloquine Hydrochloride (brand name - Mefliam®) as a 
malaria resistant drug (Gasasira, Dorsey, Nzarubara, Staedke, Nassali, Rosenthal 
& Kamya, 2003:127-132; Kindermans, 2002:1).   
 
For South African soldiers deployed in a hostile, foreign country, it is important to 
be combat ready and alert at all times.  The working conditions, the location of the 
area, as well as the living conditions in open canvas tents are conducive to the 
malaria risk (Sub-Committee for Chemoprophylaxis and Therapy (SCAT) of the 
Malaria Advisory Committee, 2003:10-14).  
 
Drug resistant malaria has become one of the most important problems in malaria 
control.  In some situations, resistance in vivo has been reported for all antimalarial 
drugs, except for Artemisinin and its derivatives.  Cross-resistance exists among 
Mefloquine, Quinine and Chloroquine (World Health Organisation, 1993:18).  
Multidrug resistance necessitates the use of alternative drugs that may be 
expensive and difficult to administrate, and may often have side-effects (WHO, 
1993:22). 
 
The British Army policy for malaria chemoprophylaxis for military exercises in 
central Kenya recommended Chloroquine 300 mg weekly and Proguanil 200 mg 
daily.  This policy was reassessed following seven cases of malaria sustained 
among 150 soldiers during an exercise in 1992 (Miller, Byers, Whiteoak & Warrell, 
1994:119).  Although compliance with chemoprophylaxis was not directly assessed, 
the policy was changed to simplify the regimen to Mefloquine 250 mg weekly.  
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The British Army policy change was interesting, considering the experience of the 
Dutch military forces, who did not favour Mefloquine.  Three battalions (± 600 
troops per battalion) of Dutch marines using Mefloquine chemoprophylaxis suffered 
falciparum malaria infections during their deployment in Cambodia during 1992–
1993 (Hopperus Buma et al., 1996:1506-1509).  Although the Dutch were operating 
in areas of potential endemic Mefloquine-resistant falciparum malaria, compliance 
with medication was only 86%, and 30% of the marines reported adverse side-
effects to the drug (Hopperus Buma et al., 1996:1506-1509). 
 
More information regarding the use of Mefloquine under military operational 
conditions arose from military peace keeping operations in East Africa.  Between 
December 1992 and May 1993, 9000 US troops were deployed in Somalia, of 
which 48 were reported as casualties of malaria (Wallace, Sharp, Smoak, Iriye, 
Rozmajzl, Thornton, Batchelor, Magill, Lobel, Longer & Burans,1996:49-55).  A risk 
factor identified was non-compliance with chemoprophylaxis (Mefloquine).  
Mefloquine effectiveness in the region was not comprehensive, as five casualties 
diagnosed with malaria were found to have had suppressive serum Mefloquine 
levels.  One year after the commencement of the operation, the US military had 112 
cases of imported malaria (Newton, Schnepf, Kennedy, O'Hara, Wallace, Ohl, 
Oldfield, Sharp, Smoak, Defraites, Magill, Wellde, Klamerus & Longfield, 1993:1; 
Robert, 2001:69-76).  During interviews, more than half of these subjects reported 
compliance with chemoprophylaxis; however, half of the group interviewed had 
been prescribed inadequate doses of Mefloquine (Newton et al., 1993:1; Robert, 
2001:70-76). 
 
Members of the Italian military forces operating in Somalia were less infected.  The 
Italian army suffered only 18 casualties from malaria among 1600 soldiers 
deployed.  They used Chloroquine 300 mg weekly and Proguanil 200 mg daily 
(Peragallo, Sabatinelli and Majori, Cali & Sarnicola, 1997:343-346).  Compared with 
the British experience in Kenya, these were pleasing results (Miller et al., 1994:119-
123).  However, the combination of Chloroquine with Proguanil began to fail the 
Italian forces, as they sustained 100 malaria casualties in the first three months of 
1992 when 4800 peacekeepers were deployed to Mozambique.  They responded 
with a similar change in chemoprophylaxis policy to the British, employing 
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Mefloquine 250 mg weekly.  This contributed to limiting the subsequent malaria 
casualties to 19 in the last two months of the operation (Peragallo et al., 1997:343-
346).  A subsequent review of these two operations, collectively involving 5120 
Italian soldiers used Mefloquine chemoprophylaxis as an anti-malarial drug, found it 
easier to comply with.  It was not associated with a greater discontinuation rate 
than Chloroquine and Proguanil chemoprophylaxis (Peragallo, Sabatinelli & 
Sarnicola, 1999:73-77). 
 
Brazilian peacekeepers deployed in Angola used Mefloquine for malaria 
chemoprophylaxis.  Brazilian peacekeepers deployed to Angola for six months in 
1995 to 1996 used Mefloquine 250 mg weekly for malaria chemoprophylaxis 
(Sanchez et al., 2000:275,282).  Despite this regimen, 78 of the 439 personnel 
contracted clinical malaria.  An investigation was conducted in collaboration with 
US military health investigators.  The conclusion was that a more updated, more 
effective chemoprophylactic agent was required for military forces, despite the 
finding that poor and erratic compliance was the major risk factor for contracting 
malaria (Ohrt, Richie, Widjaja, Shanks, Fitriadi, Fryauff, Handschin, Tang, 
Sandjaja, Tjitra, Hadiarso, Watt & Wignall, 1997:963-965).  Results of a study in 
that regard would be used as a guideline in planning malaria management for 
future military forces. 
 
This begged the question whether a more efficacious chemoprophylactic drug for 
the prevention of malaria in Burundi, eastern Africa was needed.  This study aimed 
to shed a clearer perspective on the question.  
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CHAPTER 2 
2. REVIEW OF RELATED LITERATURE  
2.1 INTRODUCTION  
 
A mere bite from the Anopheles mosquito is where it all starts!  Malaria is a 
sickness caused by a malaria-carrying organism that enters the bloodstream.  
Malaria is a life-threatening disease responsible for killing over one million humans 
per year.  On average world-wide, over 300 million clinical cases of malaria are 
reported per year; this is five times more than Measles, Leprosy, Tuberculosis and 
Acquired Immune Deficiency Syndrome (AIDS) (Du Toit, 2003:23). 
 
In Africa the saying is that malaria is a sickness of poverty and a main reason for 
poverty.  Compared to healthy families, malaria affected families are able to yield 
only 40% of their harvest, signifying the link between malaria and poverty (Du Toit, 
2003:23-26).  The direct cost of the disease in Africa is estimated to exceed two 
billion US dollar per year.  It is believed that malaria could be controlled with a 
budget of a tenth of that amount (Du Toit, 2003:25). 
 
Minimising the risk of contracting the disease is possible.  Antimalarial prophylactic 
drugs fight the parasites in the red blood cells and prevent the spread of malaria in 
the human body.  However, it is important to take the recommended medication as 
prescribed and that the regimen is completed (Du Toit, 2003:23-24; Kouznetsov & 
Beales, 1996:32,38).  Failing to complete the course may leave an insufficient drug 
level in the blood, allowing parasites to multiply and causing the disease to develop 
(Du Toit, 2003:24; Kouznetsov & Beales, 1996:37-38).  
 
Malaria parasites have, however, become progressively more resistant to one drug 
after another (Du Toit, 2003:23-26; WHO, 1995:31).  Many insecticides are no 
longer effective against the mosquitoes that carry the disease-causing organisms 
(Du Toit, 2003:23,25; WHO, 1995:20-22).  Experience has shown that a thorough 
understanding of the malaria problem and risk, knowledge of the vector, the human 
host and the environment are prerequisites for effective planning and targeting of 
vector control interventions (WHO Technical Report, 1993:18). 
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2.2 WHAT IS MALARIA? 
 
Briggs (1998:41-42) explains that malaria is a potentially fatal parasitic disease 
transmitted by mosquitoes.  In the early days it was believed that mal aria (bad air) 
originated from fetid marshes.  In 1880 Plasmodium, a single cell parasite, was 
discovered by scientists who identified it as the real cause of malaria.  It was later 
discovered that the female Anopheles mosquito parasite is responsible for the 
transmission of the parasite from person to person through her bite (Briggs, 
1998:41-42; Gubler, 2001:1-5).  
  
Currently, roughly 40% of the world's population, mostly those from the poorest 
countries, are at risk of contracting the disease (What is Malaria, 2003:1).  Malaria 
was once more extensive internationally, but it was effectively eliminated from 
many regions during the middle of the 20th century.  Today malaria is found mainly 
throughout the tropical and sub-tropical areas (Curtis, 1996:1; What is Malaria, 
2003:1).  
 
There are four types of malaria found in humans.  The four types are Plasmodium 
vivax, P. malariae, P. ovale and P. falciparum.  Plasmodium vivax and P. 
falciparum are the most widespread and P. falciparum the most fatal type of 
malaria infection.  In Africa largely south of the Sahara, Plasmodium falciparum 
malaria is most common, accounting for the extremely high mortality on the 
continent.  There are concerned indications of the spread of P. falciparum malaria 
into new regions of the world and its reappearance in areas where it was eliminated 
some time ago (Benenson, 1990:267-269; Heymann, 2004:325-326).  According to 
Richard (1974:23), De Meillon established that, of the twenty Anopheles mosquito 
types, only two types, A. fenustus and A. gambiae, are malaria carriers. 
 
2.3 LIFE CYCLE AND SYMPTOMS 
 
The malaria parasite enters the human host when an infected Anopheles mosquito 
takes a blood meal.  Inside the human host, the parasite undergoes a series of 
changes as part of its complex life cycle.  The various stages allow plasmodia to 
evade the immune system, infect the liver and red blood cells and finally develop 
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into a form that is able to infect a mosquito again when it bites an infected person.  
Inside the mosquito, the parasite matures until it reaches the sexual stage where it 
can again infect a human host when the mosquito takes her next blood meal, 
usually between 10 to 14 days later (Leech, Sande & Root, 1988:287).  
 
Adams (2006:1) explains that once injected into the bloodstream, the malaria 
parasite travels through the blood circulation system until it reaches the liver, which 
it occupies.  Within the liver cells the parasite can dwell for weeks or even months.  
This is the silent period of the disease.  During this stage no symptoms are present 
and the liver cells are protecting the parasites from any antimalarial drugs the 
individual might be taking.  The parasites then start replicating, filling the invaded 
cells to bursting point with new individuals.  Ensuing release from the liver cells 
frees billions of the organisms into the blood.  Each parasite attacks a red blood 
cell, enters it and again replicates.   
 
Malaria symptoms appear approximately nine to 14 days after the infectious 
mosquito bite.  This varies with the different plasmodium species.  Typically, 
malaria produces fever, headache, vomiting and other flu-like symptoms.  If drugs 
are not available for treatment or the parasites are resistant to them, the infection 
can progress rapidly to become life threatening.  Malaria can kill by infecting and 
destroying red blood cells (anaemia) and by clogging the capillaries that carry blood 
to the brain (cerebral malaria) or other vital organs (Heelan & Ingersoll, 2002:125-
126).  Ruptured red blood cells, the oxygen delivering pigment of blood cells, also 
discharge haemoglobin into the plasma.  This is then broken down in the body to a 
compound called urobilinogen, which is released in the urine, and can without 
difficulty be detected by a dipstick urine test (LaMar, 2000:51-52).  The damage 
and invasion of red cells can be substantial.  As blood filters of the body, the 
kidneys may be challenged with an unexpected surge of cellular debris, which 
blocks and harms the kidney’s vascular and tubular system.  Kidney failure may 
occur.  The clustered platelets and debris may congest and block the capillary 
networks in the brain, leading to cerebral malaria with convulsions, confusion, coma 
and even resulting in death (LaMar, 2000:52,56).  
Until now the reproduction of the parasites has been asexual.  Each organism 
simply divided and replicated itself exponentially during the attack of the red blood 
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cells.  For the infection to spread to other individuals, a sexual phase is required.  A 
number of parasites now change into males and females.  When a different 
Anopheles mosquito bites an infected person and drinks the blood filled with 
parasites, the male and female parasites merge within the mosquito.  The asexual 
form of the parasite dies.  After the merger, a cyst develops within which large 
numbers of new parasites develop, which then pass through to the mosquito’s 
salivary glands, creating the environment for the additional spreading of malaria 
(Perlin & Cohen, 2002:11; Sub-Committee for Chemoprophylaxis and Therapy 
(SCAT) of the Malaria Advisory Committee, 2003:8-9). 
 
Humans must be cautious of any flu-like symptoms.  If any influenza-like illness or 
fever occurs within one week of entering, or six months from leaving a malaria 
area, a medical practitioner must be informed regarding the exposure to the 
disease.  A blood test must then be done.  A fatal misdiagnosis can be avoided and 
the symptoms must be regarded as possible malaria until proven otherwise.  It can 
present as a sore throat, headache, body aches, fatigue or nausea and diarrhoea 
and then deteriorate with rapidity into serious illness.  The presence of anaemia, a 
low platelet count and increased amounts of urobilinogen in the urine during a urine 
test must make a person even more suspicious of malaria (LaMar, 2000:55; Perlin 
& Cohen, 2002:23). 
 
Positive identification of malaria sometimes requires repeated blood testing.  
During an attack of fever and rigors, the parasites are often seen within red blood 
cells on a blood smear under a microscope.  The microscopic absence of visible 
parasites does not exclude the presence of the disease (Perlin & Cohen, 2002:23).  
Very sensitive antibody tests are also available and these may need to be repeated 
up to four times, as it often takes time for antibodies to reach detectable levels 
(Perlin & Cohen, 2002:23; SCAT, 2003:8-9).  
 
Although scientists are intensifying the search for malaria control, an effective 
vaccine has still not been found (What is Malaria, 2003:1).  Science still has no 
magic answer for malaria, and many doubt that a single solution will ever exist.  
Nevertheless, effective low-cost strategies are available for its treatment, 
prevention and control, and the Roll Back Malaria (RBM) global partnership is 
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promoting these strategies in Africa and other malaria-endemic regions of the 
world.   
Figure 2.1: The simplified life cycle of the Plasmodium parasites infecting humans, 
as illustrated by Kitchener (2003:36). 
 
2.4  EPIDEMIC PREDICTION AND RESPONSE 
 
Epidemics occur when malaria attacks populations with little or no immunity.  In 
situations like these, people of all age groups are at risk of severe illness or death.  
Epidemics of Plasmodium falciparum malaria, the most severe form of malaria, can 
be devastating if not controlled.  The populations that are mostly at risk of malaria 
are those people living in highlands, arid and desert-fringe zones, as well as those 
staying in areas where successful control measures have not been properly 
managed and maintained (De Savigny & Binka, 2004:225-227; Epidemic Prediction 
and Response, 2001:1).  Factors that may stimulate a malaria epidemic are divided 
into two categories namely  
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• natural (climatic changes, natural disasters); and 
• man-made (conflicts and wars, agricultural projects, dams, mining, logging and 
failure to apply control measures) (Epidemic Prediction and Response, 2001:1; 
SCAT, 2003:11): 
 
These factors make the breeding and living environment of the mosquitoes more 
suitable to transmit malaria.  Factors such as human conflicts, as in Burundi, 
produce massive population movements that expose non-immune populations to 
the malaria parasite (Epidemic Prediction and Response, 2001:1; Grover-Kopec, 
Kawano, Klaver, Blumenthal, Ceccato & Connor, 2005:1).  
 
Malaria epidemics usually occur in populations not normally exposed to malaria.  It 
also occurs in populations that are, due to the climatic conditions of the specific 
region, only exposed for a short period of the year (Epidemic Prediction and 
Response, 2001:1; Grover-Kopec et al., 2005:1).  Local health officials are not able 
to predict, detect or control such epidemics in time, resulting in severe outbreaks 
and high mortality rates.  When control measures are eventually taken, they are 
often too late (Epidemic Prediction and Response, 2001:1; Grover-Kopec et al., 
2005:1).   
 
The outbreak of malaria is predictable to a large extent.  Prediction is based on a 
combination of socio-economic, meteorological information and local 
epidemiological knowledge.  Epidemics caused by man can be predicted and 
anticipated with considerable precision, for example during development projects 
such as irrigation projects, and the construction of fish ponds and dams.  
Multidisciplinary actions at the planning stages can help prevent such epidemics 
from occurring (Epidemic Prediction and Response, 2001:1).  In contrast, it is 
difficult to anticipate a malaria epidemic arising from natural causes.  However, 
such epidemics tend to reoccur, and it is important to learn from past experiences.  
The World Health Organisation (WHO) has supported retrospective analysis of 
malaria epidemics in several African countries.  The finding builds evidence for 
practical guidelines on malaria epidemic prevention and control and early detection 
of such epidemics in Africa (Epidemic Prediction and Response, 2001:1; WHO, 
1995:29-30).   
 12 
 
Forecasting and early warning of possible future epidemics can reinforce local 
preparedness.  Forecasting and early warning can also allow authorities and 
communities to use cost effective and emergency control plans to prevent 
excessive mortality rates (Epidemic Prediction and Response, 2001:1).    
 
2.5 TRANSMISSION AND PATHOGENESIS 
 
The Anopheles mosquito is the primary vector for malaria.  Heelan and Ingersoll 
(2002:118) state that the number and species of mosquitoes present in an area, as 
well as the climate and geography, determines the risk of being infected.  In many 
malaria endemic countries, transmission coincides with the wet season when there 
is increased agricultural activity and mosquitoes thrive.  Movement of people 
caused by political instability, deforestation and irrigation, climatic events and 
environmental changes brought on by urbanisation have all contributed to the 
increased prevalence of malaria.  An increase in international travel has raised the 
incidence of imported cases of malaria and brought about the phenomenon of 
“airport malaria” (Heelan & Ingersoll, 2002:121; SCAT, 2003:10).  Due to this 
phenomenon, international airport workers at no apparent risk have contracted 
malaria from the bite of an imported infected mosquito.  Benenson (1990:263) and 
Heymann (2004:326) report cases where patients became infected following a 
blood transfusion, after sharing contaminated hypodermic needles or through 
congenital transmission. 
 
Untreated Plasmodium vivax attacks may last for weeks and relapses are common.  
Heelan and Ingersoll (2002:120) articulate in their study that untreated Plasmodium 
vivax attacks may last three weeks to two months; relapses are common and may 
persist for five to eight years.  The first attack of Plasmodium ovale lasts from two 
to three weeks and often ends with spontaneous recovery.  Relapse is possible, 
but seldom occurs after one year.  Initial infection with Plasmodium falciparum lasts 
from three weeks to as long as twenty-four weeks.  The patient may recover 
completely or maintain a low-grade parasitemia, which results in a series of 
reoccurrences over the next two decades.  An untreated case of Plasmodium 
falciparum normally has a duration of two to three weeks, but may be marked by a 
variety of complications such as a coma or even death. Reoccurrence may occur, 
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but is seldom seen after a year.  Complications of malarial infection, particularly 
Plasmodium falciparum, are in general caused by the blocking of capillaries by cell 
debris and/or parasitised red blood cells.     In the case where the central nervous 
system is affected, it may cause cortical blindness, severe headaches, strokes and 
eventually death.  Renal complications may also be life threatening if left untreated. 
(Heelan & Ingersoll, 2002:125-126; Heymann, 2004:336).  Certain genetic 
conditions occur that cause changes to the red blood cells, resulting in some 
degree of natural immunity against malaria (Benenson, 1990:262-263). 
 
2.6  INTERNATIONAL MANAGEMENT OF MALARIA  
         INFECTION 
2.6.1 The role of the World Health Organisation (WHO) and other  
            international organisations 
 
Malaria was declared a global priority.  The worsening malaria situation in many 
parts of the world led the World Health Assembly, in resolution WHA 42.30 (1989), 
to declare malaria control a global priority and to request the Director General of 
the WHO to put in all possible efforts to mobilise appropriate human, scientific and 
financial resources to this end.  They agreed to improve the use of existing 
resources to make malaria control an essential component of health and national 
development and to involve communities as partners in control (WHO Technical 
Report, 1993:2-3).  In its support for collaborative studies on how best to assist 
malaria control programmes in planning and funding control projects, the WHO has 
emphasised the need to evaluate the susceptibility of P. falciparum to operationally 
use drugs and to determine the efficacy and safety of alternative therapeutic 
regiments as a basis for developing national policies on antimalarial drugs (World 
Health Organisation, 1992:87-88). 
 
The International Federation of Red Cross and Red Crescent Societies is the 
largest global humanitarian organisation.  This international organisation has an 
extensive network in 178 countries.  Red Cross and Red Crescent volunteers are in 
the forefront in efforts to manage and eradicate malaria.  With more than 100 
million volunteers internationally (including two million in Africa), the Red Cross and 
Red Crescent are able to reach the individuals most vulnerable to malaria.  
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Furthermore, the African Red Cross and Red Crescent Health Initiative 2010, 
involving epidemiological experts, national societies, government ministries of 
health, the WHO and other international agencies, combine all the major role-
players in the fight against malaria to guarantee a synchronised and cohesive 
endeavour (Health and Community Care, 2003:1). 
 
2.7 THE INCIDENCE OF MALARIA IN AFRICA 
 
Malaria epidemics in Africa are caused by certain primary factors.  These factors 
include rapidly spreading resistance to antimalarial drugs, climatic changes and 
population movements (Nchinda, 1998:398; SCAT, 2003:11). 
 
According to the latest statistics available in the media in November 2006, malaria 
was ranked third among major infectious disease threats in Africa after 
pneumococcal acute respiratory infections and TB (Medilinks, 2006:1; Nchinda, 
1998:398).  Malaria cases in Africa account for approximately 90% of malaria 
cases in the world.  Between 1994 and 1996, malaria outbreaks in 14 countries of 
sub-Saharan Africa caused an unacceptably high number of deaths, many in 
regions previously free of the disease.  Adolescents and young adults are now 
dying of severe forms of malaria (Nchinda, 1998:398).  Factors favouring the 
spread of malaria include:  
• resistance of parasite to drugs; 
• conflicts forcing mass migration of people to or from infected areas;  
• migration of non-immune people to infected areas for agricultural reasons, 
and 
• changing rainfall patterns favouring mosquito breeding sites (Grover-Kopec et 
al. 2005:1; Medilinks, 2006:1; Nchinda, 1998:398).  
 
In 1999 malaria was Africa's leading cause of under-five mortality (20%) and 
constituted approximately 10% of the continent's overall disease burden.  It 
accounted for 40% of public health expenditure, 30-50% of inpatient admissions 
and up to 50% of outpatient visits in areas with high malaria transmission (The 
World Health Report, 1999:52). 
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There is a variety of reasons why the African continent bears an overwhelming 
share of the malaria burden internationally.  The biggest percentage of malaria 
cases in Africa south of the Sahara is due to the P. falciparum organism, the most 
critical and acute form of the disease.  This part of the continent is where the most 
efficient, and therefore fatal, species of the mosquitoes that transmit malaria is 
found.  In addition, most of the countries on the African continent do not have the 
infrastructure and assets necessary to organise sustainable programmes against 
the disease (Africa Malaria Report, 2003:1; Malaria in Africa, 2001:1). 
 
Internationally malaria has huge economic influence on people and regional 
business.  Annual economic growth in countries with high malaria transmission has 
historically been lower than in countries without malaria.  Economists believe that 
malaria is responsible for a growth penalty of up to 1,3 percent per year in some 
countries on the African continent (Health and Community Care, 2003:1; Sachs & 
Malaney, 2002:680-685; World Malaria Report, 2005:1). 
 
When compounded over the years, this penalty leads to substantial differences in 
Gross Domestic Product (GDP) between countries with and without malaria and 
severely restrains the economic growth of the entire region.  Malaria also has a 
direct impact on Africa's human resources.  Not only does malaria result in loss of 
life and lost productivity due to illness and premature death, but malaria also 
hampers children's schooling and social development through both absenteeism 
and permanent neurological and other damage associated with severe episodes of 
the disease (Health and Community Care, 2003:1; Hotez, Molyneux, Fenwick, 
Otteson, Sachs & Sachs, 2006:1; The World Health Report, 1999:59-60).  
 
One of the primary challenges in the fight against malaria is drug resistance.  
Throughout Africa (particularly in the southern and eastern parts of the continent) 
resistance to Chloroquine, the cheapest and most widely used antimalarial, is 
common.  In eastern and southern Africa the resistance to Sulfadoxine-
Pyrimethamine (SP), often seen as the first and least expensive alternative to 
Chloroquine, is also increasing.  As a result, many countries have to change their 
current treatment policies and use drugs that are more expensive, including the 
combination of drugs, which will hopefully slow down the development of 
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antimalarial drug resistance (Huff, 2003:1; Malaria in Africa, 2001:1; Shepard, 
Ettling, Brinkmann  & Sauerborn, 1997:1-3).  
 
Political commitment by African leaders for action on malaria was given a boost.  
This was initiated by the founding of the Roll Back Malaria (RBM) global 
partnership in 1998.  During 2000 African heads of state and their representatives 
met in Abuja, Nigeria, to translate RBM’s goal of halving the malaria burden by 
2010 into solid political action.  The Abuja Declaration, signed in April 2000, 
endorsed a strategy to tackle the problem of malaria across the African continent 
(Health and Community Care, 2003:1; Malaria in Africa, 2001:1).   
 
Progress made since Abuja includes reduction or elimination of taxes and tariffs on 
insecticide-treated nets (ITNs), promoting their use.  The Country Strategic Plans 
(CSPs) were established by more than half of the malaria-endemic African 
countries, representing almost half the population at risk, to achieve the RBM goal 
and the targets set in Abuja.  Country Strategic Plans are all based on the four 
technical elements of RBM and the management thereof.  They are prompt access 
to effective treatment, promotion of ITNs and improved vector control and 
prevention and management of malaria in pregnancy.  These elements aim to 
improve the prevention of and response to malaria epidemics and malaria in 
complex emergencies (Malaria in Africa, 2001:1; Epidemic Prediction and 
Response, 2001:1).  
 
Local partnerships around the world are working together to develop their 
resources to implement their CSPs using continuous health sector reforms.  
Interaction between other initiatives such as Integrated Management of Childhood 
Illness (IMCI) and Making Pregnancy Safer (MPS) is used to improve access to key 
interventions.  Country Strategic Plans have been successful in developing new 
strategies for malaria control.  However, considering the resources needed until 
2010, only 20% of the required funds will be made available by the local 
governments.  International countries are looking to a selection of sources to 
ensure sustainable financing of their efforts.  These include funding from the 
national treasury and donors, as well as the exploration of new opportunities 
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through debt relief schemes and the newly formed Global Fund to fight AIDS, TB 
and Malaria (Huff, 2003:1; Malaria in Africa, 2001:1).   
 
2.8 MALARIA AND CONFLICT IN AFRICA 
 
In 2003, 90% of all malaria mortalities occurred in Africa, south of the Sahara.  In 
the order of 30% of Africa's malaria fatalities are found in countries experiencing 
acute, chronic or post-conflict complex emergency situations.  It is estimated that 
over 200 million people in Africa are living in countries either directly or indirectly 
affected by complex emergencies (RBM and Complex Emergencies, 2004:1).   
                                                                                                                                                                                                                                                                      
“Malaria deaths during complex emergencies usually far exceed those caused by 
the conflict at the root of the emergency itself” (RBM and Complex Emergencies, 
2004:1).  The chaos that follows war or civil unrest can destroy health systems, cut 
food supplies and expose people to multiple infections.  Insecurity and poor living 
conditions in temporary camps and war-affected towns increase both people’s 
vulnerability to disease and the chances of vector and waterborne disease 
transmission.  The collapse of medical infrastructure and facilities makes it difficult 
to address even basic health care needs (Africa Malaria Report, 2003:1; RBM and 
Complex Emergencies, 2004:1).  
 
Implementing partners, mainly Non-Governmental Organisations (NGOs), UN 
agencies and the donor community are helping to select and implement best 
practices according to WHO guidelines and standards.  Technical support is 
provided to enhance partner capacity to respond quickly and effectively to 
emergency situations (Epidemic Prediction and Response, 2001:1; WHO, 1999:55-
60). 
  
2.9 INCIDENCE OF MALARIA IN BURUNDI AND 
NEIGHBOURING COUNTRIES 
 
 “Malaria is now even affecting the highland areas of Burundi” (February 2003).   
According to a human rights organisation operating in Burundi, the number of 
 18 
 
malaria cases increased from 200 000 in 1984 to 3 million in 2002 (International 
Activity Report, 2002:1; Malaria: the leading cause of death in Burundi, 2003:1).  
"Malaria, which for years plagued only the low-lying parts of Burundi, has now 
surfaced in the highlands, and constitutes the leading cause of death in the 
country”, said health officials (Malaria: the leading cause of death in Burundi, 
2003:1). 
 
A spokesperson from Iteka, a Burundi human rights organisation, said that malaria 
patients accounted for 50 percent of individuals seeking medical care and 
assistance.  Between 30 and 50 percent of patients admitted to hospital was 
suffering from malaria (Malaria: the leading cause of death in Burundi, 2003:1).  
Iteka quoted the leader of the national project to fight vitamin deficiencies, Dr 
Ndaruhutse, as saying malaria was impeding development, because those struck 
down by it spent long periods away from their workplaces.  Iteka said that the worst 
affected parts in the country were Gitega and Ngozi, according to the statistics for 
2002-2003 (Malaria: the leading cause of death in Burundi, 2003:1). 
 
However, Iteka stated that the battle against malaria in Burundi was won, by means 
of the drug, Co-artem.  Iteka recalled, however, that when it had first been 
introduced into the market, there had been some resistance by the general public 
due to its high price, and it had not been approved by the health ministry in Burundi 
(Malaria: the leading cause of death in Burundi, 2003:1).  Iteka quoted the Director 
General of the health ministry, Dr Rirangira, as saying that the ministries of 
agriculture and livestock, education, environment, public health, interior, as well as 
NGOs, all needed to be involved in the effort to triumph over the disease.  Since 
November 2002 an increase of malaria cases, especially in the provinces of Ngozi 
and Gitega has occurred.  In Ngozi the number of malaria patients quickly rose 
from 16 000 in September to 34 000 in November, and over 48 000 in December 
2002 (Malaria: the leading cause of death in Burundi, 2003:1).  
 
The highland populations had little or no acquired immunity, making them 
extremely susceptible to the disease.  The drug policy change adopted by the 
Burundi government in 2003 has proven to be a success.  With funding from the 
European Commission’s Humanitarian Aid Office (ECHO), and technical 
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assistance from UNICEF, the government of Burundi is hopeful that malaria can be 
controlled (Menon-Broker, 2005:1).  Control of the disease includes both prevention 
and treatment.  Prevention and the use of insecticide-treated bed nets remain 
priorities (Menon-Broker, 2005:1). 
 
New drug therapies are a key element of the rolling back malaria plan.  According 
to an ECHO representative, studies proved that the new generation drugs – the 
Artemisinin Combination treatment (ACTs) – are more effective (Menon-Broker, 
2005:1).  In Burundi, the state is subsidizing the cost of the new drugs and UNICEF 
is also working to increase the supply of the safe, effective and affordable ACTs, 
spending 1.6 million US dollars in 2002 for this purpose (Menon-Broker, 2005:1).  
 
The United States of America’s Medical Research Unit (USAMRU) in Kenya, East 
Africa, is a special foreign unit.  This unit is a satellite of the Walter Reed Army 
Institute of Research (WRAIR).  USAMRU is affiliated with the Kenya Medical 
Research Institute (KEMRI).  It was established on a temporary basis in 1969 at the 
invitation of the government of Kenya to study trypanosomiasis.  The success of 
this venture led to the establishment of a permanent unit in 1973.  During that time 
research was intensively conducted on malaria in the central and eastern parts of 
Africa (United States Army Medical Research Unit – Kenya. 2003:1).    
 
USAMRU in Kenya comprises of three main facilities.  These facilities include a 
central laboratory in Nairobi and field laboratories at Kisian, on Lake Victoria, in 
western Kenya, and at Kericho, in the tea plantations of the highlands.  The Nairobi 
facility is situated within the KEMRI main campus.  Situated on the same premises 
are the Center of Disease Control and Prevention (CDC), the Japanese 
International Cooperative Agency (JICA) and the Wellcome Trust.  Capabilities of 
these units include malaria and leishmanial parasite culture and in vitro malaria and 
enteric drug sensitivity testing (United States Army Medical Research Unit – Kenya, 
2003:1). 
 
Field testing of malaria drugs and vaccines is done routinely.  Large-scale 
epidemiological studies on malaria are also done throughout the year.  Infectious 
disease activities include extensive regional monitoring for drug resistance in 
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malaria.  Accomplishments over the past include the establishment of the first in 
vitro malaria drug sensitivity laboratory in equatorial Africa and the investigations of 
high altitude and urban malaria in Africa (United States Army Medical Research 
Unit – Kenya. 2003:1). 
 
2.10 MALARIA AND INTERNATIONAL MILITARY  
         FORCES 
2.10.1 The army’s war against malaria: partnership in drug research since 
World War II  
 
Malaria crippled allied forces in the early stages of World War II.  The disease 
produced one and a half million American casualties during that time and 
influenced the capabilities of American-friendly forces as well.  By January 1943, 
malaria had, on average, infected every allied service member deployed in the 
southwest Pacific four times.  These conditions made the control and treatment of 
malaria an urgent priority of the US Army’s medical establishment (Bennett, 
2006:1-4). 
 
US Army members suffered from several types of malaria.  Plasmodium vivax and 
P. falciparum were the most common.  Bouts of chills, fever and sweating caused 
soldiers to be out of action for a week or longer (Bennett, 2006:3-5; Hart & 
Hardenberg, 1963:531).  Plasmodium vivax debilitates its victims, making them 
liable to secondary infections that could be fatal.  This type of malaria was not a 
primary cause of death among these soldiers.  It was Falciparum malaria that, if left 
untreated, could lead to death.  The most pressing question for the United States 
Army was therefore the development of a prophylactic drug or a cure for malaria 
(Bennett, 2006:37-39; Hart & Hardenberg, 1963:531). 
 
During World War II, military and civilian scientists assisted the armed forces in 
combating malaria.  These alliances produced a number of malaria studies and 
numerous new or improved remedies, some of which tested superior to traditional 
antimalarial drugs.  These co-operative efforts improved chemotherapy for the 
prevention and treatment of malaria after years of neglect in the development of 
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prophylactic drugs (Bennett, 2006:29-39).  Between World War I and World War II, 
the Malaria Commission of the League of Nations and the International Health 
Division of the Rockefeller Foundation undertook antimalarial campaigns.  These 
organisations acquired knowledge and skills that would later benefit the military.  
The Malarial Commission regarded antimalarial drugs as the main line of defence 
against malaria, whereas the Rockefeller Foundation, which soon came to 
dominate the war on malaria, favoured destroying the Anopheles mosquito which 
transmitted the illness.  The World War II programme involved both approaches, 
but it soon became apparent that the attempts to control malaria through the killing 
of the Anopheles mosquito were probably hopeless during combat situations.  
Thus, the main attack on malaria had to come through the development of drugs 
(Harrison, 1978:183-186).  War stimulated the scientific community to create 
organisations to help the armed forces control malaria (Harrison, 1978:186). 
 
During the first years of the war, research concentrated on the search for more 
effective antimalarial prophylaxis.  Scientific trials with Atabrine, a German synthetic 
drug which became the preferred operational drug after Japan had cut off the 
source of Quinine (an alkaloid of cinchona bark), were conducted.  No better 
antimalarial drug had been found by April 1943, but scientists had proved that 
Atabrine had the pharmaceutical properties that could prevent and cure falciparum 
malaria and that the drug was immeasurably superior to Quinine.  Military forces 
worldwide quickly adopted Atabrine that had the clinical trails, improved regimens 
of therapy and suppression.  Scientists in the Second World War were stimulated 
to obtain more information in a single year about Atabrine than had been published 
in the media in the decade before the war (Bennett, 2006:9-10; Condon-Rall, 
1994:2).  
 
The scientific community intensified their research when no drugs, including 
Atabrine, were found to cure of vivax malaria.  Controlled military operational field 
studies and studies within military hospitals would partly solve this challenge.  A 
board comprising military and civilian members was establishment to provide close 
association and cooperation between military field trials and civilian laboratories.  
By doing this, the second challenge would be solved (Condon-Rall, 1994:2; 
Sweeney, Blackburn & Rieckmann, 2004:187-189). 
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The Board for the Co-ordination of Malarial Studies recommended limited trials in 
keeping with protocol when advances in chemotherapy warranted clinical testing 
(tests of antimalarial drugs on humans with induced malaria in a controlled 
environment such as a clinic or medical institution).  The board also proposed to 
the scientists involved to conduct operational field tests on humans in malaria 
regions without malarial drugs passed during clinical trials.  Although Atabrine, 
when properly administrated, could suppress malaria and actually cure falciparum 
malaria, military senior management was concerned about returning soldiers 
infected with vivax malaria which could not be cured by Atabrine.  As soon as these 
soldiers returned home, they would develop full-blown symptoms of malaria after 
they had stopped taking their daily dosages of antimalarial drugs (Bennett, 2006:9-
18; Condon-Rall, 1994:3). 
 
In 1944 military and civilian research became more integrated.  In February 1944 
the Surgeon General of the US Army assigned 12 military doctors to civilian 
research centres to investigate and do laboratory experiments on malaria.  The 
army could now focus on the research of new drugs.  This was possible, because 
operational experience had proven the efficacy of Atabrine for routine suppression 
and treatment.  Malaria was only considered a problem when soldiers became lax 
about taking the Atabrine prophylaxis and the wearing of protective clothing 
(Bennett, 2006:11-33).  
 
During the first half of the Second World War, experiments on malaria parasites 
were done by civilian laboratories using more than 600 new drugs. These 
compounds were used in clinical testing for trials on humans.  From the middle of 
the war to June 1946 another 8000 new drugs were produced by affiliated drug 
companies (Condon-Rall, 1994:3-4; Sweeney, Blackburn & Rieckmann, 2004:187-
189). 
Scientists also tried a second approach, looking for a curative agent that had 
different chemotherapeutic characteristics than Atabrine and Quinine (Condon-Rall, 
1994:1-9).  The new suppressive compounds were a member of a pharmacological 
chain, named the 4-aminoquinolines, which were closely interrelated to Plasmocin 
(a tradename for Pamaquine, a slightly toxic antimalarial) (Condon-Rall, 1994:4-5; 
Russell, 1963:1-7).  Researchers screened approximately 200 of these drugs for 
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antimalarial properties.  More or less ten of these drugs were tested on human 
beings.  Two of these drugs (SN-6911 and SN-7618) that were German synthetic 
drugs, were researched more extensively.  By June of 1944, Bisulphate had 
undergone clinical testing in military and public health services and passed the 
compulsory research investigation.  The drug’s antimalarial activities were 
compared quantitatively with a standard antimalarial drug such as Quinine, 
Atabrine or Plasmocin (Condon-Rall, 1994:4; Elslager, Tendick & Werbel, 1948:93-
95).  
 
Another potentially suppressive antimalarial drug was Chloroquine.  After a long-
term chronic toxicity study performed on volunteers, scientists compared the 
effectiveness, toxicity and administrative advantages of weekly or biweekly 
dosages against the required daily doses of Atabrine (Condon-Rall, 1994:3-4; 
Russell, 1963: 4-10).  By April of 1945 the operational trials with Atabrine were 
completed, and the army and navy’s feedback was that of little toxicity and more 
rapid disappearance of fever and parasitemia.  In addition, the clinical management 
of an acute malaria attack with Chloroquine resulted in a longer period between 
relapses than with Atabrine compound drugs.  Brigadier Fairley, Director of 
Medicine for the Australian Army Medical Corps and a noted malariologist, 
forwarded similar data from Australia and added that Chloroquine as well as 
Atabrine cured and suppressed falciparum malaria.   
 
The US Military Medical Services continued to investigate promising antimalarial 
drugs after Japan had surrendered in September 1945.  Researchers conducted 
clinical trials of Chloroquine in the Philippines, India and in US Military hospitals.  
The Army School of Malariology was founded in 1944 to provide field studies and 
training under tropical conditions (Mullins, 1974:178-193).  During its trials with 
Bisulphate, Chloroquine and Oxychloroquine, the US Navy found that all of the 
experimental compounds were less toxic than Atabrine (Condon-Rall, 1994:4-6; 
Shannon, Earle, Brodie, Taggart and Berliner, 1944:307−330).  In 1946, after 
World War II, medical researchers and scientists agreed on the superiority of 
Chloroquine over Atabrine.  The administration of the former drug once weekly had 
positive results in effective suppression.  As compared to the usual five to seven 
day treatment with Atabrine, it caused an immediate termination of the clinical 
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symptoms of vivax malaria between 24 to 48 hours.  The same regimen also cured 
falciparum malaria when consumed for one or two days.  Furthermore, it did not 
cause any gastrointestinal disturbances or skin stains.  After various analyses of 
Bisulphate and Oxychloroquine, scientists made similar claims regarding these 
compounds (Condon-Rall, 1994:4-6; Elslager et al., 1948:94-97). 
  
Scientists studied another series of suppressive compounds, the Quinoline 
methanols.  This chemical was closely related to Quinine in animals, but they never 
reached the stage of testing it on humans.  Some new curative compounds in a 
series called 8-aminoquinolines, that were related to the British drug, Pamaquine, 
were tested in prisons before the war, but not in military deployed installations 
(Russell, 1963:4-10; Shannon, 1946:712-716). 
 
Although smaller and less organised than the American and Australian 
programmes, the British research efforts were impressive.  Scientists in England 
studied the clinical characteristics of malaria and conducted curative trials on the 
British Isles and West Africa, comparing Plasmocin which they called Pamaquine 
with Quinine and Atabrine (which the British called Mepacrine).  The final 
conclusion by the study group was that Plasmocin reduced relapse rates (Condon-
Rall, 1994:5; Jones, Craige, Alving, Whorton, Pullman & Eichelberger, 1948:6-9).  
 
The American government made a request to the research groups not to reveal the 
composition of this drug to commercial companies (Condon-Rall, 1994:5-7).  In 
1942 the new drug Penicillin, which had been discovered by a British company was 
patented by American manufacturers due to the fact that British companies 
seemed uninterested in the patent.  In fact Florey appealed to American 
manufacturers to get involved, since it was against ethical medical principles for 
British companies to patent medical research results for profit (Condon-Rall, 
1994:5-7). 
 
Before the Board for the Co-ordination of Malarial Studies was finally adjourned, 
they suggested the prompt publication of information on Chloroquine.  Chloroquine 
had proven superior to Quinine and Atabrine.  The Board also published 
informative literature advising the public and military community regarding dosage 
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schedules and therapeutic use of Atabrine and Chloroquine for returning soldiers.  
In October 1947, the British military adopted Chloroquine as the drug of choice for 
malaria suppression and treatment as recommended by the Board.  
 
The research and collaboration worldwide to fight malaria that was stimulated by 
World War II advanced our knowledge of the disease and our ability to prevent and 
control it.  This collaboration enhanced the therapeutic management of malaria by 
the development of new drugs that proved superior to Atabrine (Condon-Rall, 
1994:7-9; Jones et al., 1948:8-11). 
 
The armed forces were satisfied with the results, although no cure was found.  
Years of neglect in the development of antimalarial drugs had now given way to the 
development of favourable new drugs and better management of the disease 
(Condon-Rall, 1994:7-9). 
 
2.10.2   Malaria in the armed forces of Thailand 
 
Malaria was a significant threat to the military forces of Thailand (RTA).  The 
highest threats occurred on Thailand’s Burmese and Cambodian borders.  With the 
RTA units that deployed to the Tak province in 1995, one out of four patients seen 
by the medical personnel monthly suffered from malaria.  Due to ever increasing 
drug resistances, sustained research and development of more effective drugs, 
vaccines and repellents were required (Malaria is a Significant Military Threat, 
1999:1; Saito, 1998:3). 
 
Saito (1998:3) of the Cambodia Daily reported that malaria sickened 60 % of 
military patients in the Thai Defence Force.  Approximately 60 % of in-patients at 
military health centres are suffered from the disease, according to a report from the 
health department of the Ministry of Defence in Thailand (Saito, 1998:3). 
 
According to the annual review of the Ministry of Defence, malaria was one of the 
highest causes of death of all government soldiers in 1997 (Saito, 1998:3).  
Officials from the National Malaria Centre in Thailand said that a lack of malaria 
 26 
 
medicine and bed nets, combined with inadequate medical knowledge concerning 
treatment of the disease, contributed to the high statistics (Saito, 1998:3).  
 
A total of 11 142 confirmed cases of malaria was reported in 1996 and 19 166 
confirmed cases were reported in military hospitals in 1997.  Of the confirmed 
cases in 1997, 284 people died (Saito, 1998:3).  The report also attributed the high 
incidence of malaria to the increased movement of military forces in areas of high 
malaria transmission.  Military operations along the Thai borders exposed military 
members to some of the world’s most drug resistant strains of malaria (Huff, 
2003:1; Saito, 1998:3).  
 
Some strains of malaria in the north-western regions of Cambodia were found to be 
resistant to Chloroquine and Mefloquine.  Malaria statistics from the National 
Malaria Centre in Thailand has increased by 60% from 1996 to 1998 (Bussaratid, 
Wilairatana, Krudsood, Silachamroon, Walsh and Looareesuwan, 2002:5-7; Saito, 
1998:3). 
 
Officials, however, reported that the severity of cases had not increased and that 
the increase in cases could be attributed to improved reporting conditions.  Military 
health centres did not include their statistics in the national malaria reports.  
Increased movement of civilians into former Khmer Rouge regions in the north-
western part of the country and continued displacement of refugees from fighting 
along the Thai borders contributed to the higher number of cases (Bussaratid et al., 
2002:3-12; Saito, 1998:3).  
 
The National Malaria Centre planned to continue future training sessions on 
malaria treatment for medical personnel at military hospitals.  Doctors and medical 
personnel at military hospitals would receive continuous training (Miller, 
Wongsrichanalai, Buathong, McDaniel, Walsh, Knirsch & Ohrt. 2005.1; Saito, 
1998:3).  
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2.10.3 Malaria in the American armed forces 
 
Health organisations estimate that between 2,5 million and 5 million people died of 
AIDS in the first fifteen years since the pandemic started.  However the same time, 
malaria killed nearly 50 million people worldwide (Driessen, 2005:1; Gillert, 2003:1-
2).  Captain Hoffman, Navy doctor and director of the malaria programme at the 
Naval Medical Research Institute argues that, due to global climatic changes the 
occurrence of malaria could double in the next fifty years (Driessen, 2005:3-7; 
Gillert, 2003:1-2). 
 
According to Gillert (2003:1-2), Hoffman stated that this could be a challenge for 
the military.  Hoffman added, “In every US military campaign this century we lost 
more casualties to malaria than bullets”.  This was seconded in the US Army 
malaria and military online fact sheet “Malaria and the Military” (2004:1). During 
World War II and the Vietnam War, whole divisions ceased to be effective combat 
units due to malaria.  Six of the last seven United States military deployments were 
to malarial regions of the world, with Bosnia the exception.  During “Operation 
Restore Hope” in Somalia, malaria was the number one cause of casualties.  
Currently, members deployed in malarial areas take antimalarial prophylaxis to 
avoid infection.  USA soldiers take either Mefloquine weekly or Doxycycline daily.  
In 2003 the US Navy was testing a third drug, Primaquine, which would also be 
taken daily (Baird, Fryauff & Hoffman, 2003:1659-1667; Gillert, 2003:1-2). 
 
However, according to Hoffman in Gillert (2003:1-2) and SCAT (2003:14) drugs are 
not always hundred percent effective.  He adds that researchers are discovering 
more and more strains of drug-resistant malaria.  If malaria is not treated properly, 
or if the medication does not work effectively, victims may develop kidney, liver or 
lung problems.  The most serious complication affects the brain.  Patients become 
disoriented, delirious and often comatose during the advanced stage.  Gillert 
(2003:1-2) refers to Hoffman as saying that it is not unusual, however, for malaria 
sufferers to hallucinate within seven days of becoming ill, but then to fully recover.  
According to Hoffman, because of the high costs and human misery, medical 
researchers rank malaria as the top priority for new and better drugs and, 
ultimately, vaccination.  Since malaria also severely impacts on military combat 
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readiness, the US Department of Defence leads the development effort of the fight 
against malaria and the parasites causing the disease (Gillert, 2003:1-2). 
 
The concern internationally is the fact that nobody has ever manufactured a 
vaccine against a complex parasite like malaria.  These micro-organisms develop 
multiple stages of life and when inside the human host the organisms live near a 
blood source in the liver, as well as inside and outside cells in the blood stream.  
They exist at a different stage in the body of the mosquitoes (Gillert, 2003:1-2; 
Malaria, 2006:1). 
 
To be completely optimal, the vaccination must attack the parasite at all stages of 
its life cycle.  “Developing this vaccine requires a whole new type of technology, 
which we’re at the forefront of, but it takes time.  We have made enormous 
progress and should field a vaccine in five to ten years” (Gillert, 2003:1-2).  Other 
international agencies, including the World Health Organisation and National 
Institutes of Health Centers for Disease Control, try to find a malaria vaccination as 
well, but their objective is different from that of the US Department of Defence (US 
DoD).  “They are interested in preventing death from malaria, and their first 
objective is sub-Saharan Africa” (Gillert, 2003:1-2).  The US DoD, on the other 
hand, wants a vaccine that would protect people from ever falling ill with malaria.  
According to Gillert (2003:1-2), Hoffman predicted the development of a vaccine 
that would last for about a year. 
 
 “Eventually, we would like a vaccine that would be life-long.  
However, it has to offer lifelong protection against infection, which 
is far different from lifelong protection against disease.  If we can 
make children in Africa not die from malaria that will be an 
amazing contribution, because it will wipe out millions of deaths a 
year.  But that’s not good enough for the US Department of 
Defence, because, to sustain operational capability, military 
people cannot afford to get malaria at all”. 
 
Epidemiologists from the US Army recommended that Permethrin be used on 
civilian clothes of members during deployments.  Permethrin is an insect repellent 
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applied to clothes.  They agree that much of the exposure to malaria among 
military personnel may occur while the members are wearing civilian clothing.  It is 
noted that Permethrin is commercially available and there is no reason it cannot be 
applied to civilian garments and bedding (Bradley and Bannister, 2003:184-199).  
In the United States Army there were 40 confirmed cases of malaria in 1997.  The 
number of patients increased to 41 in 1998, and until October 1999, 56 cases had 
been reported.  Most of the cases (82%) during 1998 and 1999 were troops from 
the different units in the United States of America Defence Force deployed to 
South Korea.   
 
2.10.3.1 Malaria among US military personnel returning from Somalia (1993) 
 
In late December 1992 US military personnel were first deployed to Somalia as part 
of “Operation Restore Hope”.  In the first four months until April 1993, malaria was 
diagnosed in 48 members who presented with symptoms of the illness while in 
Somalia.  Additionally, from late June 1993, 83 military members were diagnosed 
with malaria following their return from Somalia.  This significant number of cases 
has underlined the concerns regarding malaria prophylaxis, the need for proper 
diagnostic tools and treatment of malaria in military personnel and the approximate 
risk for infection (Newton et al., 1993:1; Robert, 2001:67-76).  
 
Mefloquine was one of the medications used for malaria prevention (Robert, 
2001:67-76).  The use of prophylaxis was not supervised after arrival in the United 
States and compliance was reportedly low (Newton et al., 1993:1; Robert, 2001:73-
76). 
 
2.10.3.2 Malaria among active duty soldiers in the US Army (2001-2002) 
 
In the US Army, soldiers operate and train in many areas of the world where 
malaria is endemic.  In 2001, malaria was conducted by 52 US soldiers in the 
demilitarised zone in Korea.  Thirty-three of the patients were hospitalised and one 
died of the infection.  Seventeen cases of malaria infections were reported in 
Africa.  Nearly all of the malaria cases of African origin were due to Plasmodium 
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falciparum.  There were more P. falciparum induced malaria cases in 2001 than in 
any year since 1995 (Lum, 2002:2-4). 
 
In the United States Military, many soldiers are permanently assigned to malaria 
endemic regions.  In addition, many soldiers are exposed to the malaria risk during 
operations and training internationally (Fact Sheet: Malaria and the Military, 2004:1; 
Lum, 2003:2-3;).   
 
During 2002, 57 soldiers were diagnosed and treated with malaria.  Thirty-six 
soldiers were diagnosed with Plasmodium vivax malaria; 80% were white and more 
than half of the cases were younger than 25 years of age.  There was one report of 
malaria in a female soldier (Lum, 2003:2-3).   
 
In 2002, malaria was identified among US Army soldiers at more than 20 different 
locations worldwide.  More than two-thirds of all cases were diagnosed at medical 
care facilities remote from locations where malaria is endemic (Lum, 2003:2-3). 
 
Nearly 40 US Army personnel returning home from Afghanistan in 2002 may have 
contracted malaria because of inadequate use of preventative measures.  Conflict 
and war have had a long partnership with malarial epidemics.  Transporting of 
military personnel, disruptions in health care infrastructure and exposure of 
individuals with nominal or no immunity bring about an increased risk of contracting 
malaria (Kotwal, Wenzel, Sterling, Porter, Jordan & Petruccelli, 2005:212-214). 
 
US Army soldiers deployed in endemic regions are directed to consume 
antimalarial chemoprophylaxis and to use personal protection methods, including 
minimising exposed skin through proper wear of the uniform and use of bed nets, 
impregnating uniforms and bed nets with Permethrin, and regularly applying topical 
insect repellent (Kotwal et al., 2005:213-216; Robert, 2001:69-76).   
 
An anonymous post-deployment survey of 72 % (521/725) of the force, indicated a 
compliance rate of 52 % for weekly chemoprophylaxis, 41 % for post deployment 
chemoprophylaxis, 31 % for both weekly and terminal chemoprophylaxis, 82 % for 
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treating uniforms with Permethrin, and 29 % for regular application of insect 
repellent (Kotwal et al., 2005:212-213; Robert, 2001:70-75). 
 
“A major cause of malaria prophylaxis failure is patient non-
adherence to prescribed treatment.  Providing continuous education 
about the need to comply with prophylaxis medication and having 
leaders directly observe therapy and enforce personal protective 
measures may help safeguard soldiers from vector-borne disease” 
(Kotwal et al., 2005:212). 
 
2.10.3.3 Malaria among marines in the US Army 
 
United States Navy medical personnel are still investigating an incredibly high rate 
of malaria among United States Army marines and navy personnel.  These 
members were in Liberia during 2003 on a peacekeeping mission (Rhem, 2003:1; 
Smith & Hooper, 2004:1-10). 
 
Forty-four military members were evacuated from their United States navy ships off 
the West African shore to hospitals in Germany and the United States.  Medical 
doctors and personnel from the National Naval Medical Centre in Bethesda have 
confirmed that 13 cases were due to the bite of the P. falciparum mosquito (Rhem, 
2003:1; Smith & Hooper, 2004:1-10).  There were several questions regarding this 
aspect.  Healthcare workers investigated three possibilities:  
• the type of malaria had become resistant to the drug taken by the marines;  
• the members did not take the prophylactic medicine correctly;  or 
• the drug had expired, or there was a default in the manufacturing process. 
 
Medical officials said that all members going ashore changed to another 
antimalarial drug in case of resistance.  Five of the cases were serious, including 
two patients who contracted cerebral malaria, but all of them were expected to 
recover (More US Marines contract Malaria, 2003:1; Rhem, 2003:1). 
 
According to medical officials, the marines and United States navy personnel 
started taking the antimalarial drug, Mefloquine, in late June or early July 2003 in a 
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regimen that required troops to start using the medication two weeks in advance of 
a deployment, then to take the drug once a week thereafter for a month until the 
troops were out of the malarial area for a month.  The defence force members were 
also issued with a mosquito repellent cream containing DEET and a mosquito net 
per person (Rhem, 2003:1; Smith & Hooper, 2004:1-10).  
 
The 40 marines and three United States Army naval officers who fell ill went ashore 
in Liberia.  They operated from an airport outside the capital Monrovia for about 10 
days.  Other United States Army soldiers went back and forth from the ships to 
land, sometimes for as little as a couple of hours at a time (Rhem, 2003:1; Smith & 
Hooper, 2004:1-10).  Ten more US military personnel serving as part of the 
peacekeeping mission in Liberia were showing symptoms of malaria.  US military 
officials stated that another ten military members had been evacuated.  This 
followed the evacuation of 46 other United States Army naval members to 
Germany and Bethesda for treatment against malaria (More US Marines contract 
Malaria, 2003:1; Sirleaf, 2003:1).  The members formed part of a quick reaction 
force sent to the Liberian capital to assist in the peacekeeping mission in the war-
torn country.  The troops were ashore from 15 August to 26 August 2003 before 
they returned to the Iwo Jima.  The two thousand military members, most of whom 
did not go ashore, had been issued with proper prophylaxis to avoid malaria.  The 
US Army military members were issued the antimalarial drug Mefloquine three 
weeks before arriving in Liberia, and were instructed to take the Mefloquine tablets 
once a week (Rhem, 2003:1; Smith & Hooper, 2004:1-10).  These members were 
also instructed to take the medication while in the area and three weeks after 
leaving Liberia.  United States military officials articulated that the troops who 
contracted the disease were probably exposed while they were ashore (More US 
Marines contract Malaria, 2003:1; Rhem, 2003:1). 
 
2.10.4 Malaria in the Canadian forces 
 
Sixteen confirmed malaria cases and four unconfirmed cases were reported in the 
Canadian Forces during 1993.  Among the 16 confirmed cases, one member 
contracted malaria while on an official visit to Central Africa.  The infection was the 
result of a bite from the P. falciparum mosquito.  The other 15 cases all occurred in 
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military members sent to Honduras during the hurricane Mitch relief effort.  All 15 
developed malaria as a result of the bite of the P. vivax mosquito, six to twelve 
months after returning. The military members did not use prophylaxis (Malaria 
Surveillance in the DoD and Canadian Forces, 2002:1). 
 
2.10.4.1 Canadian military malarial prophylaxis under scrutiny 
 
According to Desautels, Auditor-General of the Canadian government, the 900 
Canadian military members deployed in Somalia in 1992 and 1993, failed to follow 
proper safety protocols in administering antimalarial drugs (Kondro, 1999:1507; 
Report of the Somalia commission of inquiry, 1997:1).  Desautels reported that in 
giving Mefloquine to soldiers during a clinical trial, the Department of National 
Defence failed to “consistently keep essential records or follow required procedures 
to fulfil its obligation as a participant in the clinical study of an unlicensed drug”, 
while the Health Department of Canada lacked adequate oversight procedures to 
ensure that the trial were being properly managed and conducted, (Kondro, 
1999:1507; Report of the Somalia commission of inquiry, 1997:1).  Although 
licensed in Canada, Mefloquine was associated with side-effects such as 
hallucinations and depression.  Soldiers on the mission in Somalia blamed the drug 
as being partly responsible for the excessive force used by military members, 
leading to the death of a Somalian teenager (Kondro, 1999:1507; Report of the 
Somalia commission of inquiry, 1997:1). 
 
The problem is not that the soldiers were not given the drug.  They had to be 
protected against malaria.  According to Kondro (1999:1507), what concerned 
Desautels was the manner in which it was done.  He added that the antimalarial 
drugs were obtained through a clinical trial, but were given to soldiers without 
following the required measures to monitor the effects and to keep track of the 
drugs’ distribution.  In response to the report of the Department of National 
Defence of Canada, Desautels said that Mefloquine achieved the desired effect of 
preventing malaria, and that it was internationally acknowledged as having “an 
established record of safety and efficacy” (Kondro, 1999:1507; Veterans Affairs, 
2006:1).  
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2.11 MALARIA CONTROL IN THE SOUTH AFRICAN 
NATIONAL DEFENCE FORCE (SANDF) 
2.11.1 The prevention and control of malaria in the SANDF during external 
deployments 
2.11.1.1 Control of the Anopheles mosquito 
 
When SANDF members are deployed internationally, environmental health officers 
plan malaria-spraying programmes according to epidemiological tendencies.  The 
Fertilisers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, Act 36 of 
1947 (South African Government) is used as the legislative guideline.  All 
international laws, regulations and South African Bureau of Standards (SABS) 
codes pertaining to malaria are adhered to.  The policies of the county in which the 
SANDF are deployed are respected and wide consultation with different local state 
departments, local authorities and non-governmental organisations (NGOs) is part 
of the modus operandi.  The pest control operators of the South African Military 
Health Services (SAMHS) are only allowed to execute malaria control actions within 
the boundaries of the SANDF premises in the deployed country and/or authorised 
locations (Malaria policy for the SANDF, 1996:1). 
 
It is the responsibility of the officer commanding to ensure that the unit is sprayed 
to ensure vector control.  The management and administration of malaria control 
actions of structures and buildings in endemic areas are the responsibility of the 
environmental health officer and take place according to predetermined pest 
control programmes.  The environmental health officer is responsible for the 
determination of malaria control actions by assessing the active ingredient of the 
pesticides used.  An example of factors influencing the type of pesticide used is the 
texture of the surface on which the poison will be applied, the humidity and the 
temperature (Malaria policy for the SANDF, 1996:1).  
 
Regular spraying with Pyrethroid-based insecticides forms part of the vector control 
programme to prevent malaria.  These programmes have been extremely effective 
in areas of no resistance (Curtis, 1996:3-5). 
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2.11.1.2 Prophylaxis policy and administration 
 
Although the Armed Forces of South Africa have been deployed in malaria 
endemic regions for decades, their deployment to Burundi in 2001 was the first 
formal deployment of SANDF soldiers to East Africa.  After 1994, no 
chemoprophylaxis and treatment of malaria policy was available until May 2003 
when the current policy was drafted.  According to SAMHS Order SG/12/2003, 
Mefloquine and Doxycycline are the prophylactic treatment of choice for external 
deployments (Chemoprophylaxis and Treatment of Malaria, 2003:2). 
    
The SAMHS head quarters, in consultation with the Director Medicine and Director 
Pharmacy, determines the appropriate treatment regime and malaria prophylaxis.  
The provision of the antimalarial drugs to SANDF members deployed in malaria 
areas is the responsibility of the SAMHS, while the responsibility for their use rests 
with the individual.  The officers commanding of the respective units are 
responsible to inform the military health centre of any changes in their malaria 
prophylaxis register.  This enables proper planning with regard to the ordering and 
issuing of prophylactic medication.  It is the responsibility of the officer commanding 
of the local military medical centre to ensure that the environmental health officer 
gives counselling on malaria prophylaxis and prevention to the newly arrived 
members.  The military health centre is responsible for preparing the malaria 
prophylaxis in quantity according to a register (Malaria policy for the SANDF, 
1996:1). 
 
The malaria medication will be supplied weekly, as per the guidelines of the 
manufacturers.  The malaria medication will be supplied, against signature, to the 
unit officer commanding or a delegated person for issue to members.  The 
following information must be provided in writing to the local Military Health Centre: 
• area where the members will be deployed; 
• date when the prophylaxis is required; 
• expected time of deployment; and 
• number of members involved. 
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The person in charge must issue the malaria medication to the deployed members 
according to a register.  Counselling must accompany the issuance of the 
prophylaxis.  The members will be informed about the importance of starting the 
course on time, as well as the importance of finishing the medication as stipulated.  
The possible side-effects of the medication will also be highlighted (Malaria policy 
for the SANDF, 1996:1). 
 
In the case of Mefloquine (Mefliam®), military members will be supplied with a 
minimum of four weeks’ medication before leaving for the endemic deployment 
area.  Persons visiting the areas of deployment are responsible for obtaining their 
own prophylaxis from the nearest military health centre.  It is advised that malaria 
prophylaxis registers contain the following information: 
• amount of medication provided; 
• any known side-effects;  
• date on which member received counselling; 
• date when malaria medication was issued; 
• whether the member received any repellent;  
• personal particulars of the member; 
• signature of the member; and 
• the type of medication provided (Malaria policy for the SANDF, 1996:1). 
 
The malaria prophylaxis register should be archived for audit purposes.  It is the 
responsibility of the officer commanding of the military health centre to provide 
trained individuals to issue malaria medication, identify possible side-effects and to 
provide informal counselling and education to the users.  The control of the 
registers is the responsibility of the environmental health officer.  Registers must be 
supplied to the military health centre on a monthly routine for control purposes and 
to provide the opportunity for the information to be captured on the patient 
management system (Malaria policy for the SANDF, 1996:1). 
 
2.11.1.3 Preventative measures 
 
Prevention and proper application of the following measures have the potential to 
reduce the incidence of malaria in endemic regions: 
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• Build camps and pitch tents away from marshy areas and water bodies that are 
potential larval breeding sites. 
• Make provision for the optimum drainage of rain and household water near 
accommodation. 
• Install gauze screens in front of doors and windows of tents and temporary 
accommodation. 
• Apply larvicides to standing water that cannot be drained near temporary 
accommodation. 
• Apply long acting insecticides onto interior walls of tents and/or temporary 
accommodation.  
• Repellents.  As with prophylaxis, the use of repellents is the responsibility of the 
individual.  The issuing of repellents during external deployments areas is done 
against signature in the relevant register as soon as the member arrives in the 
country of deployment.  Members on ad hoc visits in the deployed region will 
receive the repellent together with their malaria prophylaxis. 
• Mosquito nets.  It is the responsibility of each officer commanding in the 
endemic malaria area to ensure that each person entering his/her unit is issued 
with a proper mosquito net (Malaria policy for the SANDF, 1996:1). 
 
2.11.1.4 Active surveillance 
 
Active surveillance is the process of early identification of personnel exposed to 
malaria vectors.  This process provides proactive action eliminating a substantial 
amount of active malaria vectors due to early intervention at low costs.  Where 
possible, members deployed in endemic malaria areas will undergo pre-
deployment screening.  This pre-deployment screening will be in the form of rapid 
blood tests, and thereafter at a frequency established by the surgeon general, 
depending on the malaria status of the region with a positive blood smear as part of 
early intervention.  Active surveillance is the responsibility of the environmental 
health officer (Malaria policy for the SANDF, 1996:1). 
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2.11.1.5 Information 
 
The member should be informed that the symptoms of malaria might be mild.  The 
member should suspect malaria if they experience unexplained fever or other 
symptoms such as persistent headaches, muscular aching and weakness, vomiting 
or/and diarrhoea.  The soldier has to be informed that medical help should be 
sought promptly if malaria is suspected.  Self-care should be taken only if prompt 
medical care is not available, and such medical advice should still be sought as 
soon as possible after self-treatment (Malaria policy for the SANDF, 1996:1). 
 
2.11.1.6 Urine testing 
 
Random urine testing will be done per unit deployed in an endemic area on a 
weekly basis.  Non-compliance will be specifically followed up (Malaria policy for 
the SANDF, 1996:1). 
 
2.11.1.7 Notification of malaria cases 
 
All malaria cases must be notified and investigated.  These notifications will give 
indication of the effectiveness of the malaria prevention programme (Malaria policy 
for the SANDF, 1996:1).   
 
2.12 GLOBAL TREATMENT AND CONTROL  
             MEASURES 
2.12.1 Global treatment measures 
 
The treatment of malaria has become a challenge due to the sheer nature and 
tenacity of both the parasite and the anopheles mosquito (Heelan & Ingersoll, 
2002:125-126; SCAT, 2003:6-9).  Prior to World War I, only Quinine, a derivative of 
the bark of the cinchona tree, was available for antimalarial treatment (Heelan & 
Ingersoll, 2002:125-126; White, 1996:1122-1123).  Between World War I and 
World War II, several synthetic drugs were developed, of which Chloroquinine 
became the drug of choice (Heelan & Ingersoll, 2002:125-126).  The use of 
standard antimalarial drugs and incomplete courses was directly responsible for 
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drug resistant strains, particularly Plasmodium falciparum.  After years of using 
antimalarial chemicals in endemic areas, the anopheles vector has also developed 
resistance to the most common insecticides (Heelan & Ingersoll, 2002:125-126; 
TDR: Strategic Direction Malaria, 2002:1). 
 
Ideally, malarial treatment should destroy all forms of the parasite.  The medication 
must kill all from sporozoite to gametocyte, without being toxic to the user (Heelan 
& Ingersoll, 2002:125-126; Heymann, 2004:325-326).  Unfortunately each of the 
available chemotherapeutic agents acts on specific morphologic stages of the 
malarial life cycle.  Combination drug therapy may be required to prevent relapse or 
recrudescence.  Current treatment regimes generally include some form of Quinine 
or Quinine derivative.  Chloroquinine is the least toxic drug that effectively 
eliminates non-resistant forms of the parasite in areas of the world where resistant 
strains of P. falciparum and P. vivax predominate, and Mefloquine or Quinine may 
be the drug of choice.  Managing infections of P. vivax or P. ovale may require long 
term treatment with Primaquine, which is known to eliminate hypnozoites from the 
liver and prevent “true relapse” (Heelan & Ingersoll, 2002:125-126; Heymann, 
2004:326). 
 
2.12.2 Global control measures 
2.12.2.1 Malaria control 
 
“Malaria control is the business of everybody, and everyone should contribute” 
(Malaria in Africa, 2003:1; WHO, 1993:1).  It requires the joint venture of 
community members and the involvement of those engaged in education, the 
environment in general, water supply, sanitation and community development in 
particular.  The discerning use of protection methods, including vector control, is 
proving to be more cost-effective and sustainable and insecticide-impregnated 
mosquito nets are increasingly being used (Malaria in Africa, 2003:1; Robert, 
2001:68-76). 
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2.12.2.2 Multilateral initiative 
 
In January 1997, funding groups from the private and public sector joined efforts 
and the Multilateral Initiative on Malaria (MIM) aimed at malaria control in Africa 
was founded.  It was an African-led project to strengthen research capabilities, 
particularly for improving antimalarial drug policies, reducing morbidity and death, 
and conducting epidemiological and vector studies, as well as other operational 
research.  The main research components to be funded were antimalarial drug 
policy, chemotherapy, epidemiology, pathogenesis, insects (vectors), health 
systems and social science (Malaria in Africa, 2003:1; WHO, 1999:54-62). 
 
2.12.2.3 Role of the Red Cross/Red Crescent (RC/RC) 
 
The Red Cross/Red Crescent is often on the vanguard of caring and addressing 
the health problems of internally displaced people and refugees.  Experience has 
shown that malaria is one of the most important health problems confronting these 
populations.  Thus, in partnership with other role-players and by applying the 
abovementioned interventions, the RC/RC plays a leading role in the control and 
prevention of malaria during natural and man-made disasters, as well as in 
complex emergency settings.  Where possible, efforts made in the prevention and 
treatment of malaria will also be blended into pre-existing programmes.  The Red 
Cross/Red Crescent will collaborate closely with international or national ministries 
of health and fill identified gaps to complement governments’ efforts to contain 
malaria (Health and Community Care, 2003:1).  The Red Cross/ Red Crescent is 
also involved in the following missions throughout the world:    
• advocacy; 
• village or community volunteers may play a part in fever surveillance in order to 
counsel caretakers in appropriate behaviour;  
• RC/RC and branches may wish to supply insecticide-impregnated mosquito 
nets as a service to the community and generate money from the sale of nets 
and from their periodic re-impregnation every 6-12 months.  In some countries, 
the production of nets has become a small home-based industry providing 
employment and income; and  
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• RC/RC village or community volunteers can serve to motivate the residents in 
the acquisition and appropriate use of insecticide-treated bednets (Malaria in 
Africa, 2003:1). 
 
2.13 DISEASE PREVENTION 
 
The key to the control of malaria is long-term mosquito abatement and human 
treatment and prophylaxis.  In addition, effective chemoprophylaxis should be taken 
wherever and whenever the risk of malaria exceeds the probability of experiencing 
an adverse reaction to the chemoprophylaxis.  The risk of contracting malaria is 
determined by the intensity of transmission in the area and the season of visit, as 
well as the duration of stay, type of accommodation and type of activities between 
dusk and dawn (SCAT, 2003:6).  Elimination of standing water and mosquito 
breeding sites and the correct use of environmental insecticides should drastically 
reduce the vector population.  Early diagnosis and treatment of existing cases is 
also fundamental to the breaking of the human-mosquito-human cycle (Robert, 
2001:69-76; WHO, 1993:19-20). 
 
 
The “ABC” of Malaria prevention 
A: Awareness of the malaria risk 
B: Avoidance of getting Bitten by mosquitoes 
C: Compliance with chemoprophylaxis 
D: Early Detection  
E: Effective treatment 
Figure 2.2: The “ABC” of malaria prevention (SCAT, 2003:6) 
 
2.13.1 Active approaches for malaria prevention  
2.13.1.1 Procedures to prevent mosquito bites 
The following procedures are recommended: 
• Spray an insect repellent containing diethyltoluamide, for example Tabard®, 
onto exposed skin, as well as your clothing at dusk every day. 
• Wear long- sleeved shirts, long pants and socks after dusk. 
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• The mosquito is a night feeder and the thin skin over exposed ankles and 
wrists is a favoured site for feeding. 
• Burn insecticide coils in sleeping quarters at night. 
• Move around when outdoors at night; mosquitoes prefer static prey. 
• Ensure that there are mosquito screens on all doors and windows.  Spray an 
insecticide inside living quarters every evening to eliminate indoor 
mosquitoes. 
• Sleep under Pyrethroid insecticide impregnated mosquito nets tucked under 
the mattress. 
• A ceiling fan is effective.  Mosquitoes do not have the flight power to penetrate 
the downdraft of the fan.  
• Build houses and villages away from marshy areas and water bodies, which 
are potential breeding sites.  The adult mosquitoes are carried by the wind but 
few are found 1-2 km from their original larval site.  
• Make provision for optimal drainage of rainwater and household water near 
residential areas. 
• Where standing water exists near houses and cannot be drained, larvicides 
should be applied (Banck, 2004:1; Robert, 2001:70-76; SCAT, 2003:13).  
 
Ultrasound buzzers and Vitamin B supplements do not deter mosquitoes from 
biting.  The abovementioned procedures may seem to be troublesome, but 
compared to the situation when malaria is diagnosed and admission to a hospital 
becomes an emergency, these precautions are minor (Chen, Wilson and 
Schlagenhauf, 2006:2234-2244).  
 
2.13.1.2 Preventative therapy 
 
Resistant Plasmodium falciparum parasites are no longer inhibited by Chloroquine 
alone (Anderson & Roper, 2005:269-277).  There are two other antimalarial 
prophylactic groups that prove active against resistant malarial strains.  These are 
Mefloquine, for example Laruim®, Mefliam® and Doxycycline (Anderson & Roper, 
2005:269-277).  Strict adherence to the recommended doses and schedules of the 
prophylactic drugs selected is necessary for effective protection against malaria. 
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• Antimalarial tablets are to be taken on the same day and more or less the same 
time each week.  
• Tablets are to be taken after you have had a meal or while eating something. 
• The recommended doses should be taken one to two weeks before travelling, 
throughout the stay and for four weeks after leaving the malarious area. 
• Drug allergies and other contra-indications for the use of drugs to prevent 
malaria should be recorded. 
• Complete the full course (CDC/NCID Brochure Publication, 1995:3-4; SCAT, 
2003:15). 
 
2.13.1.3 Malaria chemoprophylaxis and the use of vaccines  
 
Malaria chemoprophylaxis should not be used with oral typhoid vaccine due to the 
possible inactivation of the immunisation.  The immunisation should be completed 
three days before taking Mefloquine (Griffin, 1999:25-43, WHO, 2001:3-6).  Rabies 
vaccine should not be used concurrently with malaria chemoprophylaxis.  If 
intradermal Human Diploid Cell Vaccine (HDCV) must be used, Mefloquine should 
not be given concomitantly.  Where possible, rabies immunisation should be given 
one to two months before starting the malaria chemoprophylaxis (Stockley, 
1994:145-149).   
 
2.14 MALARIA TREATMENT 
2.14.1 Strategic direction for research, disease burden and  
 epidemiological trends 
 
Malaria is a public health problem in more than 90 countries, inhabited by 2.4 billion 
people.  Best estimates for 2005 describe the annual global burden of malaria as 
1.1 million to 2.7 million deaths, 300-500 million cases and 44 million disability 
adjusted life years (Teklehaimanot, Singer, Spielman, Tozan & Schapira, 2005:13-
19; Podger, 2002:1).  Malaria has many manifestations and its impact varies 
depending on the epidemiological setting.  More than 90 percent of the disease 
burden is to be found south of the Sahara dessert, and roughly all fatalities (due to 
P. falciparum) occur on the African continent (TDR: Strategic Direction Malaria, 
2002:1; Teklehaimanot et al., 2005:13-19).  The remaining fatalities due to malaria 
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worldwide, are spread between the Indian sub-continent, Southeast Asia, Oceania, 
and the Americas.  Following P. falciparum, P. vivax is the next most significant 
malaria carrying mosquito.  About 80 million humans are suffering from the disease 
annually, with approximately 15 % on the African continent and 85 % outside Africa 
(Teklehaimanot et al., 2005:13-19). 
 
The malaria burden differs according to age and gender.  Adults have reduced 
risks due to their ability to develop a degree of immunity to the disease as a result 
of continuous exposure.  Outside Africa, where continuous exposure does not 
occur, the disease burden extends into adulthood.  Pregnant women in Africa are 
at high risk, and are the major adult risk group in Africa.  The malaria burden 
associated with pregnancy has an additional impact due to the effect on the health 
of the foetus (Rowe, Rowe, Snow, Korenromp, Armstrong, Schellenberg, Stein, 
Nahlen, Bryce, Black & Steketee, 2006:6-20; Sachs & Malaney, 2002:680-685). 
 
There is a strong economic and humanitarian dimension to the disease.  The poor 
people and marginalised communities, such as ethnic minorities and people 
displaced as a result of civil unrest, are at greatest risk of malaria (Njau, Goodman, 
Kachur, Palmer, Khatib, Abdulla, Mills & Bloland, 2006:299-306; TDR: Strategic 
Direction Malaria. 2002:1; Teklehaimanot et al., 2005:19).  Tendencies over the last 
three decades point to a deteriorating state of affairs if effective action is not taken.  
These tendencies include the following: 
• an increase in epidemic malaria;  
• a rising trend in mortality over the last few decades, including in sub-Saharan 
Africa;  
• an increase in drug-resistant P. falciparum malaria;  
• the re-emergence of P. vivax malaria in countries where it has been 
eradicated, for example Central Asia; and  
• an increase in imported malaria in the developed world, for example the 
United States of America and the British Isles. (TDR: Strategic Direction 
Malaria, 2002:1; Teklehaimanot et al., 2005:22-39). 
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2.14.1.1 Control strategy  
 
The Roll Back Malaria (RBM) strategy emphasises the following aspects:  
• early diagnosis and the timely, effective treatment of malaria patients;  
• prevention through the use of insecticide-treated products and other vector 
control measures including larvicyding,  residual indoor spraying and 
environmental management; 
• prevention of malaria during pregnancy (insecticide-treated bednets and 
intermittent treatment);  
• prevention, early detection and rapid response to epidemics (through 
preparedness, monitoring, surveillance, and timeous action); 
• strategies, methodologies, development of new tools and improvement in 
distribution of existing tools through research and development; and 
• co-ordinated planning and action through establishing partnerships that utilise 
an optimal range of measures adapted to local conditions (TDR: Strategic 
Direction Malaria, 2002:1). 
 
Emphasising each aspect is the recognition that it needs to be related to broader 
initiatives involving education programmes, public health sector development, 
partnerships (public–public and public–private) and capacity building (TDR: 
Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 2005:27-39).  However, a 
package of interventions to decrease the bulk of the malaria burden is not 
affordable in very low-income countries (Sachs & Malaney, 2002:680-685). 
 
2.14.1.2 Challenges for disease control 
 
The burden of malaria persists for numerous reasons.  Among them is failure to 
achieve sufficient coverage with and reduced costing of existing tools such as 
insecticide-treated bednets and drugs, and there is user ignorance on usage of 
these products.  This is the consequence of supplying information and reasonably 
priced control tools closer to the community, particularly at peripheral levels of the 
health care system.  Connecting the methodologies and tools related to malaria 
control and management into a logical, incorporated approach is exceedingly 
challenging (TDR: Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 
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2005:59-70).  Associated with these constraints, is the lack and failure of financial 
and human assets to effectively predict, detect, monitor and respond quickly and 
purposefully to malaria outbreaks.  These outbreaks are often tied to complex 
emergency situations with failure to detect early rises in drug resistance, and 
subsequent proactive steps to revise drug policies accordingly.  The diminishing 
effectiveness of current existing tools (e.g. surfacing of drug resistance, 
predominantly to Sulphadoxine-Pyrimethamine and Chloroquine, resistance to third 
and fourth line antimalarials in Southeast Asia, and resistance to insecticides, 
including Pyrethroids) is a challenge that demands unambiguous national 
drug/insecticide policies and consistent regional strategies.  These policies and 
strategies are not always clear or in place, and the strategic execution of the 
current existing tools is neither optimal nor adequate (Mulligan, Mandike, Palmer, 
Williams, Abdulla, Bloland & Mills, 2006:453-459; TDR: Strategic Direction Malaria, 
2002:1; Teklehaimanot et al., 2005:82-86). 
 
Highly cost-effective new tools are required urgently.  These tools are required to 
replace and supplement the existing ones.  Too little energy has been spent on 
translating scientific data into sensible solutions (tools) and rolling it out into the 
communities.  Tools such as diagnostics that are tailored and packaged for easy 
use, methodologies for rapid detection of disease outbreaks, monitoring of drug 
and insecticide resistance and inexpensive drugs are required.  The need to launch 
affordable new treatments due to the increase in drug resistance is particularly 
important.  A reasonably priced vaccine is also anticipated (TDR: Strategic 
Direction Malaria, 2002:1; Teklehaimanot et al., 2005:82-86). Poor intersectoral 
and interdepartmental collaboration, inadequate international resources and 
systems, including a lack of private sector engagement, all play major parts in the 
persistence of the disease.  These trends should be viewed within the context of 
extreme poverty and an environment in which factors external to biomedical 
science and public health systems have an impact, e.g. development projects, war, 
social unrest and weather (Sachs & Malaney, 2002:680-685; Mulligan et al., 
2006:452-457). 
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2.14.1.3 Research needed to address these constraints 
  
In order to improve execution of current malaria control tools, health care delivery 
strategies must reach the underprivileged and neglected populations.  This may 
involve the formal and non-formal sectors of the international economy, the public 
and private sectors, and even businesses that are not directly involved in the health 
sector (Sama, Owusu-Agyei, Felger, Dietz & Smith, 2006:13-21; TDR: Strategic 
Direction Malaria, 2002:1; Teklehaimanot et al., 2005:88-92). 
 
Better awareness needs to be fostered to do research on social promotion.  
Attention must also be paid to health education and the development of information 
and communication methods to develop the understanding of control tools, 
strategies and interventions at personal, community and systems level.  New 
studies have confirmed the impact of communal marketing on achieving larger 
allocation of public health goods (e.g. insecticide-impregnated bednets).  
Nonetheless, these strategies need to be united in resourceful ways with strategies 
that endeavour to achieve more impartial distribution of the products among the 
underprivileged, through subsidies or better pricing.  Overall, there has been a less 
than optimal attempt in developing valuable financing policies and strategies.  
These policies and strategies would remove the affordability barriers to accessing 
major interventions by the underprivileged and would also be suitable to 
governments, multilateral organisations and donors (Mulligan et al., 2006:453-458; 
TDR: Strategic Direction Malaria, 2002:1). 
 
New drugs are needed with qualities that enhance applicability, user-friendliness 
prolonged existence, acceptance and affordability to the consumer.  Other needs 
include an effective vaccine and new methods of disease control and vector 
control.  There is a demand to adapt fundamental, molecular data on resistance 
development and monitoring potential into useful tools for field studies.  
Additionally, molecular-based tests and superior in vitro tests for drug resistance 
could be very useful (Reyburn, Ruanda, Mwerinde & Drakeley, 2006:4; Sachs & 
Malaney, 2002:680-685; TDR: Strategic Direction Malaria, 2002:1). 
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An evidence-based information system, to support decision-making, is required in 
order to better surveillance and information management.  This system will improve 
the efficiency and rationale of malaria control and management.  This will allow 
timely detection of malaria epidemics, increased speed of response to epidemics 
and identification of resistance to drugs and insecticides as early as possible, 
enabling relevant and timely policy response.  Although some new surveillance 
tools and strategies are now being assessed, e.g. Mapping Malaria Risk in Africa 
(MARA), rapid diagnostic kits, improved linkage to a widely accessible information 
base and studies into the best way to utilise this information, would be valuable.  
Technical strategies, policies and methods to counter resistance to antimalarial 
drugs and insecticides need to be developed (Reyburn et al., 2006:4; TDR: 
Strategic Direction Malaria, 2002:1). Research is needed to identify and confirm 
indicators to measure the impact of combined antimalarial interventions.  
Evaluation and monitoring of the impact of control activities and strategies, as well 
as constant review and modification of strategies to achieve maximum impact, 
should be an integral component of disease control (Riley, Wahl, Perkins & 
Schofield, 2006:37-47; Sachs & Malaney, 2002:680-685). 
 
2.14.1.4 Continuous research on malaria 
 
In the Programme for Research and Training in Tropical Diseases (TDR) there is 
increased emphasis on economic, social and behavioural research, including a 
better application in social and economic stratification of the malaria risk.  Research 
is in progress on new methods for monitoring public health sector financing 
methods such as ‘sector-wide approaches’ (SWAps), tracking of assets to definite 
diseases within SWAps and evaluating the impact of decentralisation of the health 
system on specific health outcomes.  Investigations into better policies and 
planning to allocate funds (e.g. SWAps), and improved monatory policies for health 
care for the underprivileged, are also currently on track (Riley et al., 2006:40-49; 
TDR: Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 2005:22-27). 
 
Innovative knowledge regarding malaria epidemiology and typical risks is being 
collected by various agencies (e.g. United States National Institutes of Health 
(NIH), Wellcome Trust and United States Centers for Disease Control and 
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Prevention as primary information on drug resistance and vector control.  Related 
research is being sponsored by individuals and scientific companies to spawn fresh 
information in clinical research, microbiology of malaria parasites pathogenesis and 
immunology, epidemiology, molecular entomology and disease transmission.  
There is extensive scope for strategic planning and research linking basic 
knowledge to the development of new tools and disease management (Dike, 
Onwujekwe, Ojukwu, Ikeme, Uzochukwu & Shu, 2006:37-53; TDR: Strategic 
Direction Malaria, 2002:1). 
 
Research on new methods to apply existing control tools is endorsed by the 
Special Programme for Research and Training in Tropical Disease (TDR).  An 
example is the research done on intermittent treatment with antimalarials (MIT) on 
babies that can prevent malarial anaemia, a primary cause of morbidity and 
mortality in patients.  New applications for impregnated bednets for pregnant 
mothers, and the value of MIT with Sulphadoxine-Pyrimethamine (SP) were 
identified during studies in Kenya.  Research is also in progress with new 
formulations and new presentations of drugs  available at present, that will better 
access to malaria control tools in the communities where they are needed (TDR: 
Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 2005:59-70).  Mounting 
effort is being directed worldwide at the development of new and improved tools 
and methodologies for malaria control links to public private partnerships, for 
example Medicines for Malaria Venture (MMV).  The prospect of involving industry 
in partnership for the development of new pesticides is being addressed in an 
initiative led by the WHO Pesticide Evaluation Scheme (WHOPES).  New and 
improved strategies and surveillance tools are being assessed, for example rapid 
diagnostic kits and MARA (TDR: Strategic Direction Malaria, 2002:1; 
Teklehaimanot et al., 2005:72-79). 
 
Projects to assist with policy development occur at a functioning level.  Although 
some research is aimed at policies with specific tools in mind, more integrated 
research efforts are needed.  Efforts are being directed towards how best to inform 
those responsible for policies and how best to initiate policy changes, taking into 
consideration new tools as and when they become available.  Research is in 
progress on development of consistent drug policies for malaria treatment and 
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strategy development to prolong the shelf life of antimalarial drugs.  The first 
chapter of a plan to demonstrate the worth of combination drug therapy over 
monotherapy for better efficacy has been finalised.  This TDR-RBM initiative has 
been vital in the first steps during the development of policy changes regarding 
combination drugs as first-line malaria therapy in Africa (Njau et al., 2006:303-313; 
TDR: Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 2005:81-86).  The 
Multilateral Initiative on Malaria in Africa (MIM) has given the progress in research 
links between disease specific programmes, health systems and policy 
programmes a major boost.  This initiative finances a number of key projects in 
Africa and a number of agencies participate in it, including the TDR (TDR: Strategic 
Direction Malaria, 2002:1).  The objective of reducing malaria can in due course 
only be achieved through local capacity to complete the research, put into practice 
successful malaria control programmes and expand policy frameworks for control.  
Schemes sponsored by the Rockefeller Foundation offer generic methods, and 
some MIM projects also use this approach.  Building research capacity can be 
primarily achieved through lucrative cooperation between endemic malaria 
countries (TDR: Strategic Direction Malaria, 2002:1; Teklehaimanot et al., 2005:59-
70). 
 
International malaria-specific research capacity building tended to direct its focus 
on Africa.  Nevertheless, TDR has widespread projects in Thailand with a 
dedicated malaria component.  Projects to reinforce good practices potential have 
also had vital spin-offs for malaria, as has the setting up of initiatives such as health 
care practitioners’ assistance to the EU for the launch of the African Malaria 
Vaccine Testing Network (AMVTN) (TDR: Strategic Direction Malaria, 2002:1; 
Teklehaimanot et al., 2005:81-86). 
 
The need for ongoing research regarding Malaria Information Systems (MIS) is 
outlined in five categories, namely: 
• Mapping malaria incidence/prevalence.  This system is a basic application 
and involves mapping the incidence/prevalence of malaria over a specific 
geographic area.  The focus is on examining past trends as well as present 
situations and does not include any statistical analysis, with the possible 
exception of correlating malaria incidence/prevalence with population in 
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order to calculate populations at risk (Kleinschmidt, Bagayoko, Clarke, Craig 
& Le Seuer, 2000:355-361; Gething, Noor, Gikandi, Ogara, Hay, Nixon, 
Snow & Atkinson, 2006:271-277).  The goal of these studies will be to see if 
any obvious patterns exist. 
• Mapping of relationships between malaria incidence/prevalence and other 
potentially related variables (Hightower, Ombok, Otieno, Odhiambo, Oloo, 
Lal, Nahlen & Hawley, 1998:266-272; Gething et al., 2006:271-277).  The 
goal of this study is to see if any relationship exist between malaria 
incidence/prevalence and other variables including: temperature, rainfall, 
land use, land cover, breeding sites, control programmes, climate changes, 
population movements and demographics. 
• Using innovative methods for the collection of data (Bergquist, 2001:13-20 
Schroder, 2006:23-36).  Data collection is one of the major limitations of 
using Geographic Information Systems (GIS). GIS is mostly used for aerial 
photography and satellite imagery. 
• Modelling malaria risk (Snow, Craig, Deichmann & Le Seuer, 1999:99-104; 
Tatem, Hay & Rogers, 2006:6242-6247).  This system is future orientated 
and focuses on predicting future areas of malaria risk.  This malaria risk 
models typically use many of the same variables discussed above. 
• General commentary and reviews of GIS use in malaria control and research 
(Tanser & Le Seuer, 2002:4). 
 
According to Basu (2002:59-65), some of the challenges of malaria control in poor 
countries are the production and distribution of malaria vaccine and the control of 
mosquitoes that harbor the malaria parasite.  As stated, the development of a 
malaria vaccine is indeed likely although it will take years to produce because of 
both biological obstacles and insufficient research support.  The destitution of such 
a vaccine will require that wealthy countries promise a market to pharmaceutical 
companies who have traditionally failed to investigate diseases affecting the 
poorest of nations.  The analysis indicated that both endogenous programmes in 
malarial regions and molecular approaches to parasite control will provide 
pragmatic solutions to the malaria problem.  The successful control of malaria will 
require sustained support from the wealthy nations, without whom vaccine 
development and vector control programmes are likely to fail (Basu, 2002:65-75). 
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Genetic approaches to controlling the transmission of mosquito–borne diseases 
are being developed to augment the chemical control practices, by means of 
insecticides, and environmental manipulation methods.  Progress has been made 
in research that seeks to develop antipathogen or antivector effector genes and 
methods for genetically manipulating host vector strains.  Future challenges include 
discovering a method of spreading antiparasite genes through mosquito 
populations, determining the threshold levels below which parasites intensities of 
infection must be held, and defining the circumstances in which genetic control 
strategies would be employed in the field (James, 2002:1317).        
 
2.15 THE WAY FORWARD FOR TREATING MALARIA 
 
The growth of drug-resistant malaria means that the drugs available to 
communities are losing their effectiveness (ACT: The way forward for treating 
malaria, 2001:1; Anderson & Roper, 2005:269-278; WHO, 1999:55-61).  
Supporting research into affordable alternatives through initiatives such as the 
Medicines for Malaria Venture (MMV) is an important component of the RBM 
strategy (Medicines for Malaria Venture (MMV), 2005:1).   
 
Recent evidence indicates that the number of deaths due to malaria in Africa has 
begun to increase, and that this is attributed to failing medicines and medicines of 
poor quality (Anderson & Roper, 2005:277-280; Basco, 2004:245-250; WHO, 
1999:52-60).  Surveys indicate that due to high levels of resistance to the drugs in 
use, a high percentage of money spent on antimalarial medicines is being used to 
pay for inappropriate treatments (Anderson & Roper, 2005:269-280 ; Basco, 
2004:245-250).  On the other hand, research has shown that access to effective 
antimalarial treatment can significantly reduce child mortality and the frequency of 
severe malaria.  These findings highlight the need for greater efforts on malaria 
control, combining improved access to effective treatment with preventive 
measures such as insecticide-treated nets (ITNs) (Tami, Mbati, Nathan, Mponda, 
Lengeler & Schellenberg, 2006:1-9; What is Malaria, 2003:1; WHO,1999:55-57). 
 
Bednets must not only be seen as a tool to protect the sleeper underneath the 
bednet.  The net can and must also be used as a baited trap (Curtis, 1996:3-6; 
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Curtis, 2005:50-51).  Spraying residual insecticide on bednets is a very effective 
tool in managing mosquitoes, because the insects are attracted to the person 
underneath the net by the carbon dioxide, body odour and heat emitted by the 
sleeper (Maharaj, 2004:personal communication).  The net therefore acts as a 
baited trap.  In comparison with spraying temporary accommodation such as 
military tents, the amount of insecticide needed to treat the bednets is much less 
(Curtis, 1996:3-6; Curtis, 2005:50-51).  Netting is a more favourable substrate for a 
residual insecticide than the non-absorbent and smooth surface of a military tent 
(Curtis, 1996:3-6).  In addition, mosquitoes come in contact with the bednets in 
their search for a human blood meal, while normal residual spraying presupposes 
that the insect will sit and rest on the surface inside the tent before or after feeding, 
which is not the habit of the Anopheles mosquito (Curtis, 1996:4-7; Curtis, 2005:50-
51).   
 
Antimalarial drugs, when used as monotherapies, are rapidly losing their 
effectiveness.  In some places, malaria is resistant to all affordable first-line 
therapies.  Moreover, few new affordable drugs are being developed to replace 
those being lost due to resistance.  This is largely because malaria, being a 
disease of the poor, resulted in the research-based pharmaceutical industry not 
considering the malaria drug markets as a lucrative investment opportunity 
(Millennium Project, 2006:1; Ridley, 2001:1).   
 
Monitoring the extent and spread of drug resistance is an important aspect of 
containment.  Resistance to a drug does not necessarily extend uniformly across a 
country, and there may be pockets within regions where resistance prevails or 
where the drug is still effective.  However, too often victims of malaria and health 
care providers do not know if the malaria they are facing is drug-resistant or not.  
Areas of drug resistance therefore have to be identified and, where appropriate, 
alternative drugs have to be recommended and made available.  In order to make 
this possible, the WHO is supporting countries to map drug resistance, and 
recommends that countries begin the transition to an effective new treatment when 
or before levels of resistance to the drugs begin to exceed healthy levels (Kakkilaya 
& Chakrapani, 2006:1; Killer Number One: The Fight Against Malaria, 2005:1).  
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The next step is to line up strategies to contain the spread of resistance.  
Experience has shown that when two or more drugs with different biochemical 
targets in the malaria parasite are used in combination, the development of 
resistance to both drugs can be delayed.  Drug combinations containing Artemisinin 
derivatives have the highest therapeutic efficacy and the greatest potential to delay 
the onset of resistance.  Because Artemisinin-based combination therapies (ACTs) 
comprise two medicines which work in different ways, it is thought unlikely that the 
malaria parasite, which has rapidly developed resistance to other, single 
treatments, would evolve to resist these medicine combinations.  In many African 
countries, more than three-quarters of all malaria cases are first treated at home 
with antimalarial drugs purchased from small local shops or from travelling vendors.  
The RBM partnership is working to provide simple regimes of new, effective drugs 
and to train mothers, caregivers, shopkeepers and community workers to correctly 
diagnose malaria and provide early and appropriate treatment near or in the home 
(Malaria, 2002:1; Medicines for Malaria Venture (MMV), 2006:1). 
 
Even at cost price, many countries will not be able to afford the new recommended 
treatments from their national budgets, nor will they be able to treat sick people 
from their own resources. There is, therefore, a critical need to address worldwide 
support for the financing and pricing of ACTs, and to amplify efforts to develop 
new, affordable antimalarial drugs, preferably with simplified treatment regimes to 
encourage compliance (ACT: The way forward for treating malaria, 2001:1).  A very 
positive development is that the Board of the Global Fund to Fight AIDS, TB and 
Malaria (GFATM) has approved funding proposals from malaria endemic countries 
to roll back malaria, and to use ACTs.  Following their first-cycle awards to support 
ACT deployment in Zambia and Zanzibar, an increasing number of proposals from 
countries in Africa has been approved in subsequent funding cycles to implement 
ACT-based treatment policies.  As a result, GFATM awards for the procurement of 
ACTs in African countries have increased exponentially.  This trend, if continued, 
offers much hope (ACT: Facts On, 2005:1).  In the 1920’s Michael Kremmer, senior 
fellow in Economic Studies at the Brookings Institute in Washington, made the 
following statement (Kayle, 1999:2): 
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“The critical problem is finding the money for malaria 
research, development and distribution.  There is 
simply not enough money in malaria, as drug 
companies know.  Since the mosquito can transmit 
the disease only in warm temperatures, the disease is 
highly concentrated in tropical climates.  But people in 
the tropics are overwhelmingly poor and in no 
position to pay for antimalarial prophylaxis and so 
drug companies have little incentive to fund research.  
In short, the 2,4 billion people in the tropics who are 
vulnerable to malaria provoke remarkable little 
research effort”. 
 
As case in point is that malaria research is carried out mainly in government 
research institutes all suffering from limited budget resources.  Worldwide malaria 
research amounts to $84 million annually, or perhaps $42 per malaria fatality.  This 
expenditure is tiny compared to what is spent on diseases affecting richer and 
more temperate areas.  Most current information on research funding for asthma 
was about $800 million or $500 per fatality in 1999 (Kremer, 1999:1). 
 
Ironically, the very phenomenon that is leading to Africa’s increased malaria cases 
may actually save the continent.  Global warming is taking malaria to the rich.  The 
increase in the average temperature during winters and summers in the northern 
hemisphere is making it more tolerable for the Anopheles mosquito to live and 
breed.  The World Health Organisation has reported that Europe has experienced 
a tenfold increase in malaria during 1997 to 1999.  In 1999, 200 000 cases of 
malaria were reported in Europe (Okenu,1999:1)  
 
While the chemoprophylactic options against Chloroquine resistant malaria is far 
from ideal, the situation is improving with the licensing of Doxycycline and 
Atovaquane/Proguanil for this purpose.  The regiments still suffer from the following 
limitations: inadequate protection, unpleasant side-effects, high cost, inadequate 
trials or experience the need for prolonged continuation of drug after leaving 
malarious area, and frequent dosing.  There is hope for the future with new drugs 
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under trial either alone or in combination.  Malaria vaccines remain a hope for the 
distant future, but for the present we are dependent on reducing the risk of being 
bitten by mosquitoes and available medicines for chemoprophylaxis (Bradley & 
Bannister, 2003:180-199; Flanagan, Buckley-Sharp, Doherty & Whitty, 2006:233-
237). 
 
2.16 THE DEVELOPMENT OF MEFLOQUINE AS AN 
ANTIMALARIAL AGENT 
 
The discovery of Mefloquine and its subsequent development has been closely 
associated with military imperatives, contingencies and requirements.  The 
following discusses military experience with Mefloquine in an attempt to generate a 
perspective for future policy.  
 
2.16.1 Mefloquine as an antimalarial agent 
 
The healing properties of the bark of the cinchona tree, chewed or made into a 
mixture, were probably known by the Inca tribe long before it first attracted 
European attention.  In 1630, the wife of the Viceroy of Peru, Countess Cinchon, 
was reputedly given a concoction of tree bark by Juan Lopez, a Jesuit, for the 
treatment of an ague (Burba, 1999:1-3; Kitchener, 2003:34-38).  When the 
Countess recovered, she distributed, in her beneficence, the recipe to the poor of 
Peru for treatment of the illness.  From the year 1641 the bark was officially 
exported to Spain.  Malaria was identified as being endemic in the Iberian 
peninsula and southern Europe during that period, and the new treatment was 
gradually accepted by the people for the treatment of ague (Burba, 1999:1-3; 
Kitchener, 2003:34-38).  
 
James Lind, a surgeon, described the specific pharmaceutical applications of the 
powdered bark in 1760‘s.  The drug was listed in the London Pharmacopoeia by 
1677, and Lind specifically described the applications in an attempt to reduce the 
indiscriminate use that had developed.  During 1820, two scientists, Pelletier and 
Caventou, isolated Quinine and Cinchonine.  This allowed accurate dose 
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prescribing of the alkaloid content in the bark (Caventou, Pelletier and Quinine, 
2001:1, Kitchener, 2003:34-38). 
 
In 1865 the next milestone in the development of antimalarial drugs was achieved.  
In this year seeds were extracted from trees in the Bolivian Andes and covertly sent 
to London.  This seeds were purchased by the Dutch consul for plantations in Java.  
In doing that the production of cinchona alkaloids was diversified and that made the 
potential control of the ague in military and trade missions to the East Indies much 
more uncomplicated (White, 1996:1122-1123).  The first synthetic antimalarial 
drugs were developed in 1926.  The development was done through clinical trials 
by German pharmaceutical companies (8-aminoquinolines and Pamaquine).  After 
the development of 8-aminoquinolines and Pamaquine, Primaquine and the 4-
aminoquinolines followed, which later led to Sontoquine and Chloroquine (Method 
of Treating Malaria, 1981:1).  
 
By December 1941, Japan had conquered the Indonesian archipelago and Malaya.  
By   Japan gaining control of most of the cinchona plantations, the country had 
monopolized the supply of Quinine to the rest of the world (White, 1996:1122-
1123).  Due to that, the supply of Quinine to the Western Alliance was 
marginalised.  During the following campaign of British and Australian forces in 
Burma and New Guinea, non-battle casualties were crippling.  Subsequently, the 
Australian Army responded to this experience by founding the Medical Research 
Unit (MRU) under the command of colonel Fairley (Kitchener, 2003:34-38; Stockton 
& Clayton, 2001:1).  
 
The MRU was predominantly triumphant in the research they conducted with 
Atabrine (Mepacrine) for operational use in New Guinea.  The present Army 
Malaria Institute was born out of the MRU.  Military events and the increasing non-
battle casualties were a huge catalizer in stimulating research and development 
regarding antimalarial agents (Kitchener, 2003:34-38).  Following the success of 
Mepacrine, the United States, by means of the Walter Reed Army Institute of 
Research (WRAIR), increased their development efforts on Chloroquine (Alving, 
1954:209-218) and continued the research into prolonging the antimalarial effects 
of the cinchona alkaloids (Garnham, 1984:1305-13108; Kitchener, 2003:34-38).  
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Numerous allied nations became occupied after the Second World War in wars 
taking place in South-East Asia.  Again, these nations sustained great numbers of 
non-battle casualties from malaria.  During that period, it was discovered that 
Cinchonine and Quinine were evidently metabolised by oxidation at the 2-position of 
the cinchona side-chain (Kitchener, 2003:34-38).  
 
About 120 different compounds were manufactured at Walter Reed Army Institute of 
Research (WRAIR) after the end of the Second World War.  An early compound 
(WR30090) was taken to field trials, on behalf of the class 2-phenyl-4- Quinoline 
Methanol, which is part of the second generation of Quinoline Methanols from the 
cinchona alkaloids and Quinine (Pharmacology of Current Malaria Chemotherapy, 
1999:1).  The above mentioned drugs, which were in the class of blood 
schizonticides, developed by WRAIR, were useful  as suppressive 
chemoprophylaxis applied  in the treatment of non-relapsing (non-vivax) malaria.  
Unfortunately, these compounds have no effect against the pre-erythrocytic hepatic 
stage of any of the plasmodial species.  As a result, they do not provide any true 
causal prophylaxis against malaria.  Another concern is that the drug is also inactive 
against the liver hypnozoites of Plasmodium vivax and therefore does not inhibit 
relapses of vivax malaria (Adak, Valecha & Sharma, 2001:891-894).  
 
The research into and discovery of P. falciparum malaria resistant to Chloroquine 
stimulated the research into blood schizonticidal agents to replace Quinine, and 
particularly Chloroquine (Baird, 2004:4075-4083).  The appearance of Chloroquine-
resistant falciparum malaria in countries of military concern to the United States in 
South America and South-East Asia coincided with the intensification of preclinical 
trials with WR30090 (White, 1996:1122-1123).  In early clinical trials, the falciparum 
malaria parasite tolerated WR30090, with moderate and high resistance to 
Chloroquine (Martin, Arnold & Clyde, 1973:214-219).   
 
Consequently, WR30090 was used in Thailand for treatment trials against known 
Chloroquine-resistant falciparum malaria.  Although the drug was effective against 
malaria, it produced serious neurological and gastrointestinal side-effects in patients, 
and was thus problematic to use (Clyde, McCarthy, Robert & Miller, 1973:220-223). 
As a result of these findings, WRAIR developed WR142490 (Mefloquine).  In 1974 
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Rieckmann, Trenholme & Williams first published studies regarding the efficacy of 
Mefloquine as a prophylactic agent against falciparum malaria (Rieckmann, 
Trenholme & Williams, 1974:375-377) and the following year they wrote a paper on 
the treatment of malaria with Mefloquine (Trenholme, Williams & Desjardins, 
1975:792-794).  In 1976 Clyde and colleagues published their findings regarding the 
suppressive activity of Mefloquine against sporozoite-induced infection in humans 
(Clyde, McCarthy, Miller & Hornick, 1976:384-386). Following the necessary 
research, it was found that Mefloquine was effective against all known resistant 
strains of falciparum malaria (Kitchener, 2003:34-38).  In the decade after these 
initial pre-registration trials, it was still evident in future field trials that Mefloquine was 
effective in areas of known Chloroquine-resistant falciparum malaria.  Pre-
registration trials were done in Africa, South-East Asia, China and South America, 
which including children with complicated malaria (Chongsuphajaisiddhi, 
Sabchareon & Chantavanich, 1987:223-226).  Trials also indicated corresponding 
efficacy with Chloroquine in managing a vivax malaria patient (Alcantara, Uylangco, 
Sangalang & Cross, 1985:534-538).  During the time of Mefloquine’s general 
availability in 1985, clinical evidence of parasites resistant to the drug began to 
appear in the Australasian region (Hoffman, Rustama & Dimpudus, 1985:1039-
1040).  Due to increasing resistance of antimalarial drugs on the African continent 
and India, strategies to “protect” the new drugs, for example Mefloquine, were 
recommended in an attempt to slow down the development of resistance (Peters, 
1985:705-715).  The use of combination drugs such as Mefloquine with Sulfadoxine 
and Pyrimethamine (MSP) was one strategy recommended for delaying the 
development of resistance to antimalarial drugs.  Although initial use of MSP did not 
produce any visible benefits (Hoffman et al., 1985:1039-1040), the combination did 
become the chosen therapeutic option on the Asian and African continents, in areas 
of known or suspected Mefloquine resistance (Guo, Arnold & Fu, 1988:538-540). 
 
2.16.2 Current recommended use of Mefloquine 
 
The suggested regimen for malaria prophylaxis with Mefloquine is 250 mg weekly, 
starting three weeks prior to exposure.  For treatment, the dose of Mefloquine varies 
from 15 mg base/kg in semi-immune patients to 25 mg base/kg in non-immune 
patients (White, 1996:1122-1123).  The Australian Defence Force follows a split-
 60 
 
dose regimen of 15 mg/kg given in three doses (750 mg, followed by 500 mg six 
hours later, then 250 mg a further six hours later) to ease unpleasant side-effects 
(Kitchener, 2003:34-38).  
 
2.17    INFORMATION ON MEFLOQUINE HYDROCHLORIDE  
2.17.1  Brandname: Mefliam® (Package Insert: Annexure B) 
 
Mefloquine is a Quinoline Methanol derivative, structurally related to Quinine.  
Mefloquine is a blood schizontozide with effects on the asexual blood forms of the 
malarial pathogens that affect humans.  It is also active against the gametocytes of 
P. vivax, although the mechanisms of action are unknown.  Mefloquine has no 
effect on the hepatic stage of malaria parasites, and strains of Plasmodium 
falciparum resistant to Mefloquine have been reported.  Cross-resistance between 
Halofantrine and Mefloquine has been observed, and resistance to Mefloquine, as 
well as to any other antimalarial drug, may occur in any endemic area.  Resistance 
patterns occur and vary from region to region and with time (Mefliam® package 
insert, 2002:1). 
  
2.17.2 Pharmacokinetics  
 
The maximum plasma concentration after a single oral dose is reached in 6 to 24 
hours (average 17 hours).  This achieved plasma concentration in nanograms per 
millilitre is roughly equivalent to the dose in milligrams.  In optimal circumstances 
with weekly doses of 250 mg, a maximum plasma concentration of 1000 mg/ml has 
been recorded.  Mefloquine is 98% bound to plasma proteins and has a large 
apparent volume of distribution (13.5–29.1l/kg).  The main metabolite of Mefloquine 
2, 8-Bistrifluoromethyl-4-Quinoline carboxylic acid is inactive against P. falciparum.  
It appears that Mefloquine is mainly excreted into bile and faeces and that the 
elimination half-life of Mefloquine is three weeks.  After a single dose in healthy 
adults, it was between 12–37 days on average (Mefliam® package insert, 2002:1). 
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2.17.3 Contra-indications 
 
Mefloquine is contra-indicated in children under five kilograms in body mass.  It is 
also contra-indicated with pregnancy, lactation, a history of epilepsy or psychiatric 
disturbances and impaired liver or kidney functioning.  The drug is excreted in 
breast milk and if it must be taken, breast feeding should be discontinued 
(Mefliam® package insert, 2002:1). 
 
Special care should be taken when scuba diving, piloting an aircraft and driving 
heavy machines, as dizziness and vertigo have been reported.  Other side-effects 
include psychiatric disturbances, convulsions, cardiac abnormalities and 
gastrointestinal problems, such as diarrhoea and vomiting.  Mefloquine must not be 
used for longer than three months consecutively (Mefliam® package insert, 
2002:2).  Drug interactions include an increased risk of convulsions when Quinine 
is used if malaria does occur.  A potentially fatal conduction disorder of the heart is 
possible if Halfan is used when malaria does occur, or if taken with some 
medications for high blood pressure blockers and calcium channel antagonists, 
antihistamines and antidepressants (Mefliam® package insert, 2002:2).  
 
It is recommended that the dosage for adults and children over 45 kilograms be 
one 250 mg tablet once a week, starting one week prior to entering a malaria area 
and continuing for four weeks after leaving the area.  The tablet should be taken 
after a meal, preferably after supper.  A doctor’s prescription is required (Mefliam® 
package insert, 2002:3).  
 
Preventative medication for people entering a malaria area is absolutely essential 
(Bradley & Bannister, 2003:180-199).  Mefliam® tablets are indicated for 
prophylaxis of Plasmodium falciparum malaria in the regions where P. falciparum 
strains resistant to 4-aminoquinolines (e.g. Chloroquine) occur. 
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2.17.4 Dosage and directions for use 
 
As seen in 2.16, 2.18 and 2.19, history has shown that substantial sickness will 
occur among military forces if the use of the correct type and dosage of 
preventative medicines is delayed. 
 
Table 2.1: Weekly recommended doses of Mefliam® as malaria prophylaxis 
Body weight Weekly dose for prophylaxis 
Up to 19 kg ¼ tablet (82.5 mg) 
20 – 30 kg ½ tablet (125 mg) 
31 –45 kg ¾ tablet (187.5 mg) 
>45 kg 1 tablet (250 mg) 
(Mefliam® package insert, 2002:3) 
 
2.18 THE MILITARY EXPERIENCE OF MEFLOQUINE 
MALARIA CHEMOPROPHYLAXIS 
 
The development of synthetic antimalarial drugs was given a vital start in the 
Second World War when Japan captured the world’s core supplies of Quinine in 
Java.  Chloroquine and Mepacrine were the primary agents developed at that time 
(Cotton, 2005:1).  
 
Since World War II, the development of Chloroquine-resistant falciparum malaria 
has driven the hunt for new drugs.  Mefloquine, developed by the Walter Reed 
Army Institute of Research in the United States, was first proven to be effective for 
prophylaxis and treatment of resistant falciparum malaria in the 1970's (Laruim 
Label update, 2002:1-8).  
 
Mefloquine concentrates on the blood stages of the Plasmodium life cycle after the 
discharge of merozoites from the liver.  It does not have tissue schizonticidal 
activity, and so does not heal those forms of malaria retained in the advanced liver 
stages (hypnozoites).  It does not take action against the sexual stages taken up by 
the mosquito in the life cycle, and therefore does not block transmission.  
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Mefloquine is associated with neuropsychiatric and gastrointestinal unfavourable 
reactions, but no more so than other antimalarial drugs.  Dosage regimens for 
Mefloquine prophylaxis are simpler than those for other comparably efficient 
antimalarial drug regimens (Department of Health and Human Services, 2006:1). 
 
2.19 MILITARY USE OF MEFLOQUINE 
 
During the British military exercises in central Kenya, the British Army policy for 
malaria chemoprophylaxis, recommended Chloroquine 300 mg weekly and 
Proguanil 200 mg daily.  Following seven cases of malaria sustained among only 
150 soldiers during an exercise in 1992, the policy was reassessed (Miller et al., 
1994:119-123).  Even though compliance with chemoprophylaxis was not officially 
monitored, the policy was changed to Mefloquine 250 mg weekly (Miller et al., 
1994:119-123).  The policy change of the British Army in favour of Mefloquine was 
interesting in that the experience of the Dutch military did not favor Mefloquine.  
During their deployment to Cambodia during 1992–1993, three battalions (± 600 
troops/battalion) of Dutch marines that used Mefloquine chemoprophylaxis 
contracted falciparum malaria (Hopperus Buma et al., 1996:1506-1509).  Even 
though the Dutch soldiers were deployed in regions where Mefloquine-resistant 
falciparum malaria was potentially endemic, compliance was only 86%, and 30% of 
the marines reported unpleasant side-effects.  The Dutch nevertheless concluded 
that Mefloquine was “well tolerated”, though not entirely effective, after 
comprehensive supervision of the final group, (Jaspers et al., 1996:230-234).  
 
For the British Army, Croft pointed out in his studies that Mefloquine toxicity was 
equivalent to that of other brands of chemoprophylaxis currently in use (Croft, 
1995:191).  In later studies by Croft, he demonstrated that less than one in 6000 
soldiers deployed in Kenya had the symptoms of neuropsychiatric side-effects 
(Croft & World, 1996:326). The findings of his studies showed that operational 
British soldiers did not report any more side-effects from Mefloquine than from the 
combination of Chloroquine and Proguanil (Croft, Clayton & World, 1997:199-203).  
During subsequent military peacekeeping operations in East Africa, more 
information arose concerning the use of Mefloquine under operational conditions.  
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Between December 1992 and May 1993, 48 troops, out of a group of 9000 
contracted malaria whilst deployed to Somalia (Wallace et al., 1996:49).  
Mefloquine effectiveness in the region was incomplete.  On interview, more than 
half of these subjects reported compliance with chemoprophylaxis; however, half of 
the group interviewed had been prescribed inadequate doses of Doxycycline or 
Mefloquine (Robert, 2001:73-76; Newton et al., 1993:1).  
 
Members of the Italian military force operating in Somalia were less infected.  Only 
18 members contracting malaria were using Chloroquine 300 mg weekly and 
Proguanil 200 mg daily among 11 600 soldiers deployed (Peragallo et al., 
1997:343-346).  In the light of the British experience in Kenya, these results were 
positive (Miller et al., 1994:119-123).  Nevertheless, in 1992 the combination drugs 
of Chloroquine with Proguanil began to fail the Italian forces, as they sustained 100 
malaria casualties in the first three months of deploying 4800 peacekeepers to 
Mozambique.  Their response was to use Mefloquine 250 mg weekly, the same as 
prescribed by the British chemoprophylaxis policy.  Due to this decision the 
subsequent malaria casualties were limited to 19 in the last two months of the 
operation (Peragallo et al., 1997:343-346).  In the subsequent review of the two 
operations, collectively involving 5120 Italian soldiers, Mefloquine 
chemoprophylaxis was identified as the drug easier to comply with, and no greater 
discontinuation rate than Chloroquine and Proguanil chemoprophylaxis was 
recognised (Peragallo et al., 1999:73-77). 
 
Brazilian peacekeepers were deployed to Angola for six months in 1995–1996.  
They used Mefloquine 250 mg weekly for malaria chemoprophylaxis (Sanchez et 
al., 2000:275-282).  Notwithstanding this regimen, 78 of the 439 soldiers contracted 
clinical malaria.  Due to this outbreak of malaria, an investigation was conducted in 
partnership with the US military.  The findings of this investigation were that a more 
efficacious chemoprophylactic drug was needed for military forces deployed in 
endemic malaria areas (Sanchez et al., 2000:275-282). 
 
In another international operation supported by the US Army, non-immune 
Indonesian soldiers were deployed to Irian, Java.  These soldiers were originally 
from non-malaria endemic regions of Indonesia and were provided with Mefloquine 
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250 mg weekly, Doxycycline placebo, Doxycycline 100 mg daily and Mefloquine 
placebo or only placebo tablets for the first three months of posting (Ohrt et al., 
1997:966-969).  The regimen of Mefloquine chemoprophylaxis proved itself to be 
effective and the minimum side-effects were reported.  This result was similar to 
the finding of earlier studies by the US AFRIMS group, who did their study with the 
Royal Thai Marines on the Thai-Cambodia border. The findings of the study were 
that Mefloquine was well tolerated and compliance readily achieved (91%) 
(Suriyamongkol, Timsaad & Shanks, 1991:515-518). 
 
The Australian military experience with Mefloquine was limited.  Doxycycline 100 
mg daily was the main chemoprophylaxis regimen since replacing Chloroquine and 
Maloprim in the early 1990s.  After the increasing failure of this combination 
regimen under field conditions in Papua, New Guinea, it was changed to 
Doxycycline 50 mg daily with Chloroquine 300 mg weekly (Rieckmann, Yeo & 
Davis, 1993:446-449).  Various combinations of chemoprophylaxis were 
considered and tested, including Mefloquine 250 mg weekly, which was found 
completely effective in protecting a small group of soldiers against falciparum 
malaria.  Without using Primaquine terminal prophylaxis to address liver stages of 
the parasite, vivax malaria occurred on return to Australia.  Mefloquine was 
established as the first alternative to Doxycycline 100 mg daily for short-term 
exposures in malaria endemic areas (Edstein, Nasveld & Rieckmann, 2001:12-16).  
It was used in this capacity for those intolerant to Doxycycline during Australian 
deployments to Cambodia and Somalia and exercises in Papua New Guinea, 
although numbers of personnel using this regimen were very small (Shanks, 
Roessler, Edstein & Rieckmann, 1995:443-445).  
 66 
 
CHAPTER 3 
3. METHODOLOGY AND INTERPRETATION OF 
DATA 
3.1 OVERVIEW 
 
The previous two chapters focused on the origin, history and incidence of malaria 
in the armed forces of the world, and on the importance of studying malaria as a 
global problem.  The review of the literature also focused mainly on the incidence 
of malaria in soldiers deployed to Eastern Africa.  
 
As South African troops were deployed in East Africa as a peacekeeping force in 
Burundi, the threat of malaria infection was imminent.  This study therefore aimed 
to explore South African National Defence Force (SANDF) members’ attitudes to, 
and compliance with anti-malaria medication.  This sample group of this study was 
soldiers.  All the members that filled in the questionnaires were in their second last 
month of their deployment of six months.  Various factors influencing malaria were 
highlighted. 
 
The sample group comprised SANDF members who were in their second last 
month of a deployment period in Burundi of six months.  Data were collected using 
a questionnaire, which respondents completed voluntarily.   Questions highlighted 
various aspects of malaria as it would affect the SANDF members under 
investigation.  This chapter outlines the methodology used to approach the 
research process in order to investigate the issues in question.  The questionnaire 
design, sample selection and size, administration of data capturing and the data 
collection procedures are explained.  The limitations, as well as the criteria for 
admissibility of the data are identified.  
 
3.2 THE DESIGN OF THE STUDY  
 
It is envisaged that the results of this study will be used by the personnel of the 
SANDF and other military forces deployed in East Africa.  The findings could be 
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used by military forces designing a control programme, as well as by others 
involved in the control of malaria, such as policy and decision makers.  
 
Burundi is a country with enormous tourism potential.  When a democracy is 
achieved in the country and peaceful settlement is found among the warring rebel 
groups, this country will be a true paradise for tourists.  The Tanganyika Lake and 
the lush equatorial forests make this area a potential popular tourist attraction 
(Briggs 1998:202).  Unfortunately, the malaria mosquito is endemic to this area, 
and it is important that the results of the study be made available to tourists to 
establish which chemoprophylactic regime would be most suitable to use.  This 
should also be of interest to anyone else whose activities may have an impact on 
the malaria situation or its control in that region. 
 
3.3 THE AIM OF THE STUDY 
 
The aim of the study was to investigate the prevalence of malaria in the users of 
Mefloquine Hydrochloride – Mefliam®.  This drug was administrated to soldiers 
stationed in Burundi, East Africa. 
 
The results of this study could also be expoliated to the local population.  It was 
argued that, if Mefloquine is the drug of choice and proves to be effective during 
military deployments to Burundi, it could be presumed that the Plasmodium 
organism in that area was not resistant to Mefloquine.  Mefloquine would thus be 
regarded as an effective malaria management tool and hence as a therapeutic and 
preventative drug.  
 
The information gathered in this study would aid the armed forces of the world.  
This information would help in selecting the most effective antimalarial prophylaxis 
to use during extended deployments to Burundi.  The results of this study would 
show the efficacy of Mefloquine Hydrochloride - Mefliam® as an antimalarial drug. 
This would determine if the use of this drug would reduce the risk of malaria 
infection among military force members deployed in Burundi. 
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The results of the study could also be helpful to international travellers visiting that 
part of the continent.  The fact that hundred and eleven (111) people used 
Mefliam® and only four members presented with any malaria symptoms, is a good 
indicator that Mefliam® is a good option as an antimalarial drug in Burundi. 
 
3.4 SAMPLE SELECTION  
 
The target population was South African National Defence Force soldiers deployed 
in Bujumbura, Burundi, for more than hundred days.  Based on the advice of Mr 
C.K.M. Makgadi (MA, Research Psychology), the sample size was determined.  
The total size of the group/population was 336 members and the sample group size 
(chosen portion) was 111 members.  Of the 336 members, 11 (3.29%) were 
females.  
The demographics of the different race groups were: 
• 229 (68.37%) Black; 
• 70 (20.84%) Coloured; 
• 33 (9.87%) Caucasian; and 
• 4 (0.91%) Asian. 
 
The figures above indicate that the race groups, as well as the gender groups were 
represented according to percentage representativity in the research study.  The 
research group (111) represented 33.04% of the total group. 
 
No control group was established, as ethical and moral guidelines prohibiting 
people from entering an endemic malaria area without access to proper 
antimalarial prophylaxis. 
 
The questionnaire design, sample selection, administration of data capturing and 
data collection procedures are identified.    
 
The sample was determined by means of simple random sampling.  This method 
was used to ensure that every member of the accessible population had an equal 
chance to be included in the sample (Leedy, 1989:140).  The lottery method was 
used by allocating a number to the name of each member of the population.  These 
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were put into a container.  The container was then shaken and names were 
randomly drawn from the container until the required number of names had been 
selected (Lues, 2003:39).  The exploratory research method was used to gain 
insight into the group involved.  Using the social survey method, a questionnaire 
was designed and administered to each voluntary respondent (Lues, 2003:45).  
Before responding, each participant gave his/her informed written consent.  The 
responses to the questionnaire were analysed, interpreted and ordered. 
 
3.5 DATA COLLECTION 
 
The first objective was to identify the persons using Mefliam®.  The information 
required was identified by means of the questionnaires (Annexure A) using the 
descriptive survey method (Leedy, 1989:140).  The study was of an explanatory, 
descriptive nature and the survey mode of observation was used in the form of 
questions contained in the questionnaire. 
 
The first part of the questionnaire distributed to the soldiers determined their ethnic 
background.  The respondents were required to supply the research team with the 
name of the antimalarial prophylaxis used. 
 
This information enabled the research team to detect what kind of prophylaxis each 
respondent was using at the time of the investigation.  The alternative drugs used 
were Mefliam® and Doxycycline.  The airforce pilots and two female respondents 
used Doxycycline.  The female respondents probably used Doxycycline due to the 
side-effects of Mefliam® indicated in the Mefliam® package insert (2002:2).   
 
3.6 QUESTIONNAIRES 
 
Questionnaires were administrated to the selected soldiers of the SANDF deployed 
in Burundi, East Africa.  The questionnaire aimed to determine the following: 
• perception of the user regarding the malaria threat; 
• compliance with taking the medication; 
• possible side-effects which may have occurred due to the chemoprophylaxis; 
and 
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• the prophylactic efficacy of Mefliam®.  
 
Each respondent gave their written consent.  The questionnaire was compiled in 
English, which is the language medium of the South African National Defence 
Force. 
 
3.7 QUESTIONNAIRE FORMULATION 
3.7.1 Objectives 
 
Guidelines for the design of the questionnaire used were obtained from the 
following sources: 
• Makgadi (personal communication, 2002); and 
• Hlolongwane (personal communication, 2002)   
 
The questionnaire was developed to determine respondents’ views on sickness 
and health, this specific knowledge of malaria, and their compliance with anti-
malarial regimens. 
 
Questionnaires were then constructed in five broad analytical categories 
addressing demographic and personal data, knowledge of anti-malarial medication, 
and knowledge and beliefs about and practices with regards to malaria.  The 
questionnaire (Annexure A) was designed to attain the following objectives: 
 
3.7.2 Independent variables (zero control variables) 
 
Section one of the questionnaire obtain socio-demographic information regarding 
the users of Mefliam®: 
• Age 
• Services (occupational class) 
• Home Language 
• Home Province 
• Gender 
• Race 
 
 71 
 
3.7.3 Dependent variables 
 
The second category in section two of the questionnaire, involved experiences, 
perceptions, beliefs and views on malaria and anti-malarial prophylaxis. 
 
The third category in section three of the questionnaire, involved the respondents’ 
knowledge regarding Mefliam®. 
 
The fourth category involved the treatment regimen.   Questions explored 
respondents’ perceptions regarding the convenience of the drug use, the 
necessary behaviour change, as well as the reactions to and perceptions regarding 
the medication.  As a qualitative rather than empirical study, the content validity of 
the questionnaire was developed not through pilot studies, but by refinement and 
sharpening of the questions during the pre-testing phase that took shape in the 
form of personal interviews.  The people involved in the interviews were randomly 
chosen from the same group of people that were used in the actual study.   
 
3.7.4 Breakdown of sections 
 
In order to achieve the objectives listed in section 3.7.1, a structured questionnaire 
(Annexure A) consisting of 5 sections was designed. 
 
SECTION I 
Socio-demographic data collected 
Questions 1.1 to 1.6 
 
SECTION II 
Information on the knowledge of malaria and the use of anti-malarial prophylaxis 
before, during and after deployment in endemic malaria areas. 
Questions 2.1 to 2.6 
 
SECTION III 
Information regarding the anti-malarial prophylaxis in use and feedback concerning 
the use or experience of the drug. 
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Questions 3.1 to 3.6     
 
SECTION IV 
The users’ personal experience with the drug. 
Question attempted to determine whether the user contracted malaria while using 
the drug. 
Question 4.1 to 4.5 
 
SECTION V 
Any concerns or problems about the anti-malarial drug in use were offered by the 
respondents’ in this section.  
Question 5 
 
3.8 ADMINISTRATION OF DATA CAPTURING 
 
The questionnaires were all handed out to the respondents while in the deployment 
area.  The questionnaires were administered to eight groups of 15 SANDF soldiers 
over the course of 2 days.  The questionnaires were gathered immediately after 
completion.  
 
The front page of the questionnaire explained the importance of the study and 
requested their co-operation (Annexure A).  The respondents were informed of the 
confidential nature of their responses to the questionnaire.  The questionnaires 
were completed in the presence of the researcher.  There were no time constraints 
in completing the questionnaires. 
 
Questionnaires were used for the following reasons: 
• A questionnaire is one of the strongest measuring tools (Lues, 2003:49). 
• Due to the fact that the respondents were all military personnel, they were 
geographically fairly easily accessible. 
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3.9 SAMPLE REALISATION 
 
Questionnaires were handed to 120 participants.  As eight of the sample group 
used Doxycycline, and would therefore not conform with the aim of the study, they 
were not included.  The other 112 respondents used Mefliam®.  One of the 
questionnaires was not completed.  The return rate for the questionnaires was 
100%.  Hundred and eleven (92.5%) of the initial 120 questionnaires were relevant 
to the study. 
 
3.10 ANALYSIS OF THE DATA  
 
Data were entered onto a Microsoft Excel spreadsheet and analysed using the 
SAS Statistical Programme.  The confidence interval and Wilson reliance interval 
(score method) were utilised as statistical guidance tools.  
 
Confidence interval (CI) 
p = proportion of positive responses 
n = individuals 
r = characteristics of interest 
z = 1,96 for a 95 percent confidence interval 
begin value; top value = [p - z√; p + z√] 
n = 111 
r  = 4 
p = r/n = 4/111 = 0,036 = 3,6% 
CI of population:  p ± z√[p (1-p)]/n 
 
Wilson reliance interval (score method) 
A = 2r+z²; B = z√[z²+4r(1-r/n)]; C = 2(n+z²) 
CI = [(A-B)/C; (A+B)/C] 
 
Detailed reporting and interpretation of the data are presented in Chapter 4.   
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3.11 POSSIBLE LIMITATIONS 
 
The study took place in a military environment.  Some of the respondents could 
have been intimidated by the more senior ranks of the members who handed out 
the questionnaires, and could have responded by stating what they wanted their 
seniors to hear, and not the actual truth. 
 
To eliminate this possibility of intimidation as far as possible, the members were 
referred to the medical confidentiality of the document when completed, and the 
legal implications of information leaking out.  Before the questionnaires were 
eventually handed out, the members were also briefed by senior management 
regarding the confidentiality of the process, and their co-operation was asked.  
  
3.12 SUMMARY OF CHAPTER 3 
 
This chapter outlined the procedures followed in obtaining the data using the 
simple random sampling and lottery method.  Every member of the accessible 
population had an equal change to be included in the sample (Leedy 1989:140).  
The survey research study used observation (questionnaires) to obtain the data.  
The methodology used to obtain the data was discussed.  The process included an 
examination of the sample selection, administration of the data capturing, 
questionnaire formulation, determining criteria for the admissibility of the data and 
the interpretation of the data.  The limitations of the survey were discussed. 
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CHAPTER 4 
4. RESULTS 
4.1 OVERVIEW 
 
The method of data collection was discussed in the previous chapter.  In this 
chapter the results of the processed data are tabulated, interpreted and evaluated.  
Only relevant results that emerged are dealt with.  The following results are 
reported: 
• perceptions of malaria threat; 
• awareness of preventative methods to avoid contracting malaria; 
• malaria history of members; 
• perceptions of malaria and the use of anti-malarial prophylaxis during 
deployment; 
• knowledge of the anti-malarial drugs which were used at the time of the study; 
• the importance of taking the anti-malarial prophylaxis; and 
• ascertaining whether the users of Mefliam® contracted malaria during their 
deployment in Burundi. 
 
4.2 RESULTS 
4.2.1 Gender of respondents and malaria infection  
  
Due to the hostile nature of the area in which the SANDF soldiers are deployed, 
and the fact that Burundi is a Muslim country, only a few females were part of the 
contingency.  Although the study aimed to get maximum participation from the 
female group, only six of the eight women participated in the study (Table 4.1). 
 
Table 4.1: Gender of respondents (n = 111) 
Male Female 
% (n) % (n) 
94.6% (105) 5.4% (6) 
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According to the study 3,8% (4) of the males contracted malaria, and none of the 
females contracted malaria during the same period.  
 
Both males and females were exposed to the anti-malarial active drug found in 
Mefliam®, yet the males, and not females contracted malaria.  This begged the 
question why females appeared to be more immune to malarial infection than men.  
One possible explanation could be that the Anopheles mosquito is attracted to, or 
repelled by, particular odours.  The main olfactory cue for attracting mosquitoes is 
carbon dioxide (CO2) (Maharaj, 2004:personal communication; Robert, 2001:69-
74).  Carbon dioxide is acting as an attractant, and orientation towards the source 
of CO2 is due to the optomotor anemotaxis (Hutchinson, 2004:1).  The attraction to 
a host may be relatively fixed as with Anopheles gambiae, which is highly attracted 
to human host odours (Hutchinson, 2004:1).  For example the Anopheles 
arabiensis mosquito will reduce the number of blood meals taken from humans 
when the amount of livestock in the district has increased (Hutchinson, 2004:1).  
Researchers combined CO2 with 1-octen-3-ol (octenol) and found it to attract some 
Anopheles species (Hutchinson, 2004:1).  Hutchinson (2004:1) reported that 
octenol is identified as an odour specific to mammalian origin.  However 
deodorants and other perfumed products associated with females specifically are 
thought to interfere with the chemoreceptors on the antennae of the mosquito and 
disturb the perception of carbon dioxide and octenol identification (Maharaj, 
2004:personal communication).  It could thus be assumed that, because females 
are normally known to use more deodorants and other perfumed products than 
their male colleagues, they will be less attractive to the Anopheles mosquito 
 
4.2.2 Age of respondents and malaria infection 
 
Age is an important variable when taking malaria prophylaxis.  The ages of the 
respondents were determined and categorised (see Table 4.2).  As can be seen 
from Table 4.2, most of the respondents (107) were in the 20 to 30 and 31 to 40 
years age categories.   
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Table 4.2: Age of respondents (n = 111) 
20 – 30 31 – 40 41 – 50 50+ 
% (n) % (n) % (n) % (n) 
40.5% (45) 55.9% (62) 2.7% (3) 0.9% (1) 
 
The study showed that one person from the 20 to 30 age group contracted malaria 
and three members from the 31 to 40 group contracted malaria, while none from 
the two older age groups contracted malaria.   
 
A possible reason for this could be that, in the younger age groups, people tend to 
be more egocentric and nonchalant concerning the taking of the prophylaxis 
(Hlolongwane, 2002:personal communication, Makgadi, 2002:personal 
communication).  Members had been informed that the Mefliam® tablets should 
not be taken with alcohol, so they would rather take a few beers and postpone the 
taking of the drugs than using them as prescribed (Makgadi, 2002:personal 
communication).  It could be assumed that, this practice resulted in the members 
forgetting to take the anti-malarial medication.    
 
The members of the fifty years and older age group are not exempt from risk in a 
malarial area, and they should be routinely monitored for fluctuations in their blood 
pressure and educated accordingly.  A potentially fatal conduction disorder of the 
heart may occur if Halfan is used when malaria is contracted, or if taken with some 
medications for high blood pressure blockers and calcium channel antagonists, 
antihistamines and anti-depressants (Mefliam® package insert, 2002:3).  Other 
side-effects include psychiatric disturbances, convulsions, cardiac abnormalities 
and gastrointestinal problems, such as diarrhoea and vomiting.  There also might 
be different pharmokinetic parameters for persons older than 50 years.  Caution is 
advised in renal compromised patients and inpatients with compromised hepatic 
functions (Mefliam® package insert, 2002:1).   
 
The aim of the following statistics was to determine if there was a correlation 
between the respective age groups and the possibility of contracting malaria. 
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Age Group: 20-30 
p = proportion of positive responses 
n = individuals 
r = characteristics of interest 
z = 1,96 for a 95 percent confidence interval 
begin value; top value = [p - z√; p + z√] 
p = r/n = 1/45 = 0,022 = 2,2% 
CI of population: p ± z√[p (1-p)]/n 
= 0,022 ± 1,96√[(0,022)(0,78)]/45 
= 0,022 ± 1,96√[0,172/45 
= 0,022 ± 1,96√0,00381 
= 0,022 ± 1,96.0,0618 
= 0,022 ±  0,121 
CI = [-0,099; 0,143] 
 
Because the lower limit of the interval is less than zero, a false indication can be 
experienced regarding the probability that a member of this age group is likely to 
contract malaria.  According to a level of confidence of 95% the parameter of the 
population will lie between these two limits, but can not be negative, therefore a 
more reliable test is necessary.  For this purpose, the Wilson reliance interval was 
used. 
 
Wilson reliance interval (score method) 
A = 2r+z²; B = z√[z²+4r(1-r/n)]; C = 2(n+z²) 
CI = [(A-B)/C; (A+B)/C] 
A = 2r+z² = 2(1) + (1,96)² = 2 + 3,842 = 5,842 
B = z√[z²+4r(1-r/n)] = 1,96√[1,96²+4(1)(1-0,022)] = 1,96√[3,842+4(0,978)] 
B = 1,96√[3,842+4(0,978)] = 1,96√7,754 = 1,96.2,785 = 5,458 
C = 2(45 + 1,96²) = 2(48,842) = 97,684 
CI = (5,842-5,458)/97,684; (5,842+5,458)/97,684 
CI = 0,384/97,684; 11,3/97,684 
CI = [0,0393; 0,116] 
 
According to this statistical method there is a 95% certainty that when a population 
(age group 20-30) is using Mefloquine, the chance of getting malaria will be 
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between 0,0393 and 0,116.  In other words, an individual in this age group has a 
3,9% to 11,6% chance of contracting malaria when he/she is using Mefloquine 
(Mefliam®). 
 
Age Group: 31-40 
p = r/n = 3/62 = 0,048 = 4,8% 
Making use of the Wilson reliance interval (score method): 
A = 2r+z²; B = z√[z²+4r(1-r/n)]; C = 2(n+z²) 
CI = [(A-B)/C; (A+B)/C] 
A = 2r+z² = 2(1) + (1,96)² = 2 + 3,842 = 5,842 
B = z√[z²+4r(1-r/n)] = 1,96√[1,96²+4(1)(1-0,048)] = 1,96√[3,842+4(0,952)] 
B = 1,96√[3,842+4(0,952)] = 1,96√7,65 = 1,96.2,766 = 5,421 
C = 2(62 + 1,96²) = 2(65,842) = 131,684 
CI = (5,842-5,421)/131,684; (5,842+5,421)/131,684 
CI = 0,421/131,684; 11,263/131,684 
CI = [0,003; 0,086] 
 
According to this statistical method there is a 95% certainty that when a person in 
this age group (31-40) is using Mefloquine, he/she has a 0,3% to 8,6% chance of 
contracting malaria when using Mefloquine (Mefliam®). 
 
4.2.3 Race of respondents and malaria infection 
 
The race of the respondents was determined and categorised as shown in Figure 
4.1.  
 
68%
20%
2%
10%
Black
Coloured
Asian
White
Figure 4.1: Race of respondents (n = 111) 
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 In this section the emphases will fall on the behaviour of the mosquito and the 
stimuli (e.g. skin colour) attracting it to the host.   
 
African populations have traditional perceptions concerning disease prevention, 
treatment and management.  Some diseases are considered suitable for 
management by western medicines, while other diseases are considered the 
exclusive domain of local traditional health practitioners.  The decision to use 
western medicine for an illness is often considered as a last resort (Nchinda, 
1998:398).  There is no medical evidence to support the use of homeopathic 
preparations for the prevention or treatment of malaria (Barnes, 2005:personal 
communication; SCAT, 2003:15). 
 
The study showed that one of 11 white persons contracted malaria, while three of 
76 black members contracted malaria.  all these respondents had used Mefloquine.   
 
In an attempt to determine if there was a correlation between the respective race 
groups and the possibility of contracting malaria, the following statistical analysis 
was applied: 
 
Black 
Confidence interval (CI) 
p = r/n =3/76 = 0,039 = 3,9% 
CI = [-0,0045; 0,083] 
 
Because the lower limit of the interval is less than zero, a false indication can be 
experienced regarding the probability that a member of this race group is likely to 
contract malaria, thus the Wilson reliance interval were used.  The Wilson reliance 
interval indicated a confidence interval (CI) of [0,026; 0,128].  According to this 
statistical method, there is a 95% certainty that when a population (black) is using 
Mefloquine, the chance of getting malaria will be between 0,026 and 0,128 (2,6% to 
12,8%) when using Mefloquine (Mefliam®). 
 
White 
p = r/n = 1/11 = 0,091 = 9,1% 
 
 81 
 
The Wilson reliance interval indicates a confidence interval (CI) of [0,0162; 0,377]. 
There is a 95% certainty when using this specific statistical method that a 
population (whites) using Mefloquine will have a 1,6% to 37,7% chance of 
contracting malaria when using Mefloquine (Mefliam®). 
 
Although the compound eye of the mosquito has less resolving power than that of 
most mammals, the aperture allows better vision in the dark (Hutchinson, 2004:1).  
The eye of a mosquito performs a number of functions.  It detects movement, 
colours, shapes and edges of objects (Hutchinson, 2004:1).  Some of the first 
studies by Bellamy and Reeves in 1952, reported the importance of visual cues in 
traps for mosquitoes.  They used three transparent lard traps.  The traps were 
placed in a line about one metre apart.  The one in the middle was baited with CO2 
released via a hidden pipe.  This trap caught the least mosquitoes.  The two 
unbaited traps were made visible by placing twigs and leaves around them or by 
sticking black tape in criss cross patterns across them.  This experiment showed 
that mosquitoes followed the CO2 plume upwind, but then visual cues led them to 
the unbaited traps.  This proves that visual stimuli would lead a mosquito to fly 
towards a prominent object when lacking an odour plume (Hutchinson, 2004:1).  
Although the Anopheles mosquito prefers to rest on dark surfaces (Maharaj, 
2004:personal communication), mosquitoes are visually stimulated by objects that 
are in contrast with the background (Hutchinson, 2004:1).  Since the Anopheles 
mosquito feeds exclusively during the night, especially at dusk and dawn, lighter 
skins would be perceived as contrasting on the black background of the night, and 
would therefore attract the Anopheles mosquito.        
 
4.2.4 Home province of respondents and the risk of malaria  
 
As seen from Figure 4.2, most of the respondents were from Eastern Cape (58), 
Gauteng (15) and Western Cape (11).  Only a few members were from the 
traditionally malaria-plagued provinces of KwaZulu-Natal, Mpumalanga and 
Limpopo.  This is important because the province of origin may have an influence 
on the respondents’ knowledge and attitude towards the control of malaria, as well 
as on their potential natural immunity against malaria.  The four persons who 
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contracted malaria were all from different provinces: Eastern Cape, Gauteng, 
Mpumalanga and the Free State respectively. 
 
58
6
6
2
4
11
4
5
15 Eastern Cape
Limpopo
Mpumalanga
Northern Cape
Kwazulu Natal
Western Cape
Free State
North West
Gauteng
Figure 4.2: Home province of respondents (n = 111) 
 
Malaria normally occurs in the low altitude areas (1000 metres above sea level) in 
South Africa, for example the Limpopo Province, Mpumalanga and the north- 
eastern parts of KwaZulu-Natal.  Occasionally limited focal transmission may 
develop in the North-West Province and Northern Cape along the Molopo and 
Orange Rivers.  Infections are seldom contracted outside the malarious areas and 
are then possibly as a consequence of the importation of infected mosquitoes by 
aircraft or other transport (South Africa, 2002:2).  Members from endemic malaria 
areas are generally well informed about the disease.  They know the seriousness 
of the taking of prophylaxis and the protection against being bitten.  They have 
seen the symptoms of the disease and know the suffering that is involved.  The 
people who are living in areas of endemic malaria sometimes have a naturally 
acquired immunity against the Plasmodium mosquito in that area.  Soldiers from 
such areas will have a resistance to that specific strain of Plasmodium if they would 
move into an area where that specific Plasmodium is endemic (Anthony Conway, 
Cox-Singh, Matusop, Ratnam, Shamsul & Singh, 2005:1558-1564.  
People who have grown up in endemic malaria areas and who may have 
developed immunity, will lose this immunity within a year of being out of the malaria 
area (Walker, Williams & Raeside, 2000:11-14).  These individuals must take the 
necessary precautions when re-entering a malaria area. 
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People who are living at high altitude, where the Anopheles mosquito cannot 
survive and transmission is absent, are not exposed to malaria (Nchinda, 
1998:398; SCAT, 2003:11).  In industrialised parts of the country where the disease 
does not exist, for example in big cities, people are more susceptible to malaria and 
should be monitored accordingly. 
 
Military personnel who are living close to international airports are susceptible to 
possible “airport malaria”.  This illness is due to mosquitoes that are arriving in the 
country from endemic areas (Lusina, 2000:75-76; SCAT, 2003:10).  A person might 
be sickening from malaria after he/she was deployed internationally.  
 
Frequent armed conflicts and civil unrest in areas forced large populations to settle 
under difficult conditions.  These areas are sometimes high in malaria transmission.  
Military personnel that are working and/or living under these conditions are very 
susceptible to malaria (Health and Community Care, 2003:1; Nchinda, 1998:398). 
 
Areas with changing rainfall patterns, as well as those involved in water 
development projects, are high malaria risk areas.  Water development projects 
include projects such as new dams, canals and irrigation schemes that create new 
mosquito breeding sites.  Soldiers that are living or working in such areas must be 
even more cautious regarding the transmission of malaria (Epidemic Prediction and 
Response, 2001:1, SCAT, 2003:11). 
 
The following statistics were used to determine if there is a correlation between the 
respective provinces of origin and the possibility of contracting malaria. 
 
Eastern Cape 
p = r/n = 1/58 = 0,017 = 1,7% 
 
The Wilson reliance interval indicates a confidence interval (CI) of [0,003; 0,091]. 
With a 95% certainty, it was determined that members from the Eastern Cape who 
use Mefloquine, will have a 0,3% to 9,1% chance of contracting malaria when using 
Mefloquine (Mefliam®). 
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Free State 
p = r/n = 1/4 = 0,25 = 25,0% 
 
With this group the Wilson reliance interval indicates a confidence interval (CI) of 
[0,046; 0,699].  There is a 95% certainty that when members from the Free State 
use Mefloquine, their chances of contracting malaria will be between 0,046 and 
0,699.  In other words, an individual from this area has a 4,6% to 69,9% chance of 
contracting malaria when he/she is using Mefloquine (Mefliam®). 
 
Gauteng 
p = r/n = 1/15 = 0,066 = 6,6% 
 
Individuals from Gauteng have a 3,7% to 27,3% chance of contracting malaria 
when using Mefloquine (Mefliam®).  
 
Mpumalanga 
p = r/n = 1/2 = 0,5 = 50,0%   
 
This study showed that one of the two members who came from Mpumalanga, 
contracted malaria within the first four months of deployment to Burundi.  Although 
this sample figure is in proportion of the whole sample group it is highly coincidental 
that 50% of the members of Mpumalanga, contracted malaria.  Although 
Mpumalanga is an endemic malaria region, the member who contracted malaria 
had no previous history of malaria.   
CI = [-0,193; 1,193] 
 
4.2.5 Home language of respondents and the risk of malaria  
 
Although the population had as many as ten home languages (Table 4.3), they all 
used English to communicate internally.  Thus nobody could use language as a 
reason for not being informed regarding the proper precautionary use of anti-
malarial prophylaxis and personal protection against mosquitoes. 
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Table 4.3: Home language of respondents (n = 111) 
Afrikaans English Xhosa Zulu Sotho Thwana 
% (n) % (n) % (n) % (n) % (n) % (n) 
28.8% (32) 3.6% (4) 39.6% (44) 6.3% (7) 7.2% (8) 8.1% (9) 
Swazi Ndebele Shangaan Venda   
% (n) % (n) % (n) % (n)   
1.8% (2) 2.7% (3) 0.9% (1) 0.9% (1)   
 
4.2.6 Different armed services in the SANDF and the risk of malaria 
 
The service or unit where the member is working is an important variable during the 
deployment in an endemic malaria area.  This is also an indication of the level of 
exposure to malaria and the chemoprophylaxis that should be taken.  The services 
in which the respondents were working were determined, and  are presented in 
Table 4.4.   
 
Table 4.4: Armed services (n = 111)  
Army Medical and 
Health 
Services 
(SAMHS) 
Airforce 
(SAAF) 
Navy Military 
Police 
(MPA) 
% (n) % (n) % (n) % (n) % (n) 
70.3% (78) 3.6% (4) 9.0% (10)  3.6% (4)  4.5% (5) 
Signal Unit 
(CMI) 
Engineers Logistics   
% (n) % (n) % (n)   
1.8% (2) 3.6% (4) 3.6% (4)   
 
Logistics, transportation and other support units scattered in the deployment area 
are not always part of the communication lines and disciplinary structures.  This 
makes the compliance with the antimarial regimen of these members more of a 
challenge. 
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Engineering units are involved in construction projects in tropical conditions with the 
building of roads, sewerage works, networks, water pumps and pipelines.  These 
members are sometimes compelled to overnight in tropical conditions with constant 
rains, living in wet and humid conditions.  These conditions are the optimal 
breeding ground for mosquitoes, and therefore these individuals are at great risk of 
contracting malaria (SCAT, 2003:9).  
 
Military Police members work in shifts.  These personnel are working at night and 
are more exposed to the bites of the Anopheles mosquito (WHO, 2002:9-17).  They 
are working in and around artificial light, which attracts mosquitoes (Hutchinson, 
2004:1).  
 
Kitchen personnel are part of the logistical services.  These members often work 
during the dark hours of the day between dusk and dawn.  This is the time of day 
when members are the most exposed to the bites of the Anopheles mosquito 
(SCAT, 2003:10; Wood, 1993:67-68).  Around the kitchens in temporary military 
bases stagnant water, due to the constant cleaning of the facility, and kitchen 
sewerage water as part of the normal processes in the kitchen facilities, is usually 
found.  This stagnant water attracts mosquitoes for breeding purposes.  
Mosquitoes need relatively clean water to lay their eggs (Curtis, 1996:1; SCAT, 
2003:9).  Constant pest control and mosquito control in and around these facilities 
is crucial.  
 
Army guards patrol the area during the night or stand guard at entrances.  Due to 
the high temperatures at night in the area, it is uncomfortable to wear long sleeve 
shirts, and therefore skin is exposed for the mosquitoes to feed on.  The stationary 
and roaming guards must constantly be reminded to take precautions to prevent 
mosquito bites.  The guards must be issued with the prescribed repellents. 
 
Health care workers (SAMHS) are potentially exposed to the plasmodium 
organisms by means of a needle stick.  This is called “induced malaria” (MacArthur 
et al., 2001:28).  The medical personnel were on duty 24 hours a day, in two shifts. 
The personnel working in the evening, were therefore exposed to mosquitoes for 
the entire night. 
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Military personnel that are involved in tasks requiring fine co-ordination and spatial 
discrimination such as scuba diving (Navy), piloting an aircraft (SAAF) and those 
driving heavy machines (Engineers) are discouraged to use Mefliam®, as dizziness 
and vertigo have been reported as side-effects (Notices to Readers’ Change of 
Dosing Regimen for Malaria Prophylaxis with Mefloquine, 1991:1; SCAT, 2003:15).  
 
1
11
1
SAMHS
CMI
SAAF
Army
 
Figure 4.3: Persons from different services contracting malaria (n = 4) 
 
This study showed that one out of 78 Army members that used the Mefloquine 
(Mefliam®) tablets contracted malaria within the first four months of deployment to 
Burundi.  
 
Confidence interval (CI) 
0,0128 + 1,96√[(0,0128)(0,9872)]/78 
CI = [ - 0,0121; 0,0377] 
 
As the lower limit of the interval is less than zero, a false indication can therefore  
be experienced regarding the probability that a member of the Army is likely to 
contract malaria.  According to a level of confidence of 95%, the parameter of the 
population will lie between these two limits, but can not be negative, therefore a 
more reliable test is necessary.   
 
Wilson reliance interval (score method) 
A = 2r+z²; B = z√[z²+4r(1-r/n)]; C = 2(n+z²) 
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CI = [(A-B)/C; (A+B)/C] 
CI = [0,0099; 0,0615] 
 
There is a 95% certainty that when a member of the Army is using Mefloquine, the 
chance of getting malaria when exposed to the specific climatic and environmental 
variables this force is operating in is 0,9% to 6,2%, when using Mefloquine 
(Mefliam®). 
 
This study showed that one out of 10 Airforce (SAAF) members that used the 
Mefloquine (Mefliam®) tablets contracted malaria during the same period deployed  
to Burundi. 
 
p = r/n = 1/10 = 0,1 = 10,0%   
CI = [ - 0,086; 0,286] 
 
The Wilson reliance interval indicates a confidence interval (CI) of [0,0171; 0,405]. 
An individual in this specific service of the SANDF, that is exposed to the specific 
climatic and environmental variables this force is operating in, has a 1,7% to 40,5% 
chance of contracting malaria when using Mefloquine (Mefliam®). 
 
This study showed that one out of 4 Health Service (SAMHS) members that used 
the Mefloquine (Mefliam®) tablets contracted malaria. 
 
p = r/n = 1/4 = 0,25 = 25,0%   
CI = [ - 0,174; 0,674] 
 
The individual working in this circumstances will have a 4,6% to 69,9% chance of 
contracting malaria when using Mefloquine (Mefliam®) during this specific 
deployment. 
 
This study showed that one out of two Information Services (CMI) members that 
used the Mefloquine (Mefliam®) tablets contracted malaria within the first four 
months of deployment to Burundi.  Although two CMI members are in proportion of 
the whole sample group, it is highly coincidental that 50% of all the respondents 
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whose questionnaires were received back from CMI, contracted malaria. The 
function of this grouping is primarily administrative, and therefore office bound.  
Statistical feedback is thus of minimal value.  
 
p = r/n = 1/2 = 0,5 = 50,0%   
CI = [-0,193; 1,193] 
 
According to the confidence interval (CI) test, the lower limit of the interval is less 
than zero and the upper limit is above one.  According to a level of confidence of 
95%, the parameter of the population will lie between these two limits, but can not 
be negative or above one. 
 
4.2.7 The respondents’ knowledge of methods to prevent malaria 
 
This question served to evaluate the effectiveness of pre-deployment education.  
Health seeking behaviour, perceptions of malaria, treatments and decision making 
for health care at unit level are crucial to malaria control.  Such education must be 
accompanied by improved awareness of the importance of seeking appropriate 
treatment and complying with recommended regimens of anti-malarial prophylaxis.  
The small percentage of “no” answers (Table 4.5) indicates that the pre-
deployment educational programme had a positive impact on the awareness and 
knowledge of the members. 
 
Table 4.5: The respondents’ knowledge of methods to prevent malaria (n = 111)  
Yes No 
% (n) % (n) 
87.4% (97) 12.6% (14) 
 
All four persons who had contracted malaria had, according to the study, a good 
knowledge of methods to prevent malaria. 
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4.2.8 History of malaria infections among respondents  
 
The members (6) who reported positively (yes) to the question knew the symptoms 
of malaria.  They realised that the disease is accompanied by much suffering and 
may also realised the severity of the disease and would take the necessary 
precaution to prevent becoming a victim. 
 
The members who submitted a positive “yes” answer to this question also had to 
be identified as possible future patients of rebound malaria.  These soldiers might 
develop rebound malaria during the deployment phase, and by having the 
information of these personnel on hand, they could be treated accordingly.  This 
proactive management of rebound malaria patients will also prevent any doubt in 
the effectiveness of the current anti-malarial regimen.  All of the six (6) members 
who had a previous history of malaria infections answered positively to questions 
2.4 to 2.6 and 3.6 (Annexure A).  Most of the respondents (105) had no history of 
malaria infections and they would be the primary target group to educate, and to 
confirm that they understand malaria and the severity of the disease. 
 
None of the four members who contracted malaria had a history of previous 
malaria infections. 
 
4.2.9 The consumption of malaria tablets while the respondents were 
deployed in a malaria area  
 
The perceptions regarding malaria and the current malaria medication consumed, 
were tested and are reported in this section. 
 
The primary purpose of the process was to establish the reasons for not taking the 
anti-malarial tablets and to try and change the perception of the person.  With this 
question the effectiveness of pre-deployment education could be evaluated, and 
shortfalls could be identified.  This was also a tool to evaluate the effectiveness of 
malaria administration and the distribution plan of the malaria prophylaxis to the 
military personnel during deployment.  Discipline and supervision regarding the 
taking of the prophylaxis could be revisited in future programmes. 
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The result of this question indicates that all the respondents (111) consumed the 
chemoprophylaxis while deployed in the malaria area.  Thus the education, 
procedures and policies regarding the use of the drug seem to be effective.  The 
four members who contracted malaria, had all consumed their malaria tablets while 
they were deployed in a malaria area. 
 
4.2.10 The taking of malaria tablets before the respondents’ deployment in 
a malaria area 
 
In this section the pre-deployment education and malaria management programme 
regarding effective malaria administration and the distribution of the anti-malarial 
medication to the military personnel will be evaluated. 
 
Table 4.6: The taking of malaria tablets before the respondents’ deployment in a 
malaria area (n = 111)  
Yes No 
% (n) % (n) 
96.4% (108) 2.7% (3) 
 
It is evident from the small number of “no” answers in Table 4.6, that the 
distribution programme of the malaria tablets was successful.  The members who 
were on Mefliam had to commence the regimen one week prior to entering the 
malaria area (Mefliam® package insert, 2002:4).       
 
All four persons who contracted malaria, stated in the questionnaire that they had 
taken malaria tablets before their deployment to a malaria area. 
 
4.2.11 The maintenance of the malaria regimen while the respondents 
were deployed in a malaria area  
 
Abovementioned is an important variable associated with the respondents’ use of 
the malaria prophylaxis.  The answers of the respondents were determined and 
categorised.  All the respondents stated that they had maintained the anti-malaria 
regimen while they were deployed in the malaria area.  It was also evident from the 
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study that the four persons who contracted malaria maintained the anti-malaria 
regimen while they were deployed in the malaria area. 
 
The taking of the tablets should become part of the unit routine.  For example, 
taking the anti-malarial tablets could form part of a social activity or get-together 
where each member is issued with his/her tablets and must drink it under informal 
supervision.  This activity would serve as a vehicle to reinforce the reason why 
prophylaxis medication is being used, with senior unit members leading by 
example.  The social activity also serve as a motivation to drink the tablets on time, 
as part of a routine.  Such practice will be part of the vertical malaria management 
programme, which will fit into the holistic malaria management programme. 
 
4.2.12 The respondents’ knowledge regarding the brandname of the 
malaria tablets they used 
 
Of the 120 respondents who participated in the study, 111 (92.5%) indicated that 
they were using Mefliam®.  Eight (7.5%) respondents used Doxycycline, therefore 
they were excluded from the research project. 
 
The data therefore revealed that respondents were informed about the brand name 
of their medication.  However, as only the two names were given as options in the 
questionnaire, it is possible that some respondents could have guessed.     
 
4.2.13 Side-effects experienced by the respondents when taking the 
malaria tablets  
 
In response to question 3.2, the symptoms listed in Table 4.7 were identified by the 
military members deployed to Burundi, East Africa, as possible side-effects of 
Mefliam®.  Eleven persons experienced some sort of problem when taking the 
malaria tablets.  None of the four persons who contracted malaria stated any 
problems while taking the medication.  The following table highlights the problems 
experienced by the respondents when taking the malaria tablets. 
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Table 4.7: Side-effects experienced by the respondents when taking the malaria 
tablets (n=11) 
Abdominal 
cramps 
Sensitive 
skin 
Diarrhoea Bad 
taste  * 
Nausea Headache Perfuse 
sweating 
% (n) % (n) % (n) % (n) % (n) % (n) % (n) 
9.1% (1)  9.1% (1) 18.2% (2)  9.1% (1) 27.3% (3)  18.2% (2) 9.1% (1) 
* Chronic bad taste in mouth  
 
All the above symptoms were possible symptoms listed in the manufacturers’ 
package insert.  A factor that could have influenced the sensation of side-effects 
could be the poor quality of the water the people had to drink.  Gastrointestinal 
diseases might have contributed to the symptoms of diarrhoea and nausea 
(Benenson, 1990:267; Heymann, 2004:161; Hlolongwane, 2002:personal 
communication).  This might explain the response to the “Diarrhoea” and “Nausea” 
categories.  Headache is also a primary symptom of dehydration that is associated 
with gastrointestinal disease (Hlolongwane, 2002:personal communication).   
 
However as only 11 of the sample of 111 experienced side-effects (9.9%), it could 
be argued that these military force members showed acceptable tolerance to 
Mefliam®.     
 
Side-effects in humans as listed in the manufacturers’ package insert were the 
following: 
 
• Abdominal pains 
• Aggression   
• Agitation 
• AV Block 
• Hair loss 
• Confusion  
• Hallucinations  
• Convulsion   
• Psychological changes 
• Decrease of platelets  
• Erythema  
• Depression   
• Anxiety 
• Transient elevation of 
transaminases 
• Dizziness or disturbed sense of 
balance   
• Nausea 
• Transient cardiac conduction  
• Leucopenia or leucocytosis 
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• Psychosis 
• Headaches 
• Myalgia 
• Loss of appetite  
• Panic attacks 
• Restlessness 
• Feeling of weakness 
• Visual disturbances 
• Forgetfulness   
• Irregular pulse  
• Extrasytoles 
• Paranoia   
• Emotional instability 
• Palpitations   
• Bradycardia 
• Psychiatric reactions  
• Vomiting  
• Rash or puritis  
• Urticaria alterations  
• Paraesthesia 
 
According to the manufacturer’s instructions, if signs of unexplained anxiety, 
depression, restlessness or confusion are evident, the medication should be 
stopped immediately.  The rate of serious adverse side-effects is in the order of 
1:10 000 for Mefliam®.  Mefloquine appears to cause more disabling 
neuropsychiatric symptoms in clinical trials done.  Adverse side-effects associated 
with Mefloquine include insomnia, strange dreams, mood changes, headaches, 
diarrhoea and nausea.  These would usually be experienced within the first three 
weeks of medication.  These side-effects do not become worse in subsequent 
weeks of use (Lobel & Kozarsky, 1997:1767-1771; Peragallo, et al., 1999:73-77).  If 
the side-effects are not experienced during the first use of Mefloquine, the side-
effects are unlikely to appear during subsequent use for prophylaxis.  To forestall 
these side-effects, it is suggested, when Mefloquine is taken for the first time, that 
chemoprophylaxis should commence three weeks before exposure to malaria.  
This is to enable the member to make a timeous change to another drug, should 
side-effects occur (Bradley & Bannister, 2003:180-199; Bradley & Warhurst, 
1997:138-152; WHO, 2002:9-17).  Side-effects can develop as early as the first 
week of use and more than 75 percent of the adverse reactions are apparent by 
the third dose.  In most cases symptoms resolved within three weeks of stopping 
the drug, but there are a very small number of reports of symptoms persisting for 
months and even years (Phillips-Howard & Ter Kuile, 1995:370-383).  
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4.2.14 The attitude of the respondents towards the consumption of the 
malaria tablets 
 
The perception of the respondents regarding the anti-malarial tablets was assessed 
in this section.  Due to the extreme bitterness of the tablets and the uncomfortable 
side-effects, it is understandable that some of the users (22) did not like to use the 
tablets.  Two individuals out of the 111 respondents were uncertain.  One of these 
was also diagnosed with malaria during the deployment. 
 
With a continuous education programme, the perception of the members must be 
formed that despite the bad taste and the possible side-effects of the tablets, it is 
still a privilege to have such effective chemoprophylaxis available to protect them 
against malaria. 
 
4.2.15 Indicate where the malaria tablets were obtained 
 
By making use of the questionnaires, an indication was obtained regarding the 
place or person where the malaria tablets were obtained from.  
 
Table 4.8: Indicate where the malaria tablets were obtained from (n = 111) 
Sickbay  Platoon 
Commander 
Unit Myself 
% (n) % (n) % (n) % (n) 
74.7% (83) 16.2% (18) 8.1% (9) 0.9% (1) 
 
Although nearly 75 percent of the respondents received their tablets directly from 
the sickbay, it is not the most ideal scenario.  The commanding officer of the unit or 
a delegated person should receive/collect the tablets by means of the completing of 
a register, against signature.  The respondent who answered “myself” received the 
complete regimen of malaria tablets before they left for Burundi.  According to the 
four persons that contracted malaria, they all received their medication from the 
sickbay. 
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4.2.16 Problems that could be experienced if the respondent did not use 
the malaria tablets 
 
Question 3.5 aimed to test the knowledge of the members regarding malaria.  It 
was also of use to evaluate the impact of the pre-deployment education and 
information programmes. 
 
Table 4.9: Problems that could be experienced if the respondents did not use the    
malaria tablets (n = 111)  
Malaria Malaise Fever Die  Loss of 
water 
Yellow 
fever 
Pneumo
nia 
% (n) % (n) % (n) % (n) % (n) % (n) % (n) 
70.3% (77) 2.7% (3) 15.3% (17) 1.8% (2) 0.9% (1) 1.8% (2) 0.9% (1) 
Tiredness Don’t 
know 
Vomiting No 
appetite 
No 
problem 
  
% (n) % (n) % (n) % (n) % (n)   
0.9% (1) 2.7% (3) 0.9% (1) 0.9% (1) 1.8% (2)   
 
The mindset must be cemented into military personnel that, should they not use the 
anti-malarial medication issued to them, they could be infected with malaria.  The 
members must be informed about the symptoms and seriousness of the disease 
and knowledge of malaria must be instilled in them.  This must serve as a 
motivation for the military personnel to get into the routine of using the prophylaxis 
medication.  
 
The fact that only 70.3% of the persons knew that they could contract malaria if 
they did not drink their anti-malarial drugs presents a negative reflection on the 
effectivity of the educational tools used to empower the members.  The soldiers 
were all taking their chemoprophylaxis, as discussed in a previous section, but 
according to this result they were not sure why they actually had to use the drugs.  
 
According to the study, all four persons who contracted malaria were aware of the 
fact that they could contract malaria if they did not use the malaria tablets. 
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The females were less informed than the males about the reason for taking the 
tablets.  Five of the six females stated that nothing would happen if they did not use 
the malaria tablets, and one said that a person could contract yellow fever by not 
drinking the tablets.  The feedback regarding this question outlines a weak point in 
the educational process, and it should be revisited and rectified.  It should be 
investigated why specifically the female group was so misinformed. 
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Figure 4.4: Knowledge about problems that could be experienced if the respondent 
did not use the malaria tablets (n = 111) 
 
4.2.17 The respondents’ awareness of continuing the regimen for four 
weeks after leaving the malaria area 
 
Nine (8,1%) of the respondents were not willing to drink the anti-malarial 
medication after deployment, or did not know that they were supposed to drink it for 
four weeks after leaving the deployment area.  Experience has taught that once 
military members have left the malarial deployment area, it is very difficult to keep 
to the routine.  This is understandable, since they have to adjust to a new routine or 
take leave.  There is then often no support group to motivate and remind them to 
drink the anti-malarial medication.  The members must be informed of the 
necessity to continue using the anti-malarial medication.  The members must be 
informed of and understand the pharmacokinetics of the prophylaxis medication 
that they are using or are going to use.  Members should be educated that although 
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they are out of the “danger” area, they can still contract malaria after four weeks of 
leaving the malarial area, due to the extended lifecycle of the Plasmodium 
organism.  Exposure may have been on the last day of the stay, the incubation 
period may be variable and current chemoprophylaxis may only be effective once 
the parasites enter the red blood cells.  Members need to be well motivated and 
educated to ensure the highest possible level of compliance (SCAT, 2003:15).  
One of the four persons who contracted malaria was not aware of the fact that it 
was expected of him to continue with the malaria medication for four weeks after 
leaving the malaria area. 
 
4.2.18 The motivation of the respondents to use the malaria tablets 
 
The respondents were asked the reasons why they took the tablets.  Ninety 
percent of the respondents acknowledged that Mefliam® kept them healthy.  It is 
the aim of the malaria education and information programme to instil the mentality 
in the military personnel that it is for a member’s own benefit to use the anti-
malarial medication, and to use it correctly.  This mentality will prevent members 
from becoming malaria victims. 
 
Table 4.10: The motivation of respondents to use the malaria tablets (n = 111) 
It is important to 
keep me healthy 
It is expected of 
me to do so 
I am forced to It is the rule 
% (n) % (n) % (n) % (n) 
90.1% (100) 6.3% (7) 1.8% (2) 1.8% (2) 
 
The fact that the malaria tablets would keep them healthy was the primary 
motivation why all four persons who contracted malaria, had used it. 
 
4.2.19 Symptoms/feelings related to the taking of the malaria tablets  
 
The survey indicated that 92 persons did not have any negative symptoms or 
feelings related to the consumption of the drugs.  The 19 that had symptoms, 
presented with typical side-effects as listed in the manufacturer’s package insert. 
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4.2.20 The time of day respondents normally took their malaria tablets 
 
The feedback from the respondents was that seventy two percent (72%) of the 
members took the tablets after their meals. 
 
Table 4.11: The time of day respondents normally took their malaria tablets 
(n = 111)  
At night before I 
go to sleep 
After lunch After breakfast  When I get the 
chance 
% (n) % (n) % (n) % (n) 
18.9% (21) 42.3% (47) 29.7% (33). 9.1% (10) 
 
These results are an indication that the majority of the respondents used the 
prophylaxis medication in a routine of some sort.  
 
72%
28%
Routine
No Routine
 
Figure 4.5: The consumption of the chemoprophylaxis by the respondents 
 
The member can therefore associate a certain event (e.g. Saturday supper) with 
the use of the Mefliam® tablets.  The member remembers that after supper on 
Saturdays, he/she has to take the anti-malarial tablets.  For members who are 
suffering from side-effects, it is a good idea to drink the Mefliam® before they go to 
sleep (personal observation).  This practice will alleviate most of the side-effects 
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that might be experienced. According to the Mefliam® package insert, the 
Mefliam® tablets should be taken after a meal with plenty of fluids.  
 
2
0
1 1
After lunch
After breakfast 
When I get the chance
At night before I go to sleep
Figure 4.6: The time of day the persons that contracted malaria normally took their 
malaria tablets (n = 4) 
 
4.2.21 The perception of the respondents regarding the taste of the 
malaria tablets 
 
When answering the questionnaires, it was interesting that nearly 47 percent (52) 
of the respondents stated that the Mefliam® tablets were tasteless.  They are 
considered very fortunate, because the Mefliam® tablets are generally considered 
to be extremely bitter.  This statement can probably be accounted to the fact that 
persons are advised to swallow the tablets whole, due to the awful taste.  Some 
persons had the unpleasant experience of tasting the Mefliam® tablets when the 
tablets got stuck in their mouths or throat when swallowing.  The sensory 
perception of “sour” and “sweet” by some of the members is interesting.   
 
Table 4.12: The perception of the respondents regarding the taste of the malaria    
tablets (n = 111) 
Tasteless  Sour Sweet Bitter 
% (n) % (n) % (n) % (n) 
46.8% (52) 9.9% (11) 0.9% (1) 42.3% (47) 
 
Three of the persons who contracted malaria regarded the taste of the malaria 
tablets to be “tasteless”  while one perceived it as “bitter”. 
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4.2.22 The number of persons who contracted malaria during the 
deployment in Burundi  
 
This was the primary question of the questionnaire.  This question directly 
determined the effectiveness of Mefliam® in Burundi, East Africa.  Hundred-and-
seven respondents answered “no” to that specific question four months into the 
deployment.  However four members had contracted malaria.  
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Figure 4.7: The number of persons who contracted malaria during the deployment 
in Burundi (n = 111) 
 
According to clinical trials done in Kenya, East Africa, Mefloquine had a 95% 
prophylactic efficacy (Meuhlberger, Jelinek, Schlipkoeter, von Sonnenbeurg & 
Nothdurft, 1998:357-363).  Barnes (2005:personal communication) and Talmut 
(2005:personal communication) claimed a 95% prophylactic efficacy of Mefloquine 
internationally.  Mefloquine had a 100% prophylactic efficacy in a double-blind, 
placebo controlled trial with 204 Indonesian soldiers, who used the drug for 13 
weeks. (Ohrt et al., 1997:963-967).  The evidence from a number of large trials on 
the African continent indicated a prophylactic efficacy of over 90% (Steffen, Fuchs, 
Schildknecht, Naef, Funk & Schlagenhauf, 1993:1299-1303).   
 
4.2.23 Any concerns or problems regarding the malaria tablets that were 
not listed in the questionnaire 
 
Cognisance should be taken of individual problems and concerns regarding the 
consumption of Mefliam® in the compilation the final education programme.  Table 
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4.13 thus provides important information to educators when they emphasise the 
topic of possible side-effects. 
 
Table 4.13: Concerns or problems about the malaria tablets that were not listed in 
the questionnaire (n = 111) 
Concerns/Problems Number of respondents % 
None 94 83.8 
Sweating 2 1.8 
Affect females 3 2.7 
Not with liquor intake 2 1.8 
Emotional side-effects 4 3.6 
Sex life 1 0.9 
Expose family to malaria 1 0.9 
After-taste 1 0.9 
Big appetite 2 1.8 
Continue taking tablets after leaving 
Burundi 
1 0.9 
 
One of the four persons who contracted malaria was concerned or had a problem 
with the after taste of the tablets, while one of the females had a concern regarding 
the affect it might be having on females. 
 
4.3 SUMMARY OF CHAPTER 4 
 
It is evident from the results that all the respondents who were issued with 
Mefliam® tablets were using them, although some members were identified who 
did not take the Mefliam® tablets before arriving in Burundi.  All the respondents, 
except one who did not fill in the answer, maintained their Mefliam® regimen while 
being deployed in Burundi.  It was revealed that respondents did not realise that 
they were supposed to continue using the Mefliam® tablets for four weeks after the 
deployment.  Four respondents were diagnosed with malaria from the period of 
arriving in Burundi to the time they completed the questionnaire.  This period 
comprised a minimum of hundred days. 
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Thus four out of 111 persons who used the Mefloquine (Mefliam®) tablets 
contracted malaria within the first four months of deployment to Burundi.  The 
following is a statistical summary of the findings. 
 
The value of this section lies in the statistical determination of Mefloquine as an 
effective antimalarial prophylaxis.  The confidence interval and Wilson reliance 
interval (score method) were be utilised as statistical guidance tools.  
 
Confidence interval (CI) 
p = r/n = 4/111 = 0,036 = 3,6% 
CI of population: p ± z√[p (1-p)]/n 
= 0,036 ± 1,96√[(0,036)(0,964)]/111 
 = 0,036 ± 1,96√[0,0347/111  
 = 0,036 ± 1,96√0,000313 
 = 0,036 ± 1,96.0,0177  
= 0,036 ±  0,0347 
CI = [0,0708; 0,0012] 
 
Because (p) is so small, this was regarded as a false indication can be experienced 
regarding the prophylactic efficacy of the drug.  A more reliable test was thus 
necessary.  For this purpose, the Wilson reliance interval was used. 
 
Wilson reliance interval (score method) 
A = 2r+z² = 2(4) + (1,96)² = 8 + 3,842 = 11,842 
B = z√[z²+4r(1-r/n)] = 1,96√[1,96²+4(4)(1-0,036)] = 1,96√[3,842+16(0,964)] 
B = 1,96√[3,842+16(0,964)] = 1,96√19,266 = 1,96.4,389 = 8,603 
C = 2(111 + 1,96²) = 2(114,842) = 229,683 
CI = [(11,842-8,603)/229,683; 11,842+8,603)/229,683 
CI = 3,239/229,683; 20,445/229,683 
CI = [0,0141; 0,0890] 
 
According to this statistical evaluation, there is a 95% certainty that when a 
population is using Mefloquine, the chance of getting malaria will be between 
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0,0141 and 0,0890.  In other words, an individual has a 1,4% to 8,9% chance of 
contracting malaria when he/she is using Mefloquine (Mefliam®). 
 
Using the score method, the confidence interval out of a population of 336 is 4,7 to 
29,9 members.  The results of the study indicate that the prevalence of malaria in 
the users of Mefloquine Hydrochloride was 3,6% with a 95% Wilson reliance 
interval of 1,4%; 8,9% (Altman, Machin, Bryant and Gardner, 2000:9-11).  
According to the study, Mefloquine (Mefliam®) had a high prophylactic efficacy in 
Burundi, East Africa.  This result is in line with international tendencies and 
standards. 
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CHAPTER 5 
5. DISCUSSION AND RECOMMENDATIONS 
5.1 DISCUSSION 
 
The purpose of the study was to investigate the prevalence of malaria in 
Mefloquine hydrochloride - Mefliam® users.  This research was executed during 
the deployment of military forces in Burundi, East Africa, in 2002. 
 
According to studies done by Colonel Robert DeFreitas of the Medical Corps of the 
US Army during 2003, relapsing malaria is the primary military medical problem of 
malaria cases worldwide.  Falciparum malaria is the greatest threat to the lives of 
soldiers in the military due to drug resistance (DeFreitas, 2003:1-12).  
Complications can present very rapidly and the drug resistance can present as an 
epidemic.  One conclusion is that antimalarial prophylaxis courses are either not 
taken or are ineffective. 
 
The type of military mission also plays a role in the malaria health threats.  Most 
malaria exposure and least compliance with drug regimens occur during combat 
operations (DeFreitas, 2003:1-12).  During combat operations soldiers are living 
and sleeping in tents or in the open.  Soldiers have to work during night (dusk and 
dawn) when mosquitoes are most active (Wood, 1993:67-68).  Soldiers are working 
under pressure and there is sometimes little opportunity to take the antimalarial 
chemoprophylaxis. 
 
During non-violent operations such as peacekeeping operations or humanitarian 
assistance, low or absent threat of hostile action may permit more emphasis on 
disease and non-battle injury threats.  It should therefore be the opportunity for 
military forces during such times to actively evaluate their malaria programme, to 
do rectifications, educate and train the soldiers and medical personnel, and to 
conduct research regarding antimalarial and therapeutic drugs.  During repeated 
insertions and extractions and the short exposures in malarious areas, members 
are reluctant to take the antimalarial drugs, due to initial side-effects and the fact 
that, when they start using it, they have to use it for four weeks after the last 
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possible exposure such as in the case of the users of Mefliam®.  This is a 
particular concern for people deployed for less than two weeks at a time, or those 
persons having to go to the area with short intervals, for instance every four weeks.  
That means that the person has to use the Mefloquine chemoprophylaxis for a long 
time, although he/she is not permanently exposed during that time.  This scenario 
necessitates a different antimalarial drug regimen or more intense research for the 
quest of the ideal drug.  
 
Military members vary greatly in their need for and response to prophylaxis.  The 
regular infantry troops are normally more disciplined with a stricter disciplinary 
structure.  They are normally a bigger group and are living and working in the same 
areas for what could lead to better control and observation.  It is therefore easier to 
manage each member’s compliance with the antimalarial prophylaxis. 
 
Logistics, transportation and other support units scattered in the deployment area 
are not always part of the communication lines and the disciplinary structures, 
which renders their compliance with the antimalarial regimen of these members 
more of a challenge. 
 
Engineering units are involved in construction projects in tropical conditions with the 
building of roads, sewerage works and networks, water pumps and pipelines.  
These members are sometimes compelled to overnight in tropical conditions 
conducive to mosquito breeding.  
 
In some instances older, experienced military members often believe themselves to 
be above the need to take antimalarial medication.  The non-compliance with 
taking antimalarial drugs may create a reputation of legendary status among 
soldiers, fame or infamy, regardless of the merit of such actions.   
 
Military pilots and scuba divers are using Doxycycline due to the possible side-
effects of Mefliam®.  No reliable studies have been done on the effectiveness of 
Doxycycline in certain parts of the world, and until such research is done, or by 
experience with the drug, its effectiveness could be in doubt (Ohrt et al., 1997:965-
972).  
 107 
 
Leadership and command emphasis regarding malaria prevention is crucial in 
achieving compliance among military members.  According to the study, 75.7% of 
the soldiers received their medication from the medical personnel.  The antimalarial 
drugs should be distributed to the respective commanding officers, and they should 
in turn distribute them to the leaders of the different sections.  The structured and 
organised way in which the drugs are managed should emphasise the importance 
of achieving compliance with a drug-taking routine among the soldiers.  If the 
section leaders are issuing out and controlling the use of the drugs, it will form part 
of the weekly routine.  This behaviour will be associated with a disciplined structure 
and negative conduct will be sanctioned.  Awareness education must form part of 
the pre-deployment training.  This will determine:  
• how the troops perceive the malaria threat; and  
• whether military members have practised taking antimalarial medication in the 
past. 
 
In a studies by DeFreitas (2003:1-12), he observes that the longer the mission, the 
greater the malaria risk.  The cumulative risk of contracting malaria is proportional 
to the length of stay in an endemic malaria area.  A stay of three months carries a 
risk six times higher than a two week visit (Bradley & Warhurst, 1997: 138-152).  
This is especially true for relapsing malaria.  DeFreitas completed a range of 
studies on the optimum duration of military deployments, and one of his 
conclusions was that long deployments almost always resulted in 
chemoprophylaxis compliance failure.  This was due to the fact that command 
emphasis evaporated, the perception of disease waned and side-effects might 
persist.  He found compliance of only 40% after five months among soldiers using 
the daily medication regime.  Long deployments ensured that the military members 
got exposed during the high malaria transmission season.  The highest 
transmission typically followed the rainy season.  
 
Troops may be lulled into non-compliance if they do not notice other members 
becoming sick during the low transmission seasons.  Geographical distribution of 
malaria complicates the threat assessment.  Soldiers living in drier areas are a bad 
influence on other soldiers when they do not use their antimalarial medication 
regularly.  Due to the low presence of malaria mosquitoes in those areas, they do 
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not contract malaria.  In return, soldiers working near stagnant water sources 
perceive the threat as over-exaggerated and start to fall in the groove of non-
compliance, with the expected consequences. 
 
Soldiers generally do not like to take pills (DeFreitas, 2003:1-12).  A single episode 
of vomiting and/or dizziness will stop some soldiers from taking the antimalarial 
chemoprophylaxis again.  
 
5.2 THE OPTIMAL ANTIMALARIAL REGIMEN  
 
To choose the optimal antimalarial regimen, the following should be taken into 
consideration:   
• A short course of antimalarial medication that would result in several weeks of 
protection would be highly desirable.  Tafenoquine for 3 days protects for 10 
weeks (Queguiner & Engers, 2001:149-151; Walsh, Eamsila, Sasiprapha, 
Sangkharomya, Khaewsathien, Supakalin, Tang, Jarasrumgsichol, Cherdchu, 
Edstein, Rieckmann & Brewer, 2004:1456-1463).  
• The taking of daily medication without supervision is not successful.  Daily 
Doxycycline requires supervision. 
• Weekly regimens are generally superior to daily regimens. 
• Antimalarial chemoprophylaxis with a longer half-life allows missed doses to be 
made up. 
• Antimalarial chemoprophylaxis with a longer half-life keeps the intravenous and 
intracellular chemoprophylactic levels high to prevent the build-up of resistance 
among malaria plasmodiums.  
• Commands should create a routine of the consumption of antimalarial drugs 
among all the deployed military members in a malarious area, for example once 
weekly "Malaria Monday".  This routine will lead to more streamlined 
supervision. 
• Simpler is better. 
• A single drug is a necessity; two drugs are easily confused or forgotten. 
• Antimalarial medication administered before deployment for short exposures is 
highly desirable.  During short exposures/visits to malarious areas, people tend 
to easily forget to take the drugs, because they are not part of the unit routine. 
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• Consistent malaria policy among military personnel is essential. 
• The ultimate malaria prophylaxis would be a single dose of medication or 
immunisation administered during basic training that is 100% efficacious 
against malaria worldwide, without any adverse effects. 
• Mefloquine is contra-indicated with pregnancy.  In pregnant women malaria 
poses a particular risk to the health of the mother and the foetus, increasing the 
risk of maternal death, neonatal death, miscarriage and stillbirth.  Pregnant 
women should if possible, avoid malaria areas.  Pregnant women should take 
every precaution to prevent mosquito bites and, where applicable the 
appropriate anti-malarial drugs should be taken (South Africa, 2002:5; SCAT, 
2003:20). 
 
5.3 RECOMMENDATIONS 
  
The motto of the war against malaria is to stay one step ahead.  It is also important 
to learn more about our common malaria parasite enemy and to develop the 
means to combat it.  We must also learn from our experiences of current and 
previous military deployments.  Problems regarding compliance with and 
intolerability towards the medication should be documented, while a surveillance 
programme should also support this feedback.  With a surveillance network in 
place, there will be a better understanding of the clinical relevance of antimalarial 
drug resistance. 
 
It is critical that education regarding the proper use of chemoprophylaxis forms part 
of the pre-deployment training of soldiers.  The members must be informed 
regarding the possible build-up of resistance of the malaria parasite against 
antimalarial drugs if the medication is not used correctly.  As part of the malaria 
education programme, the military personnel should practise taking malaria 
medications.  
 
Military personnels’ perceptions should also be tested regarding possible side-
effects and allergic reactions.  A herd mentality could easily develop among 
soldiers during deployment as a result of bad experiences with the medication.  If a 
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member does not use the drugs at all or not according to the prescribed method, 
other soldiers may follow the example, and soon an entire group may be involved.    
 
The gathering of these data will also allow health care providers to manage 
patients more effectively.  Medical planners can effectively select the best possible 
drug regimens for different geographic areas.  Critical to patient management and 
triage, is a prompt and accurate diagnosis.  The ability to rapidly diagnose malaria 
in remote military healthcare echelons will help healthcare professionals treat 
malaria patients sooner.  
 
After extensive studies and research coordinated by the Director of Pharmacy 
(SAMHS) between 1997 and 2002, it was decided that Mefloquine would be used 
as a drug of choice during deployments for a period of six months, after which all 
deployed members would have to leave the deployment area (Chemoprophylaxis 
and Treatment of Malaria, 2003:2; Venter:personal communication).  According to 
Mefliam® package insert (2002:3), Mefloquine has in the past been administered to 
individuals for periods longer than one year.  If the drug is used for a prolonged 
period (longer than three months), periodic monitoring, including liver function, 
should be performed (Mefliam® package insert, 2002:3).  This practise is thought 
to contribute to the development of resistant strains of P falciparum.    Mefliam® is 
not a long term prophylaxis (Mefliam® package insert, 2002:3).  A register should 
be kept of military personnel who have taken the Mefliam® prophylaxis for more 
than three (3) months consecutively.  The current study was conducted four 
months into the deployment period.  However investigations into the monitoring of 
long-term exposure were beyond the scope of the study.  Future studies should 
take cognisance of this deficiency.          
 
Further research regarding drug resistance is required.  It is necessary to initiate 
monitoring of drug resistance in Africa, using standardised methods.  Drug efficacy 
studies using in vivo methods have been standardised by the World Health 
Organisation.  Management guidelines should be developed concerning when and 
under which conditions to change the treatment regimen for different levels of 
resistance.  Development and field testing of new malaria drugs are required to 
replace present drugs when resistance makes them unusable.  The emergence of 
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multi-drug resistant malaria will continue to confound the drug development of 
antimalarial drugs.  The medical community must have a better understanding of 
the mechanics of drug resistance.  Resistance to Mefloquine has been 
documented in East Africa and sporadic cases are occurring in West Africa.  As 
these and other reports of drug resistance continue to evolve, the need for a 
replacement drug for weekly prophylaxis will continue to escalate.  Halofantrine 
was developed as a back-up drug for Mefloquine in a collaboration effort between 
the US Army and SmithKline Beecham.  However, its usefulness is limited by 
possible cross-resistance with Mefloquine, cardiac toxicity and poor absorption. 
 
The military should document the clinical relevance of drug resistance.  They 
should also examine the potential for spread of resistance in the field.  There is 
mutual agreement that the critical methodology and approach required to describe 
antimalarial drug resistance requires well documented clinical studies with 
adequate follow up, confirmation that adequate drug levels were reached in the 
users of antimalarial prophylaxis and that the drugs were used regularly.  Mapping 
malaria transmission intensity and resistance using geographic positioning systems 
has to be developed for the mapping of malaria across the continent.  This process 
will have the potential for predicting potential malaria epidemics and monitoring 
control.  Results of these studies in other international armies have facilitated 
documentation of clinically relevant resistance to Mefloquine, Halofantrine, 
Chloroquine, Proguanil plus Dapsone and Atovaquone (Queguiner & Engers, 
2001:149-151).  These and other data will help guide the selection of the next 
generation of prophylactic drugs. 
 
Future directions must focus on basic and applied research for a better 
understanding of the modes of actions.  Future directions should also concentrate 
on the mechanisms of resistance to these drugs.  The synthesis and design of new 
drugs would hopefully result in the development of safe and effective drugs that 
circumvent the malaria parasite’s elusive mechanics of drug resistance.  Multiple 
drug resistance in falciparum malaria will continue to pose problems for targeting 
the blood stages of malaria (Queguiner & Engers, 2001:149-151).       
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There must be an increased emphasis on developing drugs with true causal 
prophylactic properties.  An increased emphasis on developing drugs with radical 
curative properties before blood stages emerge and cause clinical disease must 
also be clear.  The solution for the current malaria problem is to establish a critical 
mass of investigators, collaborators and clinical centers that are focused and 
committed to document and evaluate malaria resistance, examine the potential for 
spread of resistance in the field and the discovering and development of new 
medication. 
 
Military research on malaria in Africa is a serious requirement.  Collaborations with 
other defense forces for information on clinical trials and drug resistance 
surveillance are pivotal for future drug selection and malaria management.  No 
other private or government organisations will adopt this process, due to the limited 
monitory possibilities.  Should this endeavour not be successful, we cannot expect 
to protect deployed soldiers who will be scattered on missions in diverse 
geographic locations all over the world against malaria. 
 
An important fact that emerged from the study is the emergence of the role of 
females in the military.  Cognisance should be taken of the risk sexually active 
females take when using Mefliam®, as Mefloquine is contra-indicated with 
pregnancy.      
 
5.4 CONCLUSION 
 
Malaria is an important social, economic and developmental health problem 
affecting military members, their families and their communities.  The best chance 
to successfully combat the disease will require collaboration between those who 
control the disease and the researchers.  The eradication of malaria is placed on a 
strong research base, international collaboration and sustained governmental 
support.    
 
Mefloquine is closely aligned with military needs.  This biodefence agent addresses 
the operationally relevant malaria species, P. falciparum, and drug-resistant 
phenotypes of this species.  It has an operationally suitable frequency of dose.  
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The shortcomings of Mefloquine have been the adverse event profile on the 
background of military use, particularly neuropsychiatric events and limitations in 
suppressive management of vivax malaria.  In terms of a biodefence system, these 
are not critical, as they are reasonably predictable and manageable.  While 
chemoprophylaxis remains the cornerstone of malaria casualty control, attention 
will need to be paid to compliance.  With comparable attention to tailoring 
Mefloquine use, as that paid to appropriate uniform fit or weapon allocation, most 
service personnel will be well protected with Mefloquine during military operations 
in malarious areas.  This is in line with findings by Jaspers et al (1996:230-234).   
 
This fact must prompt researchers and health personnel to double all efforts to find 
a solution that will protect 100% of all military personnel against the risk of 
contracting malaria when deployed in malaria endemic areas. 
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ANNEXURE A: 
CONFIDENTIAL (When completed) 
 
Dear Participant, 
 
This questionnaire is aimed at finding out the effectiveness of the malaria 
tablets we are currently using in Burundi. The information that you 
provide will be important in the helping the other deployments to this area 
in the future and a possible masters degree. Your opinion is of great 
importance and will be taken into account in this study 
 
Please answer the questions as honest as possible. All the information that 
you provide as strictly confidential and will not revealed in such a manner 
as to disclose your identity. Also the biographical information asked in this 
questionnaire will only be used for the purpose of analysis. 
 
Your involvement and honest participation is greatly appreciated!  
_________________________________________________________________-
CONSENT FOR THE COMPLETING THE EVALUATION SCHEDULE FOR 
SANDF MEMBERS DEPLOYING IN EAST AFRICA (BURUNDI) 
 
Full names and surname 
 
………………………………………………………………………………...................... 
 
Hereby consent to be assessed during the above-mentioned programme by Eldrian 
Basson (98110414 PF) Environmental Health Practitioner. 
 
I further consent to the anonymous use of these results for research purposes. 
Also, to provide information in an honest and truthful manner to the best of my 
knowledge and feelings when asked during the programme. 
 
I declare that the above-mentioned information provided by myself is correct and 
the information provided during the programme will be accurate and correct to the 
best of my knowledge. 
 
Signed at …………………………….  Date …………..………. 
 
 
 
……………………………………… 
Member’s signature 
 
 
CONFIDENTIAL (When completed)
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QUESTIONNAIRE 
QUESTION OPTIONS 
1.1 Gender 
 1. 2.      
. Male Female 
  
   
 105 6      
1.2 Age 
 1. 2. 3. 4.    
 20 – 30 31 – 40 41 – 50 50+    
 
45 62 3 1    
1.3 Race 
 1. 2. 3. 4.    
 Black Coloured Asian White     
 
76 22 2 11    
1.4 Home Province  
 1. 2. 3. 4. 5. 6. 7. 
 Eastern 
Cape 
Limpopo Mpumalanga Northern 
Cape 
KwaZulu 
Natal 
Western 
Cape 
Gauteng 
 58 7 6 2 4 11 14 
 8. 9.      
 Free 
State 
North 
West 
     
 3 6      
1.5 Home Language 
 1. 2. 3. 4. 5. 6. 7. 
 Afrikaans English Xhosa Zulu Sotho Thwana Venda 
 32 4 44 7 8 9 1 
 8. 9. 10.     
 Swazi Ndebele Shangaan     
 2 3 1     
1.6 Arms of service 
 1 2 3 4 5 
 Army SAMHS SAAF NAVY MPA 
 78 4 10 4 5 
      
 CMI Engineers Logistics   
 2 4 4   
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QUESTIONNAIRE 
QUESTION OPTIONS 
2.1 Have you ever seen someone suffering from malaria? 
 1 2 3     
 Yes No Uncertain     
 35 75 1     
2.2 Are you aware of any preventative methods for malaria? 
 1 2      
 Yes No 
  
   
 97 14      
2.3 Did you ever suffer from malaria? 
 1 2      
 Yes No 
  
   
 6 105 
  
   
2.4 When you are deployed in a malaria area, do you take the malaria tablets?  
 1 2      
 Yes No 
  
   
 111 0      
2.5 When you are deploying in a malaria area, do you take the malaria tablets 
before arriving at the area? 
 1 2      
 Yes No 
  
   
 108 3      
2.6 When deployed in malaria area, do you maintain the taking of the malaria 
tablets?  
 1 2 3     
 Yes No Not 
answered 
    
 110 0 1     
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QUESTIONNAIRE 
QUESTION OPTIONS 
3.1 What is the name of the malaria tablets that you use?  
 1. 2. 3    
 Mefliam® Doxycycline Non 
responsive 
   
 111 8 1    
3.2 Did you experience any problems about the malaria tablets that you are 
using?  
 1 2      
 Yes No      
 11 100      
3.2.1 If your answer is yes, elaborate your answer: 
 1 2 3 4 5 6 7 
 Abdominal 
cramps 
Sensiti
ve 
skin 
Diarrhoea Bad 
taste 
Nauseous Headache Perfuse 
sweating 
 1 1 2 1 3 2 1 
3.3 Do you enjoy the malaria tablets?  
 1 2      
 Yes No Uncertain     
 87 22 2     
3.4 How do you obtain the malaria tablets?  
 1 2 3 4    
 Sickbay  Platoon 
Commander 
Unit Myself    
 83 18 9 1  
3.5 What problems do you think you can experience if you don’t use the malaria 
tablets? (e.g. Flu)   
 1 2 3 4 5 6 7 
 Malaria Malaise Fever Die  Loss of 
water 
Yellow 
fever 
Pneumonia 
 78 3 17 2 1 2 1 
 8 9 10 11 12   
 Tiredne
ss 
Don’t 
know 
Vomiting No 
appetite 
No 
problem 
  
 1 3 1 1 2   
3.6 When you complete the deployment, will you continue using these tablets for 
four weeks being at home?  
 1 2      
 Yes No      
 102 9      
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QUESTIONNAIRE 
QUESTION OPTIONS 
4.1 I take the malaria tablets because…  
 1. 2. 3 4 
 It’s important to 
keep me healthy 
It’s expected of 
me to do so 
I’m forced to It’s the rule 
 100 7 2 2 
4.2 When I’m taking the tablets, I’m feeling… 
 1 2 3 4 
 OK Nauseous Headache Sleepless 
 92 11 6 2 
4.3  I normally taking my malaria tablets… 
 1 2 3 4 
 At night before I go 
 to sleep 
After lunch After breakfast  When  
I get a change 
 21 47 33 10 
4.4 I find the malaria tablets to be… 
 1 2 3 4    
 Tasteless  Sour Sweet Bitter    
 52 11 1 47    
4.5 Did you get malaria during the current deployment in Burundi?   
 1 2    
 Yes No    
 4 107    
5. Please list any concerns or problems about the malaria tablets that were not 
listed in the questionnaire?  
 1 2 3 4 5 6 7 
 None Sweating Affect 
females 
Not with 
liquor intake  
Emotional 
side-
effects 
Sex life Expose 
family to 
malaria 
 94 2 3 2 4 1 1 
 8 9 10     
 After 
taste 
Big 
appetite 
Continue taken tablets 
after leaving Burundi 
   
 1 2 1    
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ANNEXURE B: 
 
MEFLIAM TABLETS 
 
SCHEDULING STATUS 
Schedule 4 
 
PROPRIETARY NAME 
(and dosage form): 
 
MEFLIAM TABLETS 
 
COMPOSITION 
Each tablet contains mefloquine hydrochloride 274 mg equivalent to mefloquine 250 mg. 
 
PHARMACOLOGICAL CLASSIFICATION: 
A: 20.2.6 Medicines against protozoa 
 
PHARMACOLOGICAL ACTION: 
Mefloquine is a quinoline methanol derivative, structurally related to quinine. Mefloquine is a blood 
schizontozide with effects on the asexual blood forms of the malarial pathogens that affect humans 
(Plasmodium falciparum, P. vivax). It is also active against the gametocytes of P. vivax. Its 
mechanism of action is unknown. Mefloquine has no effect on the hepatic stage of malaria parasites. 
Strains of P. falciparum resistant to mefloquine have been reported. 
Cross-resistance between halofantrine and mefloquine has been observed. Resistance to 
mefloquine as well as to any other antimalarial may occur in any endemic area. Mefloquine 
resistance has been described. Resistance patterns occur and vary from region to region and with 
time. 
Pharmacokinetics: The maximum plasma concentration after a single oral dose is reached in 6 to 
24 hours (average 17 hours). The achieved plasma concentration in nanograms per millilitre is 
roughly equivalent to the dose in milligrams. In steady state with weekly doses of 250 mg, maximum 
plasma concentration of 1 000 ng/mL have been recorded. Mefloquine is 98% bound to plasma 
proteins. Mefloquine has a large apparent volume of distribution (13,5-29,1 L/kg). The main 
metabolite of mefloquine, 2,8-bistrifluoromethyl-4-quinoline carboxylic acid, is inactive against P. 
falciparum. It appears that mefloquine is mainly excreted into bile and faeces. The elimination half-
life of mefloquine is three weeks. After a single dose in healthy adults it was between 12-37 days on 
average. 
 
INDICATIONS: 
MEFLIAM tablets are indicated for prophylaxis of Plasmodium falciparum malaria, in regions where 
P. falciparum strains resistant to 4-aminoquinolines (e.g. chloroquine) occur. MEFLIAM may be 
effective against malaria parasites resistant to proguanil, pyrimethamine-sulfonamide combinations. 
 
CONTRA-INDICATIONS: 
MEFLIAM is contra-indicated in the following: 
• Patients with known hypersensitivity to mefloquine or related compounds (e.g. quinine and 
quinidine). 
• Patients with depression or a past history of depression, generalized anxiety disorder, psychosis, 
including schizophrenia or other psychiatric disturbances. 
• Patients with a history of convulsions. 
• Children of body weight less than 5 kg. 
• Patients with impaired renal or hepatic function. 
• The safety in pregnancy and lactation has not been established. 
 
WARNINGS: 
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Mefloquine may cause psychiatric symptoms in some patients, ranging from anxiety, paranoia and 
depression to more serious hallucinations and psychotic behaviour. In some instances, these 
symptoms have continued long after mefloquine was stopped, according to reports. Rare cases of 
suicide and suicidal ideation have been reported, although no causal relationship with mefloquine has 
been confirmed. To minimize the chances of these adverse events, mefloquine should be avoided in 
patients with depression or a past history of depression, generalized anxiety disorder, psychosis, 
including schizophrenia or other psychiatric disturbances. 
If psychiatric symptoms such as unexplained anxiety, depression, restlessness or confusion are 
evident during mefloquine prophylaxis, the medicine must be discontinued and alternative prophylaxis 
instituted, as these could be prodromal to a more serious neuropsychiatric event. 
Quinine and quinidine which are commonly required for the treatment of severe malaria, are contra-
indicated when MEFLIAM prophylaxis has been used. 
 
• Concomitant administration of mefloquine and other related compounds (quinine, quinidine and 
chloroquine) may produce ECG abnormalities and increase the risk of convulsions. 
• As teratogenicity has been shown in animal studies, reliable contraception is recommended whilst 
taking MEFLIAM tablets and for three months after the last dose. Data in human exposure during 
the first trimester are insufficient to conclude safety in pregnancy. 
• Mefloquine is excreted into breast milk and therefore if it must be taken, breast feeding should be 
discontinued. 
• Mefloquine has been administered for longer than 1 year. If administered for a prolonged period 
(longer than 3 months), periodic monitoring, including liver function tests, should be performed. 
Although the retinal abnormalities seen with long-term chloroquine use in humans, have not been 
found with mefloquine, dose-related ocular lesions have been observed in rats after long-term use 
of mefloquine at 12.5 mg/kg/day (3-4 x human prophylactic dosage) or higher. Periodic ophthalmic 
examinations are therefore also recommended. 
• Caution is advised in patients who have cardiac conduction diseases because asymptomatic sinus 
bradycardia and other conduction abnormalities have been reported. 
• Caution must be exercised during driving, piloting aircraft, scuba diving, and operating machines as 
dizziness, disturbed sense of balance or neuropsychiatric reactions have been reported whilst 
taking MEFLIAM and for three weeks afterwards. 
• Mefloquine and halofantrine used simultaneously may lead to a potentially fatal prolongation of the 
QTC interval. 
• MEFLIAM may cause toxic encephalopathy of unknown etiology during prophylaxis. 
• There is no evidence that dose adjustment is required for patients with renal impairment. However, 
since the clinical evidence is limited, MEFLIAM should be used with caution in these patients. 
• Mefloquine prophylaxis should not exceed three months as long term prophylaxis is thought to 
contribute to the development of resistant strains of P. falciparum. 
• Resistance to mefloquine has been documented in some areas. 
• If flu-like symptoms develop in patients who have been in a malaria area they should inform their 
doctors accordingly. 
 
Additional preventative measures: As preventative medication with all antimalarials is not 100% 
effective, the following measures to prevent mosquitoes from biting should be taken to reduce the 
risk of contracting malaria: 
I. visiting endemic areas during the dry season or in years when rainfall is low; 
II. high risk persons should avoid malaria areas altogether, (high risk persons include babies and 
young children less than 5 years of age, pregnancy, immunocompromised individuals such as 
those on long term steroids, cancer patients, chemotherapy. AIDS patients and those who have 
had their spleen removed.); 
III. not going outside between dusk and dawn, when mosquitoes are most active; 
IV. applying insect repellant to exposed skin and clothes; 
V. wearing long sleeves and long trousers at night; 
VI. using mosquito nets, screens, coils and pads. 
 
DOSAGE AND DIRECTIONS FOR USE: 
The following weekly doses of MEFLIAM are recommended: 
  Body weight:         Weekly dose for prophylaxis: 
  Up to 19 kg         1/4 tablet (62,5 mg) 
  20-30 kg         ½ tablet (125 mg) 
  31-45 kg         3/4 tablet (187,5 mg) 
  >45 kg         1 tablet (250 mg) 
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Experience with MEFLIAM in infants less than 3 months old or weighing less than 5 kg does not 
exist. 
The first dose should betaken one week before arrival in an endemic area and subsequent weekly 
doses should be taken on the same day of each week. Prophylaxis should be continued for four 
weeks after leaving the malarial area, and should not exceed 3 months' duration. The tablets should 
be taken after food with plenty of fluids. 
 
SIDE-EFFECTS AND SPECIAL PRECAUTIONS: 
Side-effects: Dizziness or disturbed sense of balance, nausea, vomiting, loose stools or diarrhoea, 
abdominal pain and loss of appetite. Less frequent reactions reported include headache, 
somnolence and sleep disorders (insomnia, abnormal dreams), myalgia, feeling of weakness, visual 
disturbances, palpitations, bradycardia, irregular pulse and extrasystoles, AV-block, hair loss, rash or 
pruritus, urticaria, convulsions, psychological changes, transient elevation of transaminases, 
leucopoenia or leucocytosis and decrease of platelets. Erythema multiforme and Stevens-Johnson 
syndrome have been reported. Transient cardiac conduction alterations and paraesthesia have been 
observed in patients taking mefloquine. These adverse events can be observed several weeks after 
the last dose has been taken. 
Psychiatric reactions, sometimes disabling and prolonged, have been reported in association with 
mefloquine. These include aggression, agitation, anxiety, confusion, convulsions, depression, 
emotional instability, encephalopathy, forgetfulness, hallucinations, sensory and motor neuropathies 
(including ataxia, paraesthesia and tremor), panic attacks, paranoia, psychosis and restlessness. 
Rare cases of suicidal ideation and suicide have been reported, although no causal relationship with 
mefloquine has been established. 
Special precautions: 
Caution is advised in renal compromised patients, in compromised hepatic function and in elderly 
patients as there may be different pharmacokinetic parameters for these groups. 
If signs of unexplained anxiety, depression, restlessness or confusion are evident, the medication 
must be stopped as these could be prodromal symptoms of a more serious neuropsychiatric event. 
Interactions: 
Concurrent use of beta-blockers, calcium channel blocking agents, quinidine or quinine with 
MEFLIAM tablets may result in sinus bradycardia, prolonged QT intervals or cardiac arrest; the risk 
of seizures may also be increased with quinine; concurrent use should be avoided; if concurrent use 
is necessary, close monitoring of patient response is recommended; in addition, patients should be 
advised to take mefloquine at least 12 hours after the last dose of quinidine or quinine. 
Mefloquine and halofantrine used simultaneously may lead to a potentially fatal prolongation of the 
QTC interval. 
Mefloquine may lower serum concentrations of anticonvulsants (e.g. valproic acid, carbamazepine, 
phenobarbital or phenytoin) and cause loss of seizure control; monitoring of these anticonvulsant 
serum concentrations is recommended and dosage adjustments may be necessary during and after 
therapy with mefloquine. 
The concurrent use of the oral typhoid vaccine with mefloquine may decrease the effectiveness of 
the oral typhoid vaccine; doses of the two medications should be separated by 7 to 10 days. It must 
be remembered that the first dose of MEFLIAM should be taken one week before entering the 
malaria area. 
Patients who are taking anticoagulants and oral antidiabetic agents should be monitored and have 
the relevant parameters checked before taking these with mefloquine as it is not known if there are 
any interactions. 
 
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: 
In the event of an overdose with mefloquine, the symptoms would be those specified under "Side-
effects and special precautions" but more pronounced. There is no known specific antidote for an 
overdosage, treatment should include standard gastric decontamination procedures and routine 
symptomatic and supportive treatments. Cardiac function, neurological and psychiatric status should 
be monitored for at least 24 hours. 
 
IDENTIFICATION: 
Flat, white, circular uncoated tablets with bevelled edges. One side has a cross breakline and the 
other side is plain. 
PRESENTATION: 
MEFLIAM Tablets are available in blister packs of 6 and 8 tablets. 
 
STORAGE INSTRUCTIONS; 
Store below 25°C. Keep out of reach of children. 
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Protect from moisture. 
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